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ABSTRACT
There is great interest in the plasma research community on the potential medical applications
of non-equilibrium plasmas, called cold atmospheric plasma (CAP), yet currently no such plasma
device is approved by the US Food and Drug Administration (FDA). This dissertation seeks to
take a holistic look at five novel plasma systems with potential use in the medical field. These
systems are all analyzed from an engineering point of view to characterize the plasma and basic
biocompatibility from an electrical and thermal approach. The overall design life-cycle for these
devices is also examined, with an emphasis on deciding an approval pathway through the Food and
Drug Administration, where the intended use of the device is the driving factor.
The first device considered is a nanosecond puling circuit devised for skin electroporation. An
electrode is developed to help maximize the electric field applied to a substrate and ensure user
safety. Voltage and current traces and optical emission spectroscopy are used to characterize the
plasma generated for various substrates, showing the non-equilibrium behavior of the plasma for
a wide operating range. The second device considered is an existing FDA-cleared electrosurgi-
cal device power supply and hand piece, which has been modified for use as a CAP source. By
varying the tube length the plasma can be operated in a non-equilibrium state. The third device
is a direct write system for depositing thin films in a controlled pattern. This system consists of a
dielectric barrier discharge jet attached to a three-dimensional printer head for spatially controlling
the plasma location. Various methods of depositing material are used, including directly onto bio-
logical substrates. The final two devices are for improving the strength of additively manufactured
parts intended for use in custom printed prosthetics. The first is a nanosecond pulsed discharge
onto a printed part, which shows 100% strength improvement from the plasma treatment. The sec-
ond is a planar dielectric barrier discharge mounted onto the head of a three-dimensional printer,
which is able to print parts with the same strength as injection molded parts.
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Non-equilibrium plasma discharges are a quickly growing field with a wide range of possible
applications including medical uses. These plasmas have come from scaling existing discharges
to higher pressures and lower temperatures. Low pressure plasmas have found extensive use in
microelectronics for etching, deposition, ion implantation, and surface activation and functional-
ization. [1] In particular, plasma-enhanced chemical vapor deposition, has allowed a wider va-
riety of thin films to be deposited for various surface treatments. Atmospheric pressure plasma
discharges are typically high power discharges and are commonly used to provide the activation
energy for various processes such as combustion. These include some of the first laboratory dis-
charges discovered, such as arc and spark discharges discovered in 1803 [2] as well as dielectric
barrier discharges. [3]
Non-equilibrium plasma is created by balancing energy inflow and outflow to avoid a full
thermodynamic equilibrium from developing. Plasma, being a collection of ions, electrons, and
neutral gas species, typically has an energy input that preferentially excites only some of these con-
stituents. For example, an electric field imparts energy primarily into the electrons, since they are
electrically charged and have a much smaller mass than ions. There are various energy loss mech-
anisms that can also occur, such as diffusion of energetic particles out of the plasma or collisions
with the cooler walls surrounding the discharge. If the average energy of all of the various plasma
constituents are equal, then the plasma has become an equilibrium plasma. However if there is an
energy imbalance between some of the species, typically electrons with a high average energy and
neutral gas species with a much lower average energy, then a non-equilibrium plasma discharge
has developed. A special case of non-equilibrium plasma is a low temperature plasma, where the
bulk gas temperature is near ambient conditions. For typical low temperature atmospheric pres-
sure plasma, the gas temperature is near or under 40◦C. As such, this is also often called cold
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atmospheric plasma (CAP).
Research is now being done on these low temperature plasma discharges to achieve many of
the applications that have already been done with low pressure plasma sources or high temperature
plasmas. These discharges allow for high temperature chemistry to occur at ambient or near ambi-
ent conditions. The advantage of using ambient conditions is that new substrates can be used that
are not vacuum compatible or temperature sensitive, such as biological substrates. When used for
medical purposes, this is called plasma medicine.
Discovering an important finding in medical science is not enough; it has to be given to the
general populace to have real-world effect. To transition the results from this new field of plasma
medicine out of the lab and to a physician for practical implementation, devices need to created to
meet specific medical needs. The next two subsections will discuss the two main aspects of this
transition: identifying specific medical uses for plasma discharges and the process of developing a
medical device.
1.1.1 Medical Uses for Plasma
The first use of a plasma discharge for a medical use was on October 1, 1926, when Dr. William
Bovie used an electrosurgical generator with surgeon Dr. Harvey Cushing to remove a large brain
tumor. [4] This plasma was a lower energy thermal (equilibrium or near equilibrium) discharge
that helped maintain hemostasis during the surgery by sealing blood vessels during incisions. This
type of system is still in use today for similar applications of minimizing blood loss, both for
coagulation of blood as well as cauterization.
Low temperature plasmas have been investigated much more recently for potential medical
benefits, predominantly starting in the 1990s. [5] One of the first uses found was bacterial inac-
tivation. In addition to sterilization of surfaces, it was found that the plasma can be applied to
skin, where the bacteria can be inactivated without damaging human cells. This has developed into
treating chronic wounds with biofilms, the only application for which there are marketed low tem-
perature plasma medical devices. In addition to bacteria being more sensitive to low temperature
plasma, cancer cells have also been found to be more susceptible to plasma. [6] This has led to
2
extensive research being done on plasma as a potential cancer treatment.
Electric fields, which if high enough will invariably create plasma discharges, are also being
investigated for a number of uses. They have been shown to have a wide range of effects on cells,
ranging from electroporation of cell membranes to inducing apoptosis. [7]
Plasma can also be used indirectly for medical use. The most common example is in surface
sterilization, such as autoclaves. However, plasma discharges can also create gaseous species with
medicinal benefit, such as nitric oxide (NO) used in NO therapy. Plasma can also modify other
materials for later medical use, such as plasma activated water, which has been shown to have
sterilization potential. [8] Lastly, plasma can also modify solids, such as enhancing the strength of
additively manufactured parts as discussed in Chapter 7.
1.1.2 Medical Device Approval
Medical devices follow a design life-cycle, which begins with idea generation and identifying a
specific need to ultimately marketing the device and implementing an end-of-life plan. They gen-
erally have four stages: basic research, design development, device testing, and device marketing.
Initially an idea is explored to discover if there is sufficient benefit to create a medical device. If
there is sufficient benefit a device is developed to meet the need. After undergoing verification and
validation, a final design is found, which then undergoes testing for a marketing submission to the
regulatory body for approval.
This regulatory body acts as a gatekeeper for how a medical device is distributed to the masses.
Nearly all regulatory bodies, such as the US Food and Drug Administration (FDA), examine de-
vices with two concepts in mind: safety and efficacy. They ensure the device is safe for end users,
not posing an undue risk to the consumer, while also examining the efficacy of the device to ensure
that it effectively treats the specified condition, called the intended use of the device. They do this
by examining the evidence gathered by the testing of the final design. Devices are also normally
broken into groups based on the amount of risk they pose; higher risk devices receive more careful
scrutiny, while low risk devices can quickly be processed.
If a device is adequately shown to be safe and effective, it receives approval to be marketed.
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Typically there are also requirements to continue monitoring the device to ensure that good man-
ufacturing practices continue to be followed as well as longer term studies to ensure there are no
long term adverse effects from using the device. Device manufactures may also consider end-of-
life plans such as ways to recycle the device after its useful life is finished.
Designing and marketing a medical device, especially in a novel field such as low temperature
plasma medicine, is a serious undertaking. It involves balancing technological development, main-
taining cash flows for a burgeoning business, and navigating a complex regulatory environment.
All of these aspects must be kept in mind throughout the device development process, so that the
early designs flow smoothly to a final design ready for testing for regulatory approval.
1.2 Motivation
Innovation in medicine is always desired. In the case of plasma medicine, clinical studies have
already been conducted in which wounds have been shown to heal to the extent that amputation of
the limb is no longer needed. [9] Further development in cancer therapy may lead to treatments for
various cancers, as shown currently with in vitro and animal models. [6] These results would lead
anyone into investigating these and other uses for plasma as a medical tool, as the results show
promise to be substantially better than those currently being used in the medical field, improving
quality of life for patients and even possibly saving patients’ lives.
For those with less of an altruistic side, this is a novel yet burgeoning market currently with very
few companies. The United States’ medical device market is worth $156 billion, accounting for
40% of the world’s medical device market. [10] The low temperature plasma market is expected to
double in size in the next 5 years, primarily in wound treatment. [11] There is plenty of opportunity
as there is currently no approved low temperature medical devices in the US market, showing
incredible room for growth and also the potential benefit of being the first to the market.
The work presented in this dissertation is motivated by finding a variety of uses and plasma
sources for medical treatments. This is intended to provide a more holistic approach than is typ-
ically done in a laboratory setting, attempting to bridge the gap from basic research to targeted
medical device development to meet a specific intended use.
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1.3 Research Objectives
How can a low temperature plasma medical device be developed effectively in the US?
This dissertation seeks to answer this question by looking at five low temperature plasma med-
ical devices in four different aspects of their design.
1. Device development can encompass the entire range from idea exploration and prototype
creation through marketing approval and post-marketing studies. [12] It can even be broad-
ened to include the entire design life-cycle, which seeks to examine a device from the initial
idea (or even before with idea creation) to the end-of-life of the device. Four of the five
devices discussed in this dissertation are early in their development, but their entire design
life-cycle is investigated at least briefly, with an emphasis on the early characterization of
the designs.
2. Regulatory approval can be a key hurdle in attempting to market a device. The approach
is driven by the intended use of the device, which determines the level or rigor the testing of
the device will require, which can ultimately lead to years of additional development time.
Understanding the regulatory environment is crucial for properly developing the device. The
various approaches that these new devices can take for marketing submissions to the FDA
are explored, examining the strengths and weaknesses of the various approaches.
3. Plasma characterization is the main thrust of this dissertation, seeking to characterize the
plasma discharges of these five devices for their respective applications. The control of the
plasma is key for achieving the end result for the different designs.
4. Biocompatibility is critical to plasma medicine. It is very easy for a plasma discharge
to become dangerous or even lethal, thus careful control over the plasma is necessary to
ensure that minimal current is introduced into the substrate, the temperature remains low
to avoid thermal damage, and no dangerous chemicals are generated in the plasma. Note,
however, that a fully biocompatibility analysis is not performed in this work. For example,
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the amount of potentially hazardous gaseous species generated such as NO and ozone was
not quantified, solvents such as methanol were not replaced with a biocompatible alternative,
nor were histological studies conducted to determine if and to what extent thermal damage
was done to the biological tissues.
1.4 Dissertation Overview
This dissertation is divided into two primary sections, a background section consisting of two
chapters (Chapters 2 and 3) and an exploration of five potential low temperature plasma medical
devices (Chapters 4 through 7). Chapter 8 concludes this work and examines the future work to
be done for developing a low temperature plasma medical device as well as the future work for
each of the systems described in the earlier chapters. Two appendices are also included for further
information on the power supply developed in Chapter 4 (Appendix A) and the code developed to
directly interface with a 3D printer to create uniform area coverage for film deposition discussed
in Chapter 6 (Appendix B).
The following chapter, Chapter 2, explores the plasma medical device field. It does this by
first presenting some prerequisite knowledge of plasma operation, followed by a brief overview of
medical device development, particularly examining the approval pathways for devices for mar-
keting a device. This chapter concludes looking at the current state of the field of plasma medicine,
examining the potential uses, current devices, and standards that are being developed for plasma
medical devices. The next chapter, Chapter 3, discusses the specific techniques used in this disser-
tation to characterize the five plasma devices discussed, examining the applicability of the various
techniques and their limitations.
The next four chapters of this dissertation cover the five potential low temperature plasma
medical devices. Each of these chapters begins with an introduction of the material followed
by relevant literature and background for that specific device that was not covered in the more
general discussion in Chapter 2. Next, the device’s design is examined, noting where it is in the
overall design life-cycle as well as steps to carry the design forward. The possible regulatory
approaches are also laid out, in particular how to approach the FDA. Then, the physical design
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and development are discussed, noting the characterization that has been conducted thus far on the
device. Each chapter then concludes with a brief summary of the work completed as well as a
future outlook for the device with the necessary design and development work still to be done.
This work has generated four journal papers thus far, with three further papers being prepared
for submission as well. The electroporation system (Chapter 4) was published as “Development of
a Substrate-Invariant 2-D Array of Nanosecond-Pulsed Streamer Discharges”, [13] with a future
publication planned on the timing circuitry for imaging the discharge (as shown in Section 4.5.5).
A publication is being written on the modification of the electrosurgical power supply to create
a low temperature plasma discharge. Characterization of the metallic depositions discussed in
Section 6.5 has been published as “Copper Film Deposition Using a Helium Dielectric Barrier
Discharge Jet”, [14] which is a continuation of Cliff Tsai’s graduate work. [15] A further publi-
cation is being finalized on the direct write aspects of Chapter 6. The nanosecond pulsed system
for assisting additive manufacturing (Section 7.4) was published as “Effects of Cold Plasma Treat-
ment on Interlayer Bonding Strength in FFF Process”. [16] The FlashFuse system was published
as “Dielectric Barrier Discharge Applicator for Heating Carbon Nanotube-Loaded Interfaces and
Enhancing 3D-Printed Bond Strength”. [17]
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2. PREREQUISITE KNOWLEDGE & LITERATURE REVIEW
2.1 Introduction
This chapter will describe the prerequisite knowledge necessary for understanding plasma dis-
charges and the core literature for the context of this dissertation. The next chapter will go into
detail on the diagnostics used to characterize the plasma systems, which will include any relevant
literature describing those diagnostics. In addition, each chapter will begin with a background in-
cluding the relevant literature necessary for that specific plasma system; as such, only the literature
and relevant background information that spans multiple systems will be described here.
This chapter will first describe what a plasma is, going into some detail for various types of
discharges, how energy propagates in a plasma discharge, and the effect plasma has on the materials
exposed to it. Second, a discussion of the design life-cycle for a medical device is given. This
provides the context of where the devices discussed in this dissertation are in their development
as well as the general approach needed for further development through marketing and end-of-
life considerations. Next, medical device approval for marketing is discussed, with a focus on
the US Food and Drug Administration (FDA). Finally, low temperature plasma medical devices
are reviewed, examining the effect of plasma on live tissue, current systems in development, and
finally standards that are being developed for these systems.
2.2 Plasmas
First, one must understand what a plasma is. Plasma is the 4th state of matter.1 If one keeps
adding energy to a system it will eventually end up becoming a plasma, as shown in Figure 2.1. A
plasma also differs from a gas in that the material may not be of a uniform composition; there can
be free electrons, ions, and neutral gas species all present. Due to the presence of free electrons
(i.e. electrons no longer bound to an atom) and ions, a plasma responds to electric and magnetic
1This is sometimes confused with blood plasma, which is a completely different material. Interestingly though,
electrical plasma is named after blood plasma as the collection of ions, electrons, and neutral gas species were remi-
niscent of blood plasma. [18] Both definitions derive from the Greek word plsma, meaning moldable substance
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Figure 2.1: Plasma as a State of Matter
fields. However, unlike a solid, liquid, or gas, there is no distinct phase change that occurs to create
a plasma.2
Plasmas can be created multiple ways. If energy is uniformly added to a quantity of material
to maintain equilibrium, a thermal (or equilibrium) plasma results. This is called such because all
of the plasma’s constituents (the electrons, ions, and neutral species) are at the same temperature.
There is sufficient energy that the thermal energy alone has created the excitation process that cre-
ated the free electrons and ions. Two examples of this process are the most common examples of
plasmas people know: the sun (via compression heating of a material) and the latter stages of light-
ning (via Joule heating). In contrast to this type of plasma is a non-thermal (or non-equilibrium)
plasma. Energy is often added only into the free electrons via a strong electric or magnetic field
which begins to ionize a fraction of the neutral gas. Once a sufficient fraction has been ionized that
the gas begins to show collective behavior (i.e. it begins responding to electromagnetic fields, etc.),
the gas is now a plasma. The ionization fraction at which this occurs can be extremely low; for
example, a fluorescent lamp has an ionization fraction around 4 parts per million [21]. This type
2There is some trickiness with definitions here. In general the terms phase and state of matter are nearly synony-
mous, meaning a portion of material that is homogeneous in its chemical and physical structure, separated by other
phases by a phase boundary. [19] By this definition, a plasma is not a phase of matter because it is not homogeneous
per se nor is there a distinct phase change or boundary to differentiate it from a gas. However, at some point with suf-
ficient ionization, the behavior of a plasma is different enough from a gas that a new way of describing it is required.
This is perhaps analogous to the lack of a phase change between a liquid or gas when it becomes a supercritical fluid.
Nevertheless, it is fairly well established in literature that a plasma is a state of matter. [20]
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Figure 2.2: DC Steady State Voltage-Current Curve for Plasma
of plasma does not have a single temperature that can be used to describe the energy in every type
of particle (or even the amount of energy within the energy modes of a given particle).
2.2.1 Types of Plasma
A plasma can be thought of as any other circuit element with its own voltage-current charac-
teristics. Just as Ohm’s Law (V = IR) relates voltage and current for a resistor, there is a standard
“equation” that relates voltage and current for a plasma, which is shown in Figure 2.2. Note,
however, that this diagram is specifically for a DC steady-state plasma; some behavior of fast-
changing voltages may deviate from this. This relation is obviously much more complicated for a
plasma than for a resistor. The next few subsections deal with each portion of this voltage-current
relationship in more detail.
The voltage and current are functions of time as well as other parameters in the external circuit.
For example, the external circuit may not be able to supply the amount of power that the plasma
may be attempting to draw; as such the external circuit may place an external influence on the
plasma by limiting the amount of current through it. Figure 2.2 also does not display the time-
scales that the various plasma processes occur at; there are physical processes (e.g. the physical
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movement of electrons and ions in the plasma each of which have characteristic time-scales) oc-
curring that are coupling with the electrical circuit. Note that due to the complexity of the plasma
voltage-current relationship, it cannot be averaged out using RMS equivalents as is commonly done
for impedance with resistors, capacitors, and inductors. Thus three types of transient discharges,
streamers, dielectric barrier discharges (DBDs), and resistive barrier discharges (RBDs), are also
discussed in the following subsections.
Lastly, a section on plasma jets is included. Since plasma jets are usually operated using an
AC power supply, rather than a DC power supply, some different considerations arise. These also
deserve mentioning as the most commonly used plasma discharge in plasma medicine is a plasma
jet.
2.2.1.1 Dark Discharge (A-E)
Initially there will be a few free electrons (i.e. not bound to an atom) in any gas. This occurs
because there will always be some cosmic rays or rare high energy collisions that will ionize a few
gas particles. Normally the electrons would quickly recombine with the gas around them; however,
if a small voltage is applied these free electrons will have a small amount of net motion producing
a minute amount of current (Position A in Figure 2.2). As the voltage is increased, these electrons
will move faster, leading to a larger amount of current until a saturation value is reached (Position
B-C), which corresponds to all these spontaneously created electrons contributing to the current
flow. If the voltage is further increased, at some voltage value these electrons gain enough energy
from the applied electric field to ionize some of the neutral gas molecules they collide with as they
travel to the anode. As a result, there are more free electrons (for a binary system there is the free
electron that collided with and ionized the neutral gas particle and now the new free electron that
was created from this ionization collision), which allows for an increase in the current (Position
C-E) since there are more charge carriers (i.e. free electrons).
An electron avalanche begins. This is where one seed electron collides with a neutral gas par-
ticle and creates a second free electron. Then these two electrons are accelerated by the electric
field and both can then collide with other neutral gas particles creating an additional two electrons.
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Figure 2.3: Schematic of the Electron Avalanche Process
These four electrons continue this process as they travel toward the anode, creating a large popula-
tion of energetic free electrons. This process is shown schematically in Figure 2.3. The parameter
often used to describe this process is called the Townsend ionization coefficient, α, [22] which is
the number of electrons produced per unit length. If this electron avalanche does not reach electri-
cal ground (i.e. it is from a very high electric field, such as sharp points on an electrode, or simply
a very high voltage, often ≥20 kV) a very dim discharge called a corona discharge has developed.
However, electrons can also be lost by electron capture processes with electronegative gases, such
as oxygen. This is described using the second Townsend coefficient, β, which can be significant
in air, but is ignored in many other gases, where electron capture is rare. Sometimes this type
of discharge is called a Townsend discharge (from John Sealy Townsend who first described the
electron avalanche process), however a Townsend discharge is specifically when the discharge is
at least partially sustained by secondary electron emission. [23] Secondary electrons are those that
are released from the cathode by collisions of ions with the cathode surface. This is described
by the third Townsend coefficient, γ, which gives the number of secondary emitted electrons per
incident ion. This value is typically much smaller than 1.
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2.2.1.2 Breakdown (E-F)
If the electron avalanche shown in Figure 2.3 is able to cross the entire gas gap, a conductive
channel is formed. This is referred to as breakdown, because the gas is no longer acting as a di-
electric; it has broken down. The voltage at which this process occurs is called the breakdown
voltage (Position E in Figure 2.2), which is often a fairly constant value for a given system. For
perfectly planar electrodes the breakdown voltage is only a function of the gas and the product of
the pressure (p) and the anode-cathode gap spacing (d); this is called Paschen’s Law. In reality
surface roughness can greatly affect the breakdown voltage, so the exact value is almost always
experimentally determined. In addition, the preexisting conditions of the gap can affect the break-
down voltage, such as an unusually large presence of free electrons (e.g. a laser partially ionizing
the gap or residual electrons from a previous discharge event that has extinguished).
Historically Paschen’s Law was only used to describe breakdown processes at low values of pd
(i.e. pressure times gap spacing). Instead as the electron avalanche begins occurring local space
charge becomes significant leading to streamers or smaller filaments forming instead of a more vol-
umetric breakdown as described by Paschen’s Law. This breakdown process is sometimes called
streamer breakdown, filamentary breakdown, or Raether–Meek breakdown (after the physicists
who first described it). [24, 25] This will be described in more detail in Section 2.2.1.5.
Since the electron avalanche creates a conductive path, a much larger current is able to flow and
a lower voltage than the breakdown voltage is able to sustain the resulting discharge. This break-
down process is sometimes referred to as having negative resistance since a decrease in the voltage
corresponds to an increase in the current. Note that there is hysteresis that occurs (Positions E-F-
F′-D). After breakdown, a lower current is able to sustain the discharge than the current initially
arrived at; however, depending on the system this hysteresis may be small. This breakdown (E-F)
and extinguishing (F′-D) of the discharge gap are inherently unstable processes, hence the dashed
lines in Figure 2.2.
There are other possible breakdown mechanisms than high electric fields. Magnetic fields can
at minimum assist in the breakdown phenomenon if not initiate it as well. [26] Optical breakdown
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is also common using lasers, although this can be explained by the intense magnetic and electric
fields present in the light (an electromagnetic wave). Gravity can also supply the necessary energy,
as this is how stars operate, to create internal confinement fusion, which is a plasma.
2.2.1.3 Glow Discharge (F-H)
After breaking down, often a glow discharge will be created, depending on the voltage and
current supplied by the external circuit. A glow discharge is characterized by secondary electron
emission sustaining the discharge. Secondary electron emission is when free electrons are gener-
ated by ion collisions with the cathode. Often only one out of every 1000 or more ions that collide
with the cathode will eject an electron from the surface. The exact number, called the secondary
emission coefficient, γ (as described in Section 2.2.1.1, is dependent on electrode geometry, ma-
terial, and the gas; it is usually experimentally determined. The difference between a glow and
a Townsend discharge, which is also sustained by secondary electrons, is that a glow discharge
bridges the gap, while a Townsend discharge does not.
A glow discharge has a few recognizable features, the most common being the negative glow,
the Faraday dark space, and an anode glow. [2] There are many more potential features, but these
three are the most evident, even at atmospheric pressure. The negative glow is close to the cathode
and is often the brightest part of the discharge. There are slightly more electrons than ions hence
the name negative glow. The Faraday dark space separates the negative glow from the anode glow.
The anode glow is a region with constant electric field, where electron production equals electron
loss. This is not a necessary part of the glow discharge and will disappear if the gap is too short,
but it will expand if the gap is increased in size. This is the primary part of the discharge seen in
“neon” signs used in advertising (where neon is one of the common gases added for these glowing
signs).
Typically a glow discharge has a fairly constant voltage over a wide range of currents (Positions
F-G in Figure 2.2). The current density is fairly constant; increases in the current correspond to
an increase in the discharge size in the negative glow. An abnormal glow is when the plasma has
exceeded the size of the electrode (Positions G-H), so any further increase in current also increases
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the current density and voltage. An abnormal glow is generally not noted at atmospheric pressures
since the discharge area is typically not limited. [27] Even in pin-to-pin discharges the cathode will
wrap around the edge of the pin electrode to increase in area.
2.2.1.4 Arc Discharge (I-K)
An arc discharge is characterized by thermionic emission of electrons (Positions I-K in Fig-
ure 2.2). The cathode has heated up to a sufficient extent that the electrons are able to overcome
the work function of the cathode material and are ejected in sufficient quantity to sustain the dis-
charge. This is a very high temperature discharge. The exact transition from a glow to an arc
discharge can be due to Joule heating in the plasma or in the electrode until the electrode surface
is hot enough to thermionically eject electrons (Positions H-I). The glow-to-arc transition is often
thought to arise in the cathode fall region of the glow discharge, where there is a large voltage
drop. [28] This is also an unstable process like electrical breakdown (see Section 2.2.1.2).
2.2.1.5 Streamers and Related Discharges (Transitory Plasmas)
Unfortunately there is little consensus in the literature around the distinction between a corona,
streamer, and streamer-corona (or corona-streamer) discharge. In general, a corona is a weakly
luminous steady-state discharge centered around a region of high electric field (typically a sharp
point on an electrode), where the discharge does not have direct electrical contact with ground.
The charge is slowly dissipated into the ambient environment, where the free electrons dissipate
their energy by collisions with neutral species until recombination occurs. The space charge is
generally low enough to not greatly affect the overall electric field of the discharge gap. Coronas
are typically seen around high voltage (>∼20 kV). This type of discharge is responsible for the
characteristic hum of high voltage power lines.
A streamer discharge is a single electron avalanche process (called the streamer head) and the
ionized channel behind the avalanche, where the generated high voltage wave is propagating to-
ward ground. These growing ionized channels often have significant space charge to affect the
electric field of the discharge gap. The difference in the literature is that some authors term the in-
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dividual filaments that form a corona as streamers. To further complicate this definition are pulsed
discharges. These discharges may form a steady-state corona discharge or perhaps transition to a
glow if they were sustained, but due to the pulsed nature of the supply voltage they quickly extin-
guish. As such, some authors use the term streamer-corona to describe these pulsed discharges.
Another related discharge is a spark. A spark discharge is a transient discharge that has a
fast breakdown (electron avalanche) and quickly begins to heat up transitioning toward an arc
discharge. (You can think of this as a discharge that very quickly goes from position A to position
I in Figure 2.2, although the exact current and voltage measurements may not exactly correspond
to Figure 2.2.) However, the external circuit is not able to sustain the discharge, so it quickly dies
out. This commonly occurs when discharging capacitors, where the charge stored on the capacitor
discharges quickly, but as the charge leaves the capacitor the voltage it is supplying drops. There is
again disagreement whether the entire process is a spark or if a streamer discharge, upon reaching
ground becomes a spark only when a significant amount of current begins flowing and Joule heating
occurs. This is analogous, if not identical, to the glow-to-arc transition.
2.2.1.6 Dielectric Barrier Discharge (A Transitory Plasma)
A dielectric barrier discharge (DBD) consists of at least one dielectric barrier and a gas gap
between the anode and cathode. The dielectric barrier prevents charge from flowing between the
two electrodes, ensuring the system always has some capacitance. Due to this, a dielectric barrier
discharge must have either a periodic or pulsed voltage waveform applied—DC circuits will not
work for DBDs. Thus a DBD is a transitory discharge.
A DBD often consists of numerous microdischarges. These show up as individual filaments
in the discharge gap. Each microdischarge begins as an electron avalanche (see Section 2.2.1.2)
that occurs in the gas gap at some location along the dielectric barrier. This creates a conductive
channel across the gas gap. The electrons, however, are not able to complete the circuit due to the
dielectric barrier and a local build-up of electrons occurs on the dielectric barrier’s surface. As a
result of the charge build-up, the voltage locally across the gas gap decreases, since more voltage
is dropped across the dielectric barrier (the dielectric barrier is a capacitor with some charge now,
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which is governed by the equation Q = CV ). The conductive channel that was formed from the
electron avalanche is not able to become a sustained discharge due to the reduced voltage across
the gas gap and the discharge extinguishes. This essentially corresponds to traveling from positions
A to G and then back to A in Figure 2.2 for the local discharge.
However, DBDs are normally driven by a sinusoidal voltage waveform, so after the first half
cycle a half cycle with the opposite polarity occurs, where the electrons deposited on the dielectric
barrier are then driven across the gas gap in the opposite direction. This leads to another discharge
in the opposite direction, and as a result no net charge moves for a full voltage cycle. For large
surface area DBDs, there can be hundreds or thousands of microdischarges that occur for each
half-cycle of the voltage, so the local discharges have an overall aggregate effect of shorting the
gas gap capacitor when the voltage is above the breakdown voltage. The driving frequency is
normally on the order of kilohertz, so to the eye it appears as a continuous discharge.
Over certain ranges of gap distance and pressure a DBD may take on a diffuse glow rather
than having filamentary discharges all across the surface. In general this occurs for lower pres-
sures and gap distances which corresponds to Paschen breakdown rather than streamer breakdown
(see Section 2.2.1.2). The diffuse mode may be more advantageous for gas processing due to its
uniformity.
DBDs have been used primarily as ozone generators and gas purifiers. They are also potentially
very useful due to the dielectric barrier, which helps prevent large currents from flowing through
the discharge, since all currents are only displacement currents. This makes DBDs advantageous
for medical devices, since the dielectric barrier makes them inherently “safe”.
2.2.1.7 Resistive Barrier Discharges
A similar system to a dielectric barrier discharge is a resistive barrier discharge (RBD). An
RBD replaces the dielectric barrier with a material that has a high distributed resistance. Unlike
a DBD, net charge can flow through an RBD. Similar in operation to a DBD, an RBD often has
pulses where the plasma is intermittent, only due to a larger voltage drop across the local resistor
rather than a local dielectric. An advantage of the RBD is that is can be operated at lower fre-
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quencies, even as a DC discharge (in which case it will become a continuous discharge, rather than
intermittent discharges).
2.2.1.8 Plasma Jets
Plasma jets come in a wide variety of types and electrode configurations, but their distinguish-
ing feature is that the discharge occurs in a gas flow. Some example electrode configurations are
shown in Figure 2.4. The floating electrode-DBD (FE-DBD) jet is used in this work in Chapter 6
and has been used extensively in our lab [15,29–31], which stands in contrast to the more common
non-floating electrode counterpart, where the ground electrode is also included on the outside of
the dielectric tube. [32] The floating electrode (FE) direct plasma jet is used Chapter 5; however
its non-floating counterpart is much more common; in particular, it is used in the kINPen plasma
jet, [33] which will be discussed in more detail in Section 2.5.2.1. The final example shows some
of the diversity in the possibilities of electrode configuration, where the plasma discharges later-
ally across the gas flow in the jet and the effluent of the plasma discharge exists the tube; this is
used in the COST jet, which is often used as a reference microplasma jet. [34, 35] Some other jet
configurations are detailed in various plasma jet review articles. [36, 37]
Typically a plasma jet uses a pulsed DC waveform or an AC waveform. This is a necessity for
DBD jets, as no current would flow across the dielectric barrier in DC operation. Other plasma jets
can operate in DC; however they often require either higher voltages or currents for operation and
are thus difficult to operate in a low temperature plasma mode.
The plasma is not continuous, rather it comes in ionization waves termed plasma bullets.
Though this may seem obvious for a pulsed DC operation, this also holds true for AC excita-
tion. Often only one plasma bullet occurs per cycle or half-cycle of the AC excitation source;
however it can happen multiple times per cycle. [29] They are easily noted in current traces, as
each plasma bullet corresponds to a current spike. The plasma bullet travels on the order of 106–
107 cm/s depending upon the excitation voltage, although the current draw continues long after the
bullet has traversed the gap. [38]
Plasma jets are a very commonly used source of low temperature plasma. This is because
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Figure 2.4: Schematic of Different Types of Plasma Jets
they have a lot of versatility. The high voltage is easily shielded either by a dielectric barrier or
a long distance to the substrate, allowing easier low temperature operation. This operation is also
substrate independent for many jets as the only effect of the plasma is in its effluent (such as the
non-floating electrode DBD jet, the direct plasma jet, and the plasma effluent jet in Figure 2.4). By
varying the distance between the jet and the substrate different chemistry is possible, such as using
a more direct plasma contact or large distances with only long-lived species being able to reach the
substrate. In addition, the gas can be varied yielding a wide variety of possible treatments. Noble
gases can be used for easier operation (e.g. lower operating powers [39]). They also provide a
wider variety of chemistry, in particular helium with extremely high electronic excitation energies.
Lastly, the ability to have an admixture of different gases or various precursors in the gas stream
while still being able to run in ambient air allows for nearly unlimited possibilities for plasma jets.
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Figure 2.5: Basic Energy Flow Diagram in a Low Temperature Plasma
2.2.2 Energy In a Plasma
To get a general understanding of how a plasma works, it’s useful to understand where the en-
ergy goes. Initially with a voltage applied across a gas gap, the energy is stored in the electric field.
Any free electrons are accelerated by that electric field and as those electrons gain energy from the
electric field they begin a number of processes, imparting energy to the neutral gas, as shown in
Figure 2.5. In general, at low energies (a small electric field for the number of particles) electrons
impart energy to vibrational modes of the gas, which then spread to rotational and translational
modes in the gas via collisions. As the electrons gain more energy, they begin to electronically
excite the gas, and at higher energies they begin to ionize the gas.
The gas molecules (atoms for atomic gases like helium) are also moving around and colliding
with each other. In these collisions they exchange energy. The average translational kinetic energy
of the gas particles corresponds with the temperature of the gas that we feel (where more kinetic
energy means a warmer gas). Energy can also be stored in other modes that just the translational
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Figure 2.6: Schematics of the Various Energy Modes for Atoms and Molecules in a Plasma
motion of the gas molecules, as shown in Figure 2.6. They can rotate, vibrate (where the bond
between the two nitrogen or oxygen atoms acts like a spring), or undergo electronic excitation
(which also occurs for atomic species). Rotational energy couples very well with translational
energy; this means that when two molecules collide energy moves easily between translational and
rotational modes. Since these collisions happen often (due to the high density of gas molecules),
it usually takes less than a nanosecond for the rotational temperature (the average energy stored
in rotational energy modes) to equilibrate with translational temperature. The vibrational energy
modes take longer to equilibrate than the rotational and translational modes. This can be measured
using spectroscopy.
The concept of temperature only applies in equilibrium. This is when the energy is distributed
according to a Maxwellian distribution, as will be discussed in more detail in Section 2.2.2.3.
However, there can be a pseudo-equilibrium within an energy mode, which is often approximately
true for many low temperature plasma systems. Temperature is a measure of the spread of the
distribution of the energy present in the system, in this case the energy mode. As the temperature
increases, there are more particles that have a higher energy.
The energy in the vibrational modes can be normally distributed, but at a substantially higher
temperature than the energy in the rotational modes. However, within each mode, there can exist an
equilibrium in the energy distribution. This is then by definition a non-equilibrium plasma, because
the various modes do not have the same temperature. For low temperature plasmas discussed in
21
this dissertation, the temperature (energy) distribution among the various modes is
T e > T elex > T vib > T rot ≈ T trans = Tgas (2.1)
where the free electrons have the most energy due to their small mass but charge leading them
to be excited by the electric field. The electrons excite the gas electronically and vibrationally
via collisions, hence elevating those temperatures by imparting energy into those energy modes.
The energy slowly spreads to rotational modes via collisions, which quickly equilibriate with the
translational energy modes of the gas. The translational temperature is the gas temperature that
one feels.
2.2.2.1 “Hot” Versus “Cold” Plasma
The definition of cold atmospheric plasma (CAP) generally given in the literature is that the
plasma temperature does not exceed 40◦C at the point of application to the substrate. [40, 41]
However, the concept of a plasma being “hot” or “cold” is really a misnomer. This is a term applied
only to the observable gas temperature, namely the translational temperature. However, there can
still be a substantial amount of energy in other energy modes, yielding quite hot temperatures for
those modes, often even over 10,000 K! In particular, the average energy of the electrons can be
quite high. Nevertheless, the “cold” plasmas are able to be used on temperature sensitive substrates,
such as human patients, without the gas feeling “hot”. This often has more to do with the thermal
load of the plasma than its temperature.
For a proper definition of CAP, one needs to consider at least three aspects of the system:
• Translational temperature, which is a measure of the average speed of the gas particles and
thus the rate of energy transfer to the substrate. This rate would be expressed by Newton’s
Law of Cooling and has the potential to change drastically if the substrate changes tempera-
ture (such as using cryogenic cooling, but this is not expected in a medical situation) or the
discharge changes modes (see Section 5.5.1, for example).
• Thermal load, which measures the amount of heat traveling into the substrate, taking into
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account the heat capacity of the plasma and the substrate. Since many cold plasma treatments
are using a weakly ionized plasma jet, the thermal mass of the plasma is quite small, often
leading to a small thermal load. In addition, the substrate for medical treatments has a large
water content and thus has a very large heat capacity and thermal mass compared to the
plasma.
• Duty cycle, which is the amount of time the plasma is “on”. Most cold plasma systems are
pulsed either directly or indirectly by using an AC excitation, and thus they can have a low
duty cycle, where the plasma is not “on” for a majority of the treatment time.
These aspects are not necessarily independent of each other. For example, the translational
temperature of the plasma may vary greatly over time, with a peak temperature significantly above
the 40◦C suggested temperature limit. However, if the duty cycle is low, the thermal load may
be small and the time-averaged (over many cycles) translational temperature may also be near the
ambient temperature due to thermal diffusion into the surrounding environment. It is also possible
to have what may be considered a “warm” plasma (>40◦C translational temperature, thus not a
“cold” plasma per the literature definition), but the substrate temperature does not increase greatly
due to a high heat capacity or effective cooling system. This should however be considered a “cold”
plasma since it is not heating the substrate, even though it does not meet the literature definition of
a “cold” plasma.
Thus a better definition for CAP may be: “The interaction of the plasma does not cause the
treated material (typically a substrate, but can be the bulk gas in applications without a substrate)
to exceed a local temperature rise of >5◦C.” This does not deal directly with the the plasma but
rather with its interaction with the substrate, thus accounting for the thermal load. This is also
easily measurable using a temperature sensor on the substrate or a thermal imaging system and is
expected to be time-averaged over the interaction time of the plasma, thus also accounting for the
duty cycle of the plasma treatment. The main issue with this definition, which also plagues the
literature definition, is that the temperature or temperature rise is an arbitrary value.
The difference between a “hot” plasma and a “cold” plasma is illustrated in Figure 2.7, where
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“Hot” Plasma Mode “Cold” Plasma Mode
Figure 2.7: Infrared Images of a Plasma Discharge Operating in a “Hot” Mode and a “Cold” Mode
(Note the Temperature Scale Bar Has Units of Celsius, ◦C)
a significant rise in temperature is noted due to the interaction with the “hot” plasma, but this is not
noted with the “cold” plasma. The plasma source in this figure is the Bovie power supply, where
the “hot” and “cold” plasma conditions roughly correspond to the diffuse and concentrated modes
discussed in Section 5.5.1.
2.2.2.2 Plasma Collision Processes
One of the key ways to understand a plasma is to understand some of the basic collisional
processes that occur. Though many processes can occur only a few are highlighted below.
• Electron Impact Ionization is when an electron, e collides with a neutral gas species, A,
and imparts enough energy to remove another electron. This is one of the main ways that a
plasma is created. The electrons are accelerated by the electric field until they have enough
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energy to ionize the gas species. This produces more electrons which help sustain the dis-
charge.
e+ A→ 2e+ A+ (2.2)
• Electronic Excitation is when a gas species is excited but not ionized. A valence electron is
excited to a higher energy level, and a metastable state is created; after a certain amount of
time the electron will lose energy either via collision with another gas species or via photon
emission.
e+ A→ e+ A∗ (2.3)
• Photon Emission is when an excited gas species loses energy by emitting light. The pho-
ton energy, hν, corresponds to the decrease in energy of the gas species. This is the main
source of the light emitted by a plasma. Since the energy of the photons corresponds to elec-
tronic and other internal energy modes of the gas species this light can be collected and used
to characterize the plasma. This is called optical emission spectroscopy (see Section 3.4).
Information that can be determined from this light is the temperature of the rotational and
vibrational states (assuming there are molecular species in the gas) as well as the degree of
ionization of the gas.
A∗ → A+ hν (2.4)
• Photoionization is when a photon of light ionizes the gas species. The photon must have
at least enough energy as the ionization energy of the gas species. This process can become
significant when a gas with high electronic states (normally helium, He, or argon, Ar) is
introduced into the bulk gas.
A+ hν → e+ A+ (2.5)
• Penning Ionization is when a species with a high energy metastable state, M∗, collides with
a species with an ionization energy lower than the energy stored in the metastable state. This
can be a significant ionization mechanism for some species in a mixture. Helium is often
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the metastable species since it has extremely high electronic excitation energies often well
above the ionization energies of other gases.
M∗ + A→M + e+ A+ (2.6)
• Recombination is when an electron is captured by an ionized gas species. This is one way
that electrons are lost in a plasma. A third body, M , is usually needed to carry away the
excess energy from this recombination event to prevent the electron from immediately being
re-emitted.
e+ A+ +M → A+M∗ (2.7)
• Electron Capture is when an electron is captured by a neutral gas species. This usually only
occurs with electronegative gases, such as oxygen. As such, this is negligible in many gases,
such as noble gases and N2; however this process is significant for air. Like recombination,
often a third body is needed to carry away the excess energy to prevent the electron from
being re-emitted.
e+ A+M → A− +M∗ (2.8)
• Elastic Collision (Diffusion) is when there is no net energy loss in a collision; this is the
typical billiard ball collision. Often the particles travel in a different direction. This can
lead to electrons diffusing out of the discharge and is one of the main loss mechanisms of
electrons for plasmas.
e+ A→ e+ A (2.9)
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2.2.2.3 Energy Distribution Function
Each of the reactions in Section 2.2.2.2 has an associated rate constant, ki that describes the










where σi(E) is the energy-dependent cross section (a measure of probability in units of area), m is
the mass of the species, and f(E) is the distribution function. This is often highly dependent on the
energy of the species (often electrons), thus knowing the distribution of the species in energy space
becomes critical to understanding a plasma’s behavior. One of the main distribution functions
is a Maxwell–Boltzmann distribution function (also commonly called a Maxwellian distribution)










where f(E) is the energy distribution function, the initial term is a normalization term (total area
under f is 1), E is the species’s energy, kB is the Boltzmann constant, and T is the temperature.
Only a single parameter, the temperature (T ), determines this distribution. The Maxwellian distri-
bution function describes equilibrium, which is rarely completely true for the electrons, but may
be a reasonable approximation for heavier species in a plasma; nevertheless they are often tend-
ing towards this type of distribution. This is technically the only way temperature is defined; if
the distribution of particles does not fit an equilibrium distribution, then the temperature of those
particles is not defined.
Particularly for electrons, the electron energy distribution function (EEDF) can become skewed.
This often occurs due to a depopulating effect particularly for higher energy electrons. This is
because many processes, such as ionization, have an energy threshold upon which the process sud-
denly becomes dominant (based on the reaction cross section, σi, which is a component of the rate
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Figure 2.8: Plot of the Maxwell–Boltzmann (Maxwellian) Distribution Function for Multiple Tem-
peratures on Both a Linear and Logarithmic Scale
coefficient, ki). As such, it is often easier to plot the EEDF on a semi-log plot (see Figure 2.8),
upon which any nonlinearity is easily visible, because the exponential portion of the distribution
function dominates at higher energies (i.e. it is linear on a semi-log plot). For comparison, a sim-
ple exponential curve (blue line) is also plotted in Figure 2.8. Often other types of distributions
are used instead of a Maxwellian, such as the Druyvesteyn distribution or other more generalized
distributions, to adequately model the EEDF. These distributions better capture the physics for the
high energy tail in the EEDF. Only a small fraction of the electrons need to have sufficient energy
for ionization to sustain a plasma, while the other electrons may participate in electronic excitation
reactions, which leads to the the characteristic light emission of a plasma. [42, 43]
For other species, the distribution function can deviate from equilibrium due to an unbalanced
energy input, where some input is preferentially exciting only certain states, such as a laser tuned
to specific energy transition. This can also occur as the energy input rate, such as from electron
impact processes, does not have time to equilibrate in the system, especially compared to energy
outflow rates. However, though the energy may not be in equilibrium between various internal
28
energy modes, internally to each energy mode there may be at least a quasi-equilibrium. This is
especially useful, since this can be probed spectroscopically to determine not only the degree of
non-equilibrium, but also the distribution function, which yields the temperature of the various
energy modes. However, the translational energy cannot be determined due to not being able to
resolve the various translational lines.
2.2.3 Effect of Plasma on Materials
The effect a plasma has on a substrate can be quite diverse. This section will break those effects
apart into three different aspects of the plasma, namely the electric field, the ultraviolet (UV) light
generated, and the radical species created, and each will be discussed separately. For the potential
medical applications of these effects, see Section 2.5.1.
2.2.3.1 Electric Field Influence
A plasma is generated from a high electric field such that the normally conducting air or other
gas has broken down and has become conducting. If the substrate is sensitive to changes in the
electric field, substantial changes can occur. One such example is electroporation of cells which is
discussed in Chapter 4. Another example is the effect of electric fields on piezoelectric materials,
where a change in the voltage across the material creates a physical change in the material. This
occurs because the electric field causes a change in the unit cell of the crystal, in an effect called
polarizability. [44] This effect has been explored in the plasma field. [45–48]
The applied electric field can also cause charges in the substrate to move. This movement can
be dissipated in the form of heat in the substrate. If the substrate is a dielectric, the dipole moment
of the molecules can reorient themselves to the applied electric field rather than having bulk charge
movement. If the field is oscillating fast enough this causes substantial heating, which occurs in
microwave ovens. This effect was also explored to heat additively manufactured parts. [49] If the
substrate is conducting, this heating effect is called Joule heating, which is exploited in Section 7.5
for additively manufactured parts. This is also one of the main drivers for the gaseous heating
occurring in plasma discharges.
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2.2.3.2 UV Light Emission
Plasmas are the most common UV generating source for UV lamps. Direct UV light is a com-
mon bactericide. [50] This is a common sterilization technique that can be used with a plasma
system, either as the main use or as a beneficial aspect apart from its primary goal, such as wound
healing (see Section 2.5.1 for more information on the biomedical uses of plasma). UV light
can also induce polymerization in polymers; this is called photopolymerization or photocrosslink-
ing. [51] This was the first type of additive manufacturing developed, where a UV laser polymerizes
a liquid monomer. [52] However, research in this area is still ongoing to explore the various types
of materials that can be used. [53] Photopolymerization occurs by UV light imparting enough en-
ergy to create a radical species that will participate in polymerizing reactions. This radical species
can be a metastable state, an ionic species (i.e. created via photoionization), or a radical created
from the UV light breaking a bond. [54] When degradation of a material occurs due to UV expo-
sure, this is called photodegradation; this is commonly seen in color degradation of materials left
outside to sun exposure.
2.2.3.3 Radical Species Generation
Plasma can also generate a huge variety of radical species that can interact with a substrate.
Particularly for air discharges these are often called reactive oxygen and nitrogen species (RONS).
These species can interact and bond with surfaces (as noted in XPS results in [17]). Many of
these species have biological significance as well, leading to enhanced sterilization, [5, 55, 56]
immunoresponse, [57] etc., which will also be discussed further in Section 2.5.1.
Plasma-generated species are also used for surface modification. These can be various depo-
sitions from plasma enhanced chemical vapor deposition, where a film is deposited on various
substrates. [58, 59] Everything from polymers [30] to metals [14] to dielectrics [60, 61] can be
deposited. Etching of surfaces is common with low pressure discharges, particularly in microchip
fabrication, [1] although it has also been noted with atmospheric pressure plasmas. [62] Surface
functionalization is another application, where a surface can be treated to increase wettability for
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later processing. [62, 63] This is especially common using corona discharges and DBDs. [64, 65]
2.3 The Design Life-Cycle
The design life-cycle is a concept to look at the entire design process from the initial idea
generation to the end-of-life of the product. [66] In particular for medical products, the design
life-cycle is shown in Figure 2.9. The design begins with an idea, often from identifying a need.
Initial exploratory studies are conducted to examine what possible device could meet the identi-
fied need. This is the current status of most of the devices discussed herein; only the FlashFuse
system has been carried forward to a market launch. In addition, market research is conducted to
determine if there is a sufficiently sized market for a device to meet this need. Ultimately a more
formal feasibility assessment is conducted to determine if this idea deserves full consideration to
carry forward into developing a device. If there is a sufficient market need with enough scientific
knowledge to produce a suitable device to meet the need, a formal needs statement is developed.
The needs listed in the needs statement have to be well defined such that a device can be tested
against them. A prototype device is generated that attempts to meet these needs. The design is
iterated on and tested, making sure the device is verified to act as intended. In this process, there
may be many design review steps until a “final” design is created. This “final” design must pass
validation against the needs to ensure it adequately meets the intended use. [67] The US Food and
Drug Administration (FDA) has the ability to regulate the device controls; thus the developer must
ensure that the device development starting with the needs statement is properly documented in
the design history file.
After a “final” device design has been settled upon, testing is conducted for confirmation of the
design to support a marketing submission to the FDA (see Section 2.4.1 for the various considera-
tions with approaching the FDA). If the device fails at any point in this process it can go back to the
development stage to produce a new “final” device design. Device testing is conducted to ensure
that good laboratory practice (GLP) is followed, making sure everything is properly documented
and all controls are followed. Bench top testing usually leads to animal testing in support of ulti-












































Figure 2.9: Basic Schematic of the Design Life-Cycle for a Medical Device
a success and enough data is acquired to prove the safety and efficacy of the device, a submission
to the FDA can be made so that the device can be marketed.
Upon acceptance by the FDA, the device can be marketed. The device can be put into produc-
tion and distributed to end users. There should be continual monitoring of the device in the form
of post-market studies, to ensure that no issues may occur once the device is used on a broader
population. Further, good manufacturing practice (GMP) should be followed to ensure a quality
device is being produced. Lastly, the end-of-life for the device should be considered, such as final
disposal or possible recycling of the device.
The following subsections provide more detail on some aspects of the design life-cycle. The
next subsection examines the various types of testing a device will undergo. Other considerations,
such as designing a quality system, are then discussed. For specifics on the marketing approval
aspects, including further information on the FDA, see the next section, Section 2.4.
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2.3.1 Testing Considerations
Testing is crucial to device development, as this is the way to both verify a device is acting as
desired as well as validate the device that it meets the need it was created to meet. Testing results
are also required as part of any marketing submission to the FDA. Thus testing ensures both the
manufacturer and the FDA that the device is safe and effective for its intended use. There are three
main tiers of testing: bench top testing, animal testing, and clinical testing. These will each be
addressed in the following subsections.
2.3.1.1 Bench Top Testing
Bench top testing in an informal term used to refer to preclinical studies, often even before
animal studies are conducted. This can include all testing from initial idea experimentation to pre-
GCP studies. These can generally be broken down into prototype testing and pre-GLP validation
studies.
Prototype testing is testing done to experiment on the design of a medical device and can
include anything from testing in one’s garage to large-scale tests to verify and validate a design.
The goal of this type of testing is to iterate on the design to achieve a final design that can be
consistently and reliably manufactured as well as doing as much as possible to verify that the
design meets all of the design criteria. These types of studies are not regulated, thus the FDA is
not concerned with them and no records need to be kept from the regulatory standpoint. This is the
scope of all testing done in this dissertation.
The next phase of bench top testing is when regulation begins. This is known as pre-GLP test-
ing, where the device design should be stable. Any changes deemed necessary to the design may
lead one back to conducting more prototype testing. Pre-GLP testing includes final verification of
design aspects as well as holistic design verification. This testing generally supports a submission
to an institutional animal care and use committee (IACUC) for subsequent animal testing. In rare
cases this may be sufficient for an FDA submission, almost certainly only for a 510(k) submission




It is often unethical to test a new device directly on a human subject due to the unknown risks
associated with the device. Instead, testing is often done first on animals. This can also serve a
two-fold purpose, possibly helping the device to be used for veterinary use as an alternative market
as well as establishing the safety and efficacy of the device on an animal model before running
clinical trials.
All testing done with animals involves getting approval from an institutional animal care and
use committee (IACUC). The IACUC will review the study protocol to ensure that it is done in
the most ethical and humane manner possible. In particular, the protocol is examined with respect
to what is known as the four R’s: replacement, reduction, refinement, and re-use. Replacement
is to determine if the animal can be replaced with a lower class of animal, such as swapping a
vertebrate out for an invertebrate. Reduction is to determine if a statistically significant result can
still be obtained using fewer animals. Refinement is to determine if the protocol can be changed to
ensure humane treatment of animals while still meeting the endpoints of the study, such as using a
different analgesic, rather than not treating the animal for pain. Re-use is to determine if an animal
can be used for multiple parts of a study or multiple studies, such as serving as its own control
or even rarely using the same animal in multiple studies that have non-conflicting endpoints. In
general, animal studies are to support later clinical studies, rather than being sufficient alone for an
FDA submission. This is because an animal is not a perfect analog to a human; what works for an
animal may not work for a human.
2.3.1.3 Clinical Testing
Clinical testing is highly regulated due to a number of abuses over the years, from unethi-
cal treatment and experimentation during the Nazi regime in Germany (leading to the Nuremberg
Code) to the often cited Tuskegee syphilis study in the US, where patients were not adequately in-
formed of alternative treatments among other abuses. [68] Now the process is wrapped up in what
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is called good clinical practice (GCP). GCP includes following a protocol approved by an insti-
tutional review board (IRB), getting freely given informed consent, following a study monitoring
plan, and properly documenting all aspects of the study. [69] Some of the details here pertain solely
to the US, but similar rules are in effect in other countries.
An IRB is an independent body that acts to protect the rights, safety, and well-being of human
subjects. They have the power to approve, require modification or disapprove research. They are
composed of at least 5 members with diverse backgrounds.
Informed consent is the permission of the study participant. It generally takes physical form in a
document that must be provided to study subjects informing them about the study, what treatments
will be provided, and any and all risks associated with the treatment. Alternative treatments that
they can seek must also be disclosed. The study participants must have adequate time to consider
if they want to join the study, understand the informed consent document, and cannot be coerced
in their decision about joining the study. Further, the informed consent document must explain
that the study participants are not waiving any of their rights by joining the study, nor are the
study providers released from any liability. Study participants are allowed to revoke their informed
consent at any time during the study. Lastly, a point of contact must be provided if they have any
questions or concerns in regards to the study.
To be able to use an unapproved device for a clinical study, the manufacturer has to have
permission, in this case via an investigational device exception (IDE) from the FDA. However, if
an IRB approves the device as not posing a significant risk an IDE is not required. Some devices are
IDE exempt; if they are noninvasive, do not have a high risk sampling procedure, do not introduce
energy into the patient, and are not a sole diagnostic for a condition. To file an IDE, a manufacturer
should follow design controls, have IRB approval, and properly label the device as unapproved;
they are exempt from most other regulations, since the device is not approved yet. However they
must monitor the study and ensure all records are kept in case they are audited by the FDA. The
FDA evaluates an IDE within 30 days (or it is assumed approved).
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2.3.2 Quality System
A quality system, also known as a quality management system, is concerned with ensuring that
the quality of the product (a medical device in this case) does not degrade. This is encompassed in
ensuring that good manufacturing practices (GMP) are followed, as well as good laboratory prac-
tice (GLP) and good clinical practice (GCP) are followed during testing of the device. This system
ensures design controls are followed, corrective and preventative actions are taken appropriately,
the production is properly followed, and everything is properly documented in case an audit oc-
curs. The end goal of this system is to ensure that the device being manufactured is the same as
the device that was approved by the FDA. Though a quality system is not necessarily part of the
device development, it must be in place before the device can be marketed, and many aspects are
also needed during device testing. Quality systems are enforced by the FDA in the code of federal
regulations (CFR) under 21 CFR 820; the European counterpart is ISO 13485, as a medical device
specific standard rather than solely relying on ISO 9001, the general quality management system’s
standard. [70]
2.3.2.1 Good Manufacturing Practices (GMP)
Good manufacturing practices form a system to ensure that the manufacturing process are
producing a consistent product. They are to prevent any adulteration in the product; these could be
in the form of small deviations in manufacturing equipment adding up to large changes in the end
product or even poor hygiene contaminating an otherwise sterile product.
Good manufacturing practice is especially important with additively manufactured parts. Specif-
ically “AM may introduce variability into the manufacturing process that would not be present
when using other manufacturing techniques.” [71] Special considerations are given to the entire
workflow process for AM parts. This includes the design aspect of the device (such as defining tol-
erance ranges for parts or ensuring the imaging technique used to match a AM device to a patient),
the materials used, the build process (how the part is printed), post-processing on a part (such as
how a surface finish is applied), and final testing done on the device (to ensure no defects or de-
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ficiencies exist in the final part). These are challenging especially with patient-matched devices
(PMD), that is devices custom designed for an individual patient.
2.3.2.2 Design History File
A file is created for every design even at the research stage that continues into manufacturing,
called the design history file. This contains all aspects of the device’s design and any changes
that have been made to it. Specifically the manufacturer’s design history file contains “the records
necessary to demonstrate that the design was developed in accordance with the approved design
plan and the requirements of this part.” [70]
2.3.3 Business & Financial Considerations
It would be remiss to not at least briefly mention the business and financial considerations that
go into the device design. The technical side would not exist if the needed financial capital was not
being supplied. Often device development is done in small companies, thus venture capital is one
of the primary funding mechanisms. In addition protecting the intellectual property of the device
is important, usually done through patents.
The primary influence of the business side on the specific design is do decide whether a design
will be pursued at all. A useful device without a market will not be developed; there must be a
reasonable return on investment to get any device created. Business strategy also becomes involved
in determining what sort of approval pathway to use. By selecting a more difficult pathway (e.g.
a PMA over a De Novo request, see Section 2.4.1 for details), a precedent is set that can serve as
a large barrier to entry for other companies, effectively blocking them from the market. However
this means a much harder approval process that requires substantially more time and funding to
accomplish, which may be too much for some companies. Without having a patent on the idea,
any other company can manufacture the same device, thus there is no protection of the intellectual
property. Many investors will not consider a venture unless they are certain there are protections
on the intellectual property of the device being developed.
37
2.4 Medical Device Approval
Creation of a medical device is not sufficient. The device also needs to be marketed to have
any significant impact on the health of the community. Different countries approach the process of
device regulation in a variety of ways. This dissertation will primarily focus on the US; however
there are currently devices being marketed in Europe, which serve as useful examples of how to
approach device design.
2.4.1 The Food and Drug Administration (FDA)
The United States Food and Drug Administration (FDA) “is responsible for protecting the pub-
lic health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological
products, and medical devices; and by ensuring the safety of our nation’s food supply, cosmetics,
and products that emit radiation... FDA is responsible for advancing the public health by helping
to speed innovations that make medical products more effective, safer, and more affordable and by
helping the public get the accurate, science-based information they need to use medical products
and foods to maintain and improve their health.” [72] Thus all medical devices must have either
FDA clearance or approval in order to be sold as such.
The FDA was established in 1930 in response to the growing concern of unsafe products on the
market in the US.3 It’s authority and scope have grown since, starting with the 1938 Federal Food,
Drug, and Cosmetic Act (FFDCA). It grew to cover responsible device manufacturing (added in
1976 as the Medical Device Amendment to the FFDCA), including the design for devices (added
in 1990 under the Safe Medical Device Act).
The FDA classifies a medical device as “an instrument, apparatus, implement, machine, con-
trivance, implant, in vitro reagent, or other similar or related article, including any component,
part, or accessory, which is
1. recognized in the official National Formulary, or the United States Pharmacopeia, or any
supplement to them,
3The duties of the FDA, however, have existed under control of a differently named regulatory body since at least
1906 with the passage of the Pure Food and Drugs Act.
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2. intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation,
treatment, or prevention of disease, in man or other animals, or
3. intended to affect the structure or any function of the body of man or other animals, and
which does not achieve its primary intended purposes through chemical action within or on the
body of man or other animals and which is not dependent upon being metabolized for the achieve-
ment of its primary intended purposes.” [73] A device stands in contrast to a drug (chemical action)
and a biologic.
Devices are classified as Class I, Class II, or Class III devices, where higher classes receive
more scrutiny and restrictions. All previously approved devices have a product classification in the
FDA regulations that can be consulted, which lists the device class and approval method. Espe-
cially for new devices, the manufacturer should first undergo a risk assessment of their device to
determine the appropriate classification before approaching the FDA. In general any CAP device
will most likely be a Class II device, since this class requires special controls to ensure safety but
is not a high risk (e.g. life-sustaining) device. These special controls can be as simple as including
special labeling (e.g. high voltage warnings) or as complex as following a performance standard
established by some regulating body (such IEEE, ASME, etc.). [74] Since nearly any CAP device
will require high voltage to operate, there will be some form of special controls required to ensure
safety. These special controls are beyond the nine general controls for devices (not adulterating
the product, not misbranding, registering and listing the device, following the relevant premar-
ket notification, not marketing a banned device, notifying of device changes, keeping all relevant
records and reports, restricting the use of the device as needed, and following good manufacturing
practices). [75]
There are three main pathways for approaching the FDA with a medical device: premarket
approval (PMA), 510(k) clearance, and a De Novo request. These will be discussed in some
detail in the next subsections, along with other lesser known mechanisms for device marketing
and related considerations. The basic process for classifying these devices and determining the
appropriate pathway is shown in Figure 2.10.
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Figure 2.10: Basic Flowchart for Approaching the FDA with a Medical Device
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2.4.1.1 Premarket Approval (PMA)
The FDA only approves devices that go through the premarket approval (PMA) pathway, which
is the default pathway for a device. A PMA4 is required for nearly all Class III devices. If a
device does not have a class because it is a new device it is automatically assigned a Class III
designation. “PMA approval is based on a determination by FDA that the PMA contains sufficient
valid scientific evidence to assure that the device is safe and effective for its intended use(s).” [76]
Since the PMA must prove the device is safe and effective it often requires years of clinical trials
to support this, making this a very time-consuming and expensive process. It does not help that a
PMA submission to the FDA carries a price tag of $340,995. [77] Average development costs to
the manufacturer though are substantially higher, averaging $94 million. [78]
An older version of the FDA’s PMA website [76] also mentioned that “an approved PMA is, in
effect, a private license granting the applicant (or owner) permission to market the device.” This
is one advantage of a PMA for a company—it is a large barrier to entry for any competitors, since
they must also go through this approval pathway for their device. A competitor’s only alternative is
to petition the FDA to reclassify the device into a lower risk class (via a process called 513(e) from
its location in the act establishing the FDA), which can take up to years to finally get approved
though the system. However, this can also have the unintended side effect for devices that are later
deemed “safe” (via the 513(e) process) and do not warrant this approval pathway. The company
that initially went through the effort to get the device approved opened the door for other companies
to use a 510(k) clearance for their devices, greatly reducing a competitor’s barrier to entry in the
market. As a result the FDA may have unintentionally stifled innovation for new “safe” medical
devices until creating the De Novo pathway.
4Though technically the term PMA refers to the final granting of approval by the FDA, this term is applied to the
submission and process, as well. It is often done without regard to the meaning of the acronym, too.
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2.4.1.2 510(k)
Under the 510(k) pathway5, also called a premarket notification, a device is not approved,
rather it is cleared by the FDA. This is because the device is compared to an existing device called
the predicate device. The device must demonstrate substantial equivalence to the existing device.
To be substantially equivalent the new device must have:
1. The same intended use as the predicate and
2a. The same technological characteristics of the predicate or
2b. Different technological characteristics that do not raise new questions of safety and effec-
tiveness as well as being at least as safe and effective as the predicate device. [79]
This is often used for small modifications to an existing device. As such, it is the least difficult
pathway, with the smallest submission cost (only $11,594 [77]) and the shortest review time of 90
days. Nevertheless, the total development costs average $31 million. [78]
Generally 510(k) clearances are for Class I or Class II devices; however, rarely Class III de-
vices that have been grandfathered into the regulations (i.e. existed before these regulations were
implemented) and have not been reassigned into a lower class or explicitly required to use a PMA
pathway can also use this pathway for marketing approval. This is not necessarily a straightfor-
ward pathway as no CAP device is currently on the market for use as a predicate device; thus any
predicate device will have different technological characteristics of the predicate device. Care must
then be taken to ensure the most appropriate predicate is chosen and sufficient testing is done to
show there are no new questions on the safety or efficacy of the device.
2.4.1.3 De Novo
Since a PMA is a very burdensome pathway for a new device without a predicate, a third
pathway was introduced and is becoming more popular called the De Novo pathway. When it was
first introduced, it was only a viable option after a 510(k) submission was rejected as not being
5This pathway is named from section 510(k) of the Food, Drug, and Cosmetic Act.
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substantially equivalent. It was only later created as a new option as a direct De Novo request for
a new device. However, in so doing, the price has increased to $102,299. [77] An older version
of the FDA’s website [80] read “The de novo process provides a pathway to classify a low to
moderate risk device for which general controls or general and special controls provide reasonable
assurance of safety and effectiveness, but for which there is no legally marketed predicate device.
De novo is a risk-based and evidence-based classification process. Devices that are classified into
Class I or Class II through the de novo process may be marketed and used as predicates for future
premarket notification [510(k)] submissions.”6 The De Novo pathway serves as an intermediate
pathway between the PMA and 510(k) for devices that have no predicate, making it a viable option
for many CAP systems.
2.4.1.4 510(k) Exempt Devices
Some devices pose a low enough risk they do not require a 510(k) for marketing. [81] These
are generally Class I devices, but a few Class II devices (i.e. low risk devices that still require
special controls) are considered low enough risk to not require a 510(k), such as mercury ther-
mometers. [82] Due to the possible shock hazard with any plasma device, it will never be deemed
a 510(k) exempt device; however, it may assist in creating medical devices that are 510(k) exempt
devices, such as prosthetics, [83] as discussed in Chapter 7.
2.4.1.5 Humanitarian Device Exception
Certain conditions are rare, defined as affecting under 8,000 people per year. For these cases, a
humanitarian device exception (HDE) can be made that has to only show that it is safe at treating
the condition, rather than the safe and effective requirement for a PMA. [84] The device will then be
designated as a humanitarian use device (HUD). This is done so that device developers can create
and market devices to treat these rare conditions without having to go through the same rigorous
testing of a PMA. This would be especially difficult in patient recruitment for clinical studies. This
is often used to get a device to market quicker for a condition that has a subset condition that affects
6In more recent publications the FDA has decided to capitalize the words De Novo, which is how this dissertation
will treat the term.
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fewer people. This allows a company to market a device, as well as collecting some useful clinical
data, and begin making a small profit before expanding to a wider condition. This may be a useful
strategy for certain conditions that a CAP could treat, such as certain types of wounds that cannot
be treated by conventional methods.
2.4.1.6 Custom Device Exception
The custom device exemption allows only 5 units per year to be manufactured and is thus not
a viable option for marketing a device. [85] Instead it is useful for devices that will only rarely be
needed, such as changing the size of a device to accommodate a patient who is greatly different
in size than the average population. Unless there is a medical use found for a CAP device that
affects such a small population, this is generally not worth pursuing. Note that a device that is
additively manufactured to meet the custom needs of a patient would not be considered under this
exemption. [71]
2.4.1.7 Combination Products
A “combination product [is]
• A product comprised of two or more regulated components, i.e. drug/device, biologic/device,
drug/biologic, or drug/device/biologic, that are physically, chemically, or otherwise com-
bined or mixed and produced as a single entity (a ’single entity’ combination product, such
as a prefilled syringe or drug-eluting stent);
• Two or more separate products packaged together in a single package or as a unit and com-
prised of drug and device products, device and biological products, or biological and drug
products (a ‘co-packaged’ combination product, such as a surgical or first-aid kit containing
bandages and an antiseptic drug);
• A drug, device, or biological product packaged separately that according to its investiga-
tional plan or proposed labeling is intended for use only with an approved, individually
specified drug, device, or biological product where both are required to achieve the intended
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use, indication, or effect and where upon approval of the proposed product the labeling of the
approved product would need to be changed (e.g., to reflect a change in intended use, dosage
form, strength, route of administration, or significant change in dose) (a ‘cross-labeled’ com-
bination product, as might be the case for a light-emitting device and a light-activated drug
indicated for use together for treatment of a dermatologic condition); or
• Any investigational drug, device, or biological product packaged separately that according to
its proposed labeling is for use only with another individually specified investigational drug,
device, or biological product where both are required to achieve the intended use, indication,
or effect (also a ‘cross-labeled’ combination product)
A combination product is assigned to an Agency Center that will have primary jurisdiction (i.e.,
‘the lead’) for that combination product’s premarket review and regulation.” [86] As such, a com-
bination product may be approved via a drug or biologic pathway even though it is primarily a
device. Nevertheless, a combination product will go through the same rigorous treatment as if
it were both a device and drug/biologic separately. In addition, any issues with the combination
will also be evaluated. In general, a 510(k) clearance will only be given if the predicate is also a
combination device.
This approach may be significant for a number of devices considered here. Particularly, the
electroporation system considered in Chapter 4 would most likely be combined with a specific drug
for uptake, which would most likely be considered a device-drug combination product. This would
even be the case for an electrochemotherapy system involving a known and approved chemother-
apy drug, such as bleomycin.
2.4.1.8 Emergency Use Authorization (EUA)
This is not an approval pathway but warrants a brief mention as this is a means that a low
temperature device may be used in a clinical setting.7 In the event of an emergency declared by
7At the time of the writing of this dissertation the disease COVID-19 has become a worldwide pandemic. It is
conceivable that a plasma-based device could be used either directly for sterilization, indirectly for ozone generation
(which our lab is currently investigating as a fabric sterilization method), or some other means to help combat this
viral spread, hence the brief treatment in this dissertation.
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the Secretary of Homeland Security, Secretary of Defense, the Secretary of Health and Human
Services, or the Secretary of Homeland Security the FDA has the authority to allow unapproved
devices to be marketed to combat the emergency situation. The FDA does this by issuing an
emergency use authorization (EUA) for a specific device after evaluating it. The EUA will expire
either when the emergency ends, at which time the device can no longer be legally marketed,
or if the approval status of the device changes, such as a device receiving a PMA during the
emergency. [87]
For an EUA to be issued, the following criteria must be met:
1. A serious or life-threatening disease or condition exists,
2. There is evidence for effectiveness of the treatment,
3. The benefits outweigh the risks, and
4. There are no alternatives (at least that adequately meet the demand).
As such, when submitting a request for an EUA, a manufacturer should address at least the follow-
ing in the submission:
• Product description with intended use, explaining which emergency and need this product
will satisfy,
• Current FDA approval status (especially useful if extending the use of an already approved
product),
• The need for the product, noting any alternatives and the availability of those alternatives
(especially useful when alternatives exist but cannot meet the demand),8
• Safety and efficacy data on the product so that the FDA can evaluate the device,
8This occurred for the COVID-19 pandemic for personal protective equipment (PPE) and ventilators where the
demand was much higher than the supply of these products.
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• A risk-benefit discussion to determine if the known risks will outweigh the benefits of using
this device,
• Details on the chemistry, manufacturing (including location and quantity that can be pro-
duced), and controls of the device, and
• Any instructions for use and all appropriate labelling to determine if this is sufficient for
providers to understand and follow proper use of the device.
The FDA will do a review of the device, but it is not as thorough as a review done for an actual
submission (such as a 510(k), PMA, or De Novo). This is because the FDA is trying to quickly
get the device out to meet the emergency need; thus time is critical. A manufacturer can submit an
EUA even before an emergency occurs; this is called a pre-EUA. The FDA can conduct most of
the evaluation before the emergency occurs, allowing the EUA to be granted possibly within hours
of an actual emergency being declared.
2.4.2 Other Countries
The US is the largest single market for medical devices, but there are a number of other impor-
tant locations to consider. It can be advantageous for a company to approach multiple markets in
hopes of receiving faster approvals and having an income stream while approaching another mar-
ket. Often as well, studies can be conducted that will be used in multiple submissions for multiple
countries, thus greatly saving costs for the company.
The standard for Europe (specifically the European Economic Area, consisting of the Euro-
pean Union, Iceland, Liechtenstein, and Norway, as well as Switzerland, Turkey, and the United
Kingdom9) is the CE marking. [89] Each country has their own competent authority who ensures
the medical device directives developed in common between the various countries is included in
national law. The competent authorities designate notified bodies that act as third party assessors
of the manufacturer’s compliance will all relevant regulations.
9This includes the United Kingdom until at least January 1, 2021 pending any further changes as they fully transi-
tion out of the European Union (i.e. Brexit) [88]
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Manufacturers determine the class of their device, and ensure they follow all relevant regula-
tions, including developing a design dossier for the device as part of a quality management system
per ISO 13485 (standard developed by the International Organization for Standardization). All
relevant information is submitted to a notified body for certification before they can manufacture
the device. Upon certification by the notified body, the manufacturer may apply the CE marking
on their device, often with the number of the certifying notified body included. The manufacture,
however, must still register with the competent authority in the country they are marketing the de-
vice. Post-marketing surveillance and monitoring is conducted to monitor the safety and efficacy
of the device. [90,91] However, approval is often easier and quicker because the approval is based
on safety and performance, rather than safety and efficacy, which is required for the US FDA. [66]
Japan is the second largest medical device market in the world, yet a challenging market due to
language barriers in addition to a more rigorous approval system compared to some countries. [92]
Like many other systems, Japan uses a risk-based assessment of devices, separating high and low
risk devices. High risk devices require review by the Pharmaceutical Medical Devices Agency
(PMDA); while low risk devices can have third party certification. [92] Ultimately the Ministry of
Health, Labor, and Welfare (MHLW) has the final judgment in device approval. [93] Clinical trials
are required for new or improved medical devices, often required to take place in Japan. [94]
Though there are some differences, most countries’ approvals are done with a risk-based ap-
proach, allowing low risk devices to be approved easily, with more stringent requirements as the
risk of using the device increases. Focus is increasingly being placed on quality management
systems with standards such as ISO 13485, 21 CFR Part 820, or similar ones being developed
in various countries. Further harmonization is expected as countries attempt to adapt their local
policies to align with those of other countries. [95]
2.5 Low Temperature Plasma Medicine
Low temperature plasma medicine is a quickly growing field, with many publications that
could be reviewed. This section is divided into three subsections with limits placed on the in-
cluded sources to avoid this section from becoming too large. The first section deals with the
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potential medical uses for low temperature plasmas. Only studies with relevant clinical studies,
animal studies, or human cell lines are included. This excludes plasma sterilization of surfaces and
bacterial inactivation as well as many computational studies. The second section attempts to find
all devices that are currently marketed or are being developed for use as a marketed device. How-
ever, due to the ability for plasma devices to quickly be marketed in less-regulated countries, the
investigated devices are limited to those being developed in the US and those with a CE marking
or a number of journal articles for non-US devices. The third section examines the standards that
are being developed for these types of systems. The broad standards that apply to many types of
devices are briefly mentioned; the focus is given on the only plasma-specific standard, currently
issued in Germany.
2.5.1 Medical Uses of Low Temperature Plasmas
Though high temperature plasmas have been in use by the medical community since 1926
when the first electrosurgery took place, [4] cold plasmas for direct medical use (as opposed to
sterilization of equipment such as autoclaves) is a much more recent development. This began
with efforts to use atmospheric pressure plasma for sterilization of surfaces, which then led to in-
terest in wound sterilization; further effects were also discovered, such as enhancing phogocytosis
and inducing apoptosis. [5] This led to the creation of the field of plasma medicine, the common
name applied primarily to low temperature atmospheric pressure plasma use for medicinal effects.
Though high temperature plasmas, such as electrosurgical devices, and lower pressure plasmas,
such as some ethylene oxide sterilization units, can have medicinal benefits, they are generally not
included under the term “plasma medicine”. [96]
Plasmas have been noted to have a diverse number of effects including killing microorgan-
isms, inactivation of mammalian cells based on dose/time (senescence to apoptosis to necrosis),
stimulating microorganism metabolism, detaching cells from matrices, modifying cell migration,
changing cell surface proteins, stimulating cell proliferation and angiogenesis, and permeabilizing
cells. These diverse effects are achieved by the high electric fields that create radical species in the
plasma and are also achieved by the chemistry initiated by the plasma in the environment of the
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cell, which is often a liquid. [96, 97] As such, plasma-liquid interactions is also a growing field of
study that also has relevance in the plasma medicine community.
This section is divided into four subsections. The first subsection will explore the mechanisms
of plasma interaction with tissues. This forms the basis for the medical applications discussed in the
following subsections. Then the following two subsections discuss the two main low temperature
plasma applications: wound treatment and cancer treatment. A final subsection will discuss other
applications. Any relevant studies using a specific marketed plasma device will be discussed in the
next section rather than in the subsections below.
2.5.1.1 Plasma-Tissue Interaction Mechanisms
As previously discussed in Section 2.2.3, there are diverse effects of plasma on materials. The
influence of the electric field on tissues, the main effect being electroporation (also called cell
permeabilization), will be discussed in Section 4.2. Like other substrates, biological substrates can
also be heated by the dissipation of the currents caused by the electric fields. The gas temperature,
however, appears to only scale with average power for a plasma discharge. [98] However, the
discharge current can also pose a hazard for electrical shock [99] but are often kept near or below
the perception threshold for a patient and thus are far from risking loss of muscle control or shock.
This can also be minimized by using a different electrode configuration, such as a those with a
ground electrode that receives the majority of the current. [41]
UV light is often broken into three types based on wavelength: UVA (320–400 nm), UVB
(290–320 nm), and UVC (200–290 nm) with differing effects for the different ranges. UVA is
used by the body to regulate hormones. UVB can help with the synthesis of vitamin D. UVC can
cause oxidative damage to lipids, proteins, and DNA, particularly with thymine and cytosine in
DNA. [41] This is the main mechanism for UV sterilization. In general short term, low intensity
exposure is safe, but longer exposure accumulates the amount of damage that occurs until a cell no
longer becomes viable. However, since most plasma treatment uses low powers for short times, the
UV light generated by plasmas is assumed to have negligible biological effect; other mechanisms
dominate. [40] This has generally been proven true by insertion of a UV transparent medium
50
between the plasma and the substrate leading to know effect; however this also removes possible
synergistic reactions involving UV light with other plasma effects. [100]
The dominant mechanisms involved in plasma medicine are based on the radical species that
are generated, generally plasma generated radical gas species that are termed reactive oxygen and
nitrogen species (RONS). The reactive oxygen species include ozone (O3), hydrogen peroxide
(H2O2), superoxide (O2−), singlet oxygen (1∆g O2), and the hydroxyl radical (OH); reactive ni-
trogen species include nitric oxide (NO), nitrite (NO2−), and nitrate (NO2−). All of these radicals
participate in an extensive number of biochemical reactions, such as modifying proteins and lipids
and signaling molecules in immunoresponse mechanisms. [41, 57] However, these species may
not directly cause these diverse biochemical responses; rather they initiate a series of chemical
reactions that ultimately lead to these responses. These reactions predominantly take place in the
liquid medium that the cells are in making characterization difficult. [40, 96, 100]
Most studies have shown that low doses of plasma (typically defined as low power density,
∼1 J/cm2, and shorter treatments, ∼1 min, note that time of treatment is the most common way
to increase the dose) have beneficial effects on cells, such as inactivation of bacteria while not
affecting the human cells. Higher doses (∼5 J/cm2) can cause some more serious but potentially
beneficial effects, such as inducing apoptosis and repairable DNA damage, while some cases of
cell proliferation have also been observed. Even higher doses (∼10 J/cm2) can cause cell death and
necrosis. [40, 57, 97, 100] These are described in more detail in Section 2.5.1.3 However, similar
plasma sources can generate a wide range of species and other effects, leading to very different
treatment results, thus careful investigation of each device is required. [101] This can also be
exacerbated by small changes in setup, such as the well size or depth for cell treatments, affecting
the results due to complex plasma-substrate interactions. [102]
2.5.1.2 Wound Treatment
There are two main goals with wound treatment using plasmas. The first is to inactivate any
bacteria and possible biofilm that has built up in the wound preventing the body from healing
properly. This is viable because bacteria have been shown to have a lower tolerance for plasma
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treatment than human cells. [103] The second is to stimulate the body’s immune system and en-
courage cell proliferation to heal the wound. [40] The relevant research on these two topics is
discussed in this section. Clinical trials are discussed in Section 2.5.2, as nearly all of them have
been to support CE marking for one of the devices discussed in that section.
Perhaps the greatest asset for plasma wound treatment is in biofilms, which are often a chal-
lenge to disinfect using conventional methods. There is disagreement in the literature as to whether
gram-negative or gram-positive bacteria are more susceptible; this is most likely dependent upon
the plasma source used. [104, 105]
One of the earliest studies on directly treating skin with a plasma used a floating electrode
dielectric barrier discharge (FE-DBD), which used the skin as the second electrode in the circuit.
This showed that direct low temperature plasma treatment was possible on a live patient. [106] The
FE-DBD was shown to have skin damage (tested using live pig models) associated with dose rate
(frequency of the discharge), which increases the gas temperature, as well as dose (input power);
nevertheless, the damage to the skin occurs at a dose substantially larger than the dose that was
found to inactivate bacteria (<2 min at 0.17 W/cm2). [107, 108]
However, plasma treatment has been effective in faster healing rates than conventional treat-
ments. [104] The exact mechanisms are not understood but there are a number of theories. Ni-
tric oxide (NO) therapy is an FDA approved therapy for vasodilation. As plasmas can produce
NO some of the improved healing could be due to increased blood flow to the wounded re-
gion. [109] Growth factor proteins and genes can be stimulated, but the exact mechanism is not
understood. [110–112] Angiogenesis has also been noted as a result of plasma treatment. [97,113]
Further testing has been conducted on mice models using a different plasma source. Increased
blood flow and faster wound closure was noted over three weeks with mice having an argon jet
plasma treatment only on the initial day of the wound and even more for those with plasma treat-
ments for the first three days. No mention was given of possible bacterial infection on the wounds.
The authors imply the increased NO exposure from the plasma treatment is the mechanism but no
control with NO therapy was given. [114] Using a similar treatment with an argon plasma, another
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group also found improved healing over the course of 15 days for mice with plasma treatment. In
this case, a 1 min plasma treatment was given daily over the course of the experiment. They noted
higher amounts of growth factor hormones present in the mice with the plasma treatment. Though
no bacterial load was intentionally added in the treatment, it was monitored; a statistically lower
microbial load was only noted for days 3–7. [115]
Not every study has been completely positive. Using a plasma jet in a similar configuration as
the kINPen (Section 2.5.2.1) on corneal injury induced in rabbits, CAP had no effect on wound
healing. This was a small study with only 12 rabbits (5 in the treatment group) and the only study
treating corneal injury. It is unclear if the eye behaves differently from wound on other parts of
the body. Nevertheless, the treatment did not have any negative side effects; it simply yielded no
better results compared to the control. [116]
It is worth noting that the optimal conditions for bacterial inactivation and accelerated wound
healing may not be the same. For example, comparing the same plasma jet in a contact and non-
contact mode by changing the distance between the plasma jet and the treated substrate yielded
different results for bacterial inactivation and wound healing. [117] The contact mode was better
at inactivating bacteria than the non-contact mode. The non-contact mode was better at wound
healing; the contact mode was actually significantly worse than the control for wound healing,
having a visibly larger wound even after 14 days. Thus the plasma treatment needs to be tailored
for the specific treatment desired.
2.5.1.3 Cancer Treatment & Cell Death
Various amounts of plasma treatment can induce effects from senescence (stoppage of cell
growth) to apoptosis (programmed cell death or “cellular suicide” [118]) to necrosis (cell death not
undergoing a highly controlled programmed cell death). [96,119] In addition, plasma treatment can
stimulate the immune system possibly leading to induction of immunogenic cell death. [120] The
mechanism is perhaps similar to that described in the previous section (Section 2.5.1.2) for stim-
ulating the immune system for wound healing. The plasma treatment can also act synergistically
with other treatments, such as nanoparticles. [121, 122]
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The main advantage of plasma treatment is the selectivity of targeting and killing cancer cells
rather than healthy cells. It achieves this by “by interfering with the mitotic cell cycle and inducing
cell cycle arrest, DNA damage, and apoptosis via ATM [ataxia-telangiectasia mutated, a protein]
expression and phosphorylation of p53” among other possible mechanisms yet to be explored. [6]
For example, using a helium plasma jet for 90–120 s yielded at least 50% cell death for three
glioma (cancer) cell lines with negligible cell death for healthy endothelial cells. [123] This has
also been shown to kill a variety of types of cancer. [124]
In an attempt to determine the mechanism of cell death, a number of studies have been con-
ducted. Using a shroud (or shielding) gas flow of either N2 or air with an argon plasma jet, it was
shown that oxygen chemistry is the dominant factor in viability of human immune cells. This was
ascribed to H2O2, but further research is needed to adequately determine the mechanism. [125]
Quantifying the amount of H2O2, NO2−, and NO3− in a solution exposed to a helium plasma jet
allowed for comparison of the viability of human fibroblasts to the plasma and solutions of those
various chemicals. It was found that a synergistic combination of both H2O2 and NO2− yields com-
parable loss of viable cells. [126] Similar results were found with an argon plasma jet on human
glioma cells, where a synergistic effect of both H2O2 and NO2− were required to have substan-
tial cell death; however the corresponding amounts of those two species as those measured in the
plasma activated medium had a lower effect compared to the plasma, suggesting other effects are
also present to fully explain the loss of cell viability. In addition, healthy, non-cancerous mammary
epithelial cells remained viable despite the plasma treatment or H2O2 and NO2− addition, showing
good selectivity in the treatment for cancer cells. [127]
Using a nanosecond pulsed FE-DBD, it was shown that murine mesenchymal stem cells are
no longer viable after increasing the energy delivered to the cells (higher frequency with the same
energy per pulse, applied voltage, and treatment time). This same experiment was run attempting
to exclude other plasma aspects to determine the mechanism. Running in an oxygen atmosphere
yielded lower cell viability compared to air, while a nitrogen atmosphere showed no loss in cell
viability; this also supports the conclusion that radical oxygen species are a main contributor to
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cell death. Longer-lived species were exposed to the cells by using a copper mesh as a ground
electrode (i.e. no longer a FD-DBD system) which showed some loss in cell viability but not
as much as by using the FD-DBD for a more direct plasma treatment. The electric field (using
a stronger dielectric to avoid plasma formation) and UV light (using quartz glass to shield the
cells from the plasma) did not cause any loss in cell viability, although synergistic effects with
these may yield more significant effects. A final condition with a larger gap distance was used
to create a less uniform discharge with streamers present; lower cell viability was noted but most
conditions were not statistically significant from the uniform case, suggesting the plasma chemistry
is perhaps slightly more favorable in the streamers for creating the reactive species that resulted
in cell death. [128] These results also appear to be consistent with other results for a longer pulse
duration, which also measured the damage to DNA occurring as a result of direct plasma treatment
but not indirect (using a grounded mesh or treating the medium and then plating the cells). [129] It
was also shown with testing on melanoma cancer cells that the effect of inducing apoptosis in the
cancerous cells is not based on a poisoning of the growth medium the cells were placed in but by
direct action of the plasma. [130]
Electroporation has also been used as a method for killing cancer cells, in particular irreversible
electroporation in which the pores induced by the high electric fields do not close leading to cell
death. There is also a possibility that irreversible electroporation works in combination with the
reactive species generated by the plasma. [131] Electroporation is discussed further in Section 4.2,
with a focus on reversible electroporation.
2.5.1.4 Other Applications
Plasma treatment has a number of other applications. One of the first noted was blood coagu-
lation, in addition to cauterization that occurs with “hot” plasma treatment (see Section 5.2). [100,
106] Electric fields, heating, calcium ion (Ca2+), pH changes, and albumin modification were all
excluded as the primary mechanism for this effect. The only mechanism that was found was direct
conversion of fibrinogen into fibrin, although further mechanisms are expected to be significant as
well. [132] This may be similar to other effects of cell mobility that have been noted, where cells
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can detach from the extracellular matrix they are held in due to plasma treatment. [6]
Another field with extensive research is plasma dentistry. This is related to plasma sterilization,
where bacteria can be inactivated and biofilms can be broken down by the plasma. [133] Plasma
jets can be scaled down to even fit in small areas for use in root canal surgeries. [134] Plasma can
also functionalize dentin to help with bonding implants to teeth. [135] It can also be used to whiten
teeth as a plasma discharge can produce some of the same chemical compounds used to bleach
teeth. [135]
Plasma activated media is another novel field, where the plasma interacts with a medium which
is then transferred to cells for an effect remote from the plasma. This has been shown to have
an antibacterial effect dependent upon the medium used. [55] Anti-cancer media have also been
investigated, where the concentration of H2O2 was noted to change with various media for different
storage conditions. This lead to cell death 3 days after plasma treatment for certain media, noting
that two amino acids, cysteine and methionine, were reduced apparently by the H2O2 in the stored
plasma treated medium. [136]
Plasma could also be used in a system to clean hands for basic hygiene. A possible system was
developed and shown to inactivate bacteria in a little as 5 s, leading to a possible use to supplement
conventional hand washing or use of hand sanitizer. [137] Surface DBDs also can be used for either
hand cleaning or surface sterilization as an atmospheric pressure, ambient temperature equivalent
to an autoclave. [138]
2.5.2 Development of Low Temperature Plasma Devices
A variety of plasma devices have been used for biomedical applications. They are often divided
into three general categories based on their electrode configuration: direct, indirect, and hybrid. [6]
Direct devices use the body as one of the electrodes, as done in the PlasmaDerm, Drexel Univer-
sity’s FE-DBD [106] or FE-DBD jet (used in Chapter 6). Indirect devices have both the high
voltage and ground electrodes far from the patient, with gas flow carrying the plasma generated
species to the treatment location, such as the MicroPlaSter or the kINPen MED. Hybrid devices
have a ground electrode taking the majority of the current, but small currents may still pass through
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the patient, such as the plasma care, a surface DBD. [6, 139] Despite the wide variety of devices
being used in laboratory and research settings, very few are being developed as marketed devices,
which is the primary focus of this section.
Unfortunately, most device development occurs in-house and does not become public knowl-
edge, so for many of these devices there is limited information available. Fortunately five devices,
which have all now also been approved for medical use in Germany (i.e. received a CE mark-
ing), [96, 140, 141] are being developed in close collaboration with universities.As such, there are
a number of published studies on these devices. Numerous clinical studies have been done using
them and have found that they are effective for healing chronic wounds, [142–144] have antibac-
terial effects, [145] and even reduce pain. [146] No device is currently approved by the FDA for
use in the US; however one device has been used twice under the FDA’s rule as a Compassionate
Use Exemption for inoperable colon [147] and pancreatic [148] cancer and has started clinical
trials. [149]
A number of devices are excluded, since they do not generate a cold plasma, per se. For
example, the Plason, which uses an arc discharge to generate a high concentration of NO from
atmospheric air, which is then quenched to reduce the temperature of the resulting NO-containing
gaseous jet. [150] This is a common device used for NO therapy to help accelerate wound healing,
where the concentration of NO can be regulated by the distance from the arc generating it. [109,
151] Other systems, such as electrosurgical systems that can be modified to generate a cold plasma,
are discussed in Chapter 5.
The following subsections will examine each of the five devices that have currently received a
CE marking in Germany: the kINPen MED, the PlasmaDerm, the MicroPlaSter, the plasma care,
and the Plasma ONE, focusing on the characterization and development of these devices. A final
subsection will investigate the various devices that are being developed in the US for FDA approval
as well as other notable devices.
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(a) Entire System (b) Jet Head
Figure 2.11: Image of the kINPen MED (Reproduced under Fair Use from [154])
2.5.2.1 The kINPen MED
The most investigated low temperature plasma device is the kINPen MED10 developed by the
Leibniz Institute for Plasma Science and Technology (INP Greifswald) and consequently spun off
to into a company called neoplas tools GmbH. An image of the device is shown in Figure 2.11. It
was the first low temperature plasma device to receive a CE marking in May 2013 for local treat-
ment of chronic or infected wounds. [96] The kINPen MED is a direct radio frequency (1 MHz)
argon plasma jet (see Figure 2.4), although small admixtures of other gases have also been explored
to tailor the chemistry. For example, small admixtures of air greatly increase the amount of NO
in the resulting effluent. [33, 40] In addition, the kINPen MED is the instigation of the DIN-SPEC
91315 for low temperature plasma medical devices (Section 2.5.3). [153] As such, this device has
been well characterized in regards to temperature and thermal output, light and gaseous emissions,
current characteristics, inactivation of microorganisms, and effect on human cells. Further itera-
tions on the kINPen MED are also under development. [33]
The kINPen MED has been studied extensively in vitro and ex vivo. [33,56,101,105,140,155–
10This device has undergone many iterations, where the medical device has limited controls compared to the re-
search variations. The medical device is based off of the kINPen09. [33, 152]
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161] These studies have examined the resulting species generated by the plasma, [56, 101, 156,
158–160], bacterial inactivation, [105,155,157] and the toxicity of the plasma treatment to human
cells. [56,101,140,156,158,161] Overall, the kINPen MED has shown itself to be safe for human
cells while still able to inactivate a variety of bacteria. The main complaint has been the small size
of the kINPen MED jet, which requires significant time to treat a large area.
A number of clinical studies have been conducted with the kINPen MED. Initial studies in-
vestigated the biocompatibility of the plasma with skin. [162] Combining plasma treatment with
conventional treatment of wounds with the antiseptic octenidine dihydrochloride yielded lower
bacterial loads than either individually; plasma treatment and octenidine dihydrochloride were
comparable to each other. [144] A number of trials on cancer patients have also been conducted.
Plasma treatment on advanced squamous cell carcinoma was shown to reduce pain, lower micro-
bial load, help with tumor shrinkage, and assist with wound healing. [146] Apoptosis of cancer
cells was detected in patients with advanced head and neck cancer, reducing the size of the tu-
mor. [163] A small study of two patients showed increased microcirculation as a result of plasma
treatment, but due to the small size no conclusive results can be determined. [164]
2.5.2.2 The PlasmaDerm
The PlasmaDerm by Cinogy GmbH was the first FE-DBD device to receive a CE marking in
2013 (shown in Figure 2.12). [165] Initial tests showed it was successful at inactivating a number
of bacteria in vitro, [155] including a range of difficult to kill species, such as methicillin-resistant
Staphylococcus aureus (MRSA). [105] It was also well characterized to show it as a safe device,
without producing unsafe levels of reactive species, introducing excessive current into the sub-
strate, or damaging ex vivo skin samples. [166] A small clinical study was conducted on reducing
the bacterial load in chronic wounds from 14 patients. [145] Patients received a 45 s/cm2 treatment
three times per week for eight weeks in addition to standard care. There was a significant reduc-
tion in bacterial load, but not a significant reduction in the size of the wound. Overall patients
mentioned less pain with the plasma treatment as well. Further work is ongoing to elucidate the
mechanisms of bacterial reduction and effects on human cells. [167]
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Figure 2.12: Image of the PlasmaDerm (Reproduced under Fair Use from [168])
2.5.2.3 The MicroPlaSter
The MicroPlaSter11 was developed by the European branch of Adtec Plasma Technology Co.
Ltd. in conjunction with the Max Planck Institute for Extraterrestrial Physics in Germany. [169,
170] The device is often classified as a plasma torch, since it is a microwave (2.45 GHz) argon
plasma jet with six exposed electrodes in a grounded metal cylinder, as shown in Figure 2.13b.
Additional air is used to ensure a low temperature output. [152] The device was shown to have
low UVC output; most UV output appears to be OH and NO bands. [143, 171] It was shown to
have large area bactericidal effects, which leads to chronic wound treatment as the primary use, as
shown in Figure 2.13a. [170]
Unlike the previous two devices (the kINPen MED and PlasmaDerm), some of the first pub-
lished studies are clinical trials (and the first clinical trials of a cold plasma device), suggesting
that substantial development was done in-house to warrant these trials. These studies showed a
substantial reduction in a wide range of bacterial loads in chronic wounds for both a 5 min [172]
11This has been rebranded as the SteriPlas [169], but appears to be essentially the same device as the previous
generations, the MicroPlaSter α and MicroPlaSter β (sometimes misspelled with an ß or different capitalization, a
25% smaller unit than the α model), which are discussed in the literature. As such, the older name will be used in this
dissertation.
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(a) Clinical Treatment (b) Exposed Electrodes
Figure 2.13: Images of the MicroPlaSter Being Used in a Clinical Setting and Its Electrode Con-
figuration (Reproduced under Fair Use from [169])
and a 2 min [143] treatment time. This led to further studies, with secondary endpoints of wound
healing in addition to the primary endpoint of bacterial load reduction. Significant wound size
reduction was noted in addition to broad bacterial inactivation in the wounds. [173] No adverse ef-
fects have been noted from the plasma treatment. [139] Further clinical studies for wound healing
in skin grafts and on herpes zoster were also conducted; treating skin grafts suggested a positive
effect, [174] while the study on herpes zoster treatment showed faster clinical improvement and
reduced pain. [175]
Further studies have investigated the MicroPlaSter in vitro and animal studies. Low levels
of toxicity were noted for in vitro tests while no mutations were detected, supporting the use
for clinical studies. [176] gram-negative bacteria were found to be more susceptible to plasma
treatment than gram-positive bacteria. [104] In addition, thicker biofilms were noted to be more
difficult to inactivate. Increased cell proliferation was noted from treatment leading to faster wound
healing. [177]
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(a) Clinical Setting (b) Electrode Design
Figure 2.14: Images of the plasma care and Its Electrode Configuration (Reproduced under Fair
Use from [178])
2.5.2.4 The plasma care
The most recent device to receive a CE marking is the plasma care from terraplasma medical
GmbH, an offshoot company from the Max Planck Institute for Extraterrestrial Physics. The device
is shown in Figure 2.14. The plasma care is a surface DBD, directly spun out of the university rather
than working initially with an external company, such as Adtec, which had a partnership with the
Max Planck Institute for Extraterrestrial Physics. [138] This device appears to be a variant of an
Adtec device, which was originally called the FlatPlaSter (or some variant). [179–181] General
characterization experiments were run showing that it does not produce unsafe amounts of reactive
species yet still has sterilization potential. [138] Initial results for inanimate object sterilization
proved effective even against difficult to kill bacteria. [180] This was continued for sterilization on
a skin surrogate, where sterilization was effective without damaging the skin. [179,182] The effect
of destroying biofilms was also noted, which is one of the drivers for this device’s clinical use. [183]
Currently this is now being explored in vitro as a cancer therapy as well. [181] In addition, it is
being marketed for household veterinary use. [184]
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Figure 2.15: Image of the Plasma ONE (Reproduced under Fair Use from [188])
2.5.2.5 The Plasma ONE
The Plasma ONE by plasma MEDICAL SYSTEMS GmbH has also received its CE mark-
ing. [185] This is an unusual device compared to the previous four, as it does not appear to have
been worked on extensively in a partnership with a university, and thus there are not many jour-
nal papers concerning it, making this more analogous to development that has been done in the
US. It is mentioned to be a volumetric DBD in air, but the system appears to be a type of plasma
jet in images (see Figure 2.15); typical treatments are done for 60 s with voltages from 3–18 kV,
where the plasma was shown to assist in wound healing by increasing cell proliferation post treat-
ment. [111,112] Is has also been shown to reduce biofilms on titanium surfaces, a common material
used for medical implants. [186] Nevertheless, not all results are positive; it did not successively
sterilize a number of bacteria for a number of run conditions in an aqueous setup intended to mimic
the human mouth. [187] This shows that determining the appropriate conditions for a plasma sys-
tem is highly non-trivial and requires fairly extensive study.
The company’s website only lists two clinical trials that have been conducted using the Plasma
ONE; [189] although a further one has been found. This last one, however, was most likely not
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done in part of the CE approval process, as it has only a single patient, thus further clinical results
may exist, just not in the open literature. As part of post-operative care for an ear carcinoma,
one patient was prescribed treatment using the Plasma ONE to assist in wound healing. [190]
Interestingly, as this was a carcinoma, this treatment could also be considered as an anti-cancer
therapy, as this was apparently a reoccurring cancer. However, no long-term results are given to
determine if this helped prevent resurgence of the cancer for this particular patient.
2.5.2.6 Other Devices
A number of startup companies have been created in the US, some of the earliest ones being
Harmonic Cold Plasma, Plasma Technologies, and Sterionics, Inc., all with the intention of gen-
erating a plasma device for wound healing. Unfortunately it seems most of these companies no
longer exist; at minimum their websites no longer exist. Harmonic Cold Plasma reached animal
trials, but apparently progressed no further. [191] Sterionics, Inc. received a small business inno-
vation research (SBIR) grant for “disinfection efficacy of a novel non-thermal-plasma-generating
technology that produces a variety of reactive ionic species.” [192] However, since no further in-
formation is available since 2013, it is assumed that their CAP device intended for FDA approval
was never realized. [193] Another more recent company ChiScan LLC is also operating in this
space using a corona discharge device; however it appears they may have also gone out of business
as their website also is unresponsive. [194]
However, US Medical Innovations is still doing well with their development of a low tempera-
ture plasma jet, called the Canady HeliosTM Cold Plasma Scalpel, named after a surgeon on staff
at the company. [195] The system is shown in Figure 2.16 being used in a surgical procedure.
This company already produces electrosurgical equipment, so there is perhaps minimal changes
needed to their existing devices (e.g. see Section 5.4) to convert it to a low temperature plasma
device. In addition to already having a revenue stream as an electrosurgical device manufacturer,
US Medical Innovations is working with a number of universities with prominent cold plasma
researchers. [196] They have already published preliminary bench scale research for operating
conditions. [197] This device has already been used twice under the FDA’s rule as a Compassion-
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Figure 2.16: Image of the Canady HeliosTM Cold Plasma Scalpel in a Clinical Setting (Reproduced
under Fair Use from [195])
ate Use Exemption for inoperable colon [147] and pancreatic [148] cancer, as well as at least once
outside of the US for retroperitoneal sarcoma. [198] This device has now also just been permitted
to undergo clinical trials in the US for cancer treatment. [149]
Drexel University’s FE-DBD has been used in clinical trials for wart removal in pediatric pa-
tients. [199] Though successful, this was a small-scale study needing further results with a larger
population for conclusive results.
Another company with a device family, the Bioplasma Cell Modulator by Photo Bio Care in
Thailand, also deserves mentioning due to the number of studies done. Two different systems are
tested, one is a DBD similar to Drexel’s FE-DBD system; the other is a direct plasma jet (see
Figure 2.4) usually run with helium. The first study found used the FE-DBD system for acne
treatment; skin oil production was reduced for up to 4 weeks after plasma treatment. [200] This is
the only study found for acne using a cold plasma treatment, although there appears to be a device
on the market in Australia claiming to use cold plasma for similar skin treatments. [201] Three
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results were found using the direct plasma jet. DNA modification was investigated using the direct
plasma jet with helium, showing that this device can modify bacterial DNA. [202] This plasma jet
with a small admixture of oxygen in the helium has also been investigated for root canals, where
it was shown to be useful in inactivating E. faecalis, especially when combined with the standard
treatment. [203] Lastly a clinical study was conducted with the jet using argon rather than helium
to heal pressure ulcers with a secondary objective of reducing the bacterial load in these ulcers. A
significant reduction in size was noted after 1 week compared to the control group; the bacterial
load was also reduced. [204]
2.5.3 Standards for Low Temperature Plasma Devices
There exist a number of standards for medical devices. These include general standards for
medical devices such as ISO 13485 for “the design, production, installation and servicing of med-
ical devices and related services.” [205] These general standards focus on the overall system that
generates medical devices. Then there are some more specific standards that the FDA or another
regulatory agency will recognize as pertaining to a device that can have a very narrow scope, such
as “IEC TR 60878:2015 Graphical symbols for electrical equipment in medical practice.” The
FDA usually relies on standards developed by other organizations rather than creating their own,
particularly to “support a least burdensome regulatory framework.” [206] Thus any plasma device
would have to follow a variety of standards that are relevant for such a device that is converting
electrical energy to a medical use. Relevant standards that should be followed include electrical
ones (such as ensuring minimal electromagnetic interference (EMI) is generated and patients are
protected against electrostatic discharges [207]), as well as medical ones for the medical treatment
being conducted.
However, in addition to these very general to relatively specific standards, there is a standard
being developed specifically for low temperature plasma devices in Germany, namely DIN-SPEC
91315: General requirements for medical plasma sources. [208] The goal of this standard is not
necessarily to address all aspects of plasma design and characterization for a medical device but
to provide a basic set of characterization standards and performance metrics for low temperature
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plasma devices; it is anticipated that other standards will be used as well or further standards will be
developed that more fully address the mandatory metrics for low temperature plasma devices. [40,
153] Nevertheless, this standard is the first attempt to give reasonable standards for manufacturers
who are beginning to develop a number of plasma medical devices. [153]
The DIN-SPEC 91315 characterization was designed primarily for plasma jets with applica-
tions in sterilization, such as the kINPen MED, but can be applied to any plasma medical de-
vice. [153] The specifications are divided into three sections: general requirements, physical as-
sessment criteria, and biological assessment criteria. [208] The general requirements specify that
any experiment should be as controlled as possible with all relevant factors noted (e.g. humidity,
ambient temperature, etc.). It is also expected that sufficient tests will be conducted for some
measure of statistical significance (i.e. all results presented in triplicate at a minimum).
Physical assessment criteria include measuring the temperature, thermal load, optical radia-
tion, gas emissions, and electrical currents. For temperature, a variation along the plasma region
is expected with a spatial resolution of 1 mm or smaller. The thermal load is to show the energy
deposited by the plasma into the substrate. The optical radiation emitted is to determine the spec-
tral rays emitted, particularly in the ultra-violet range (200–400 nm). The gas emissions should
characterize the amount of ozone and NO2 generated by the plasma to determine if they approach
a hazardous level. Lastly, the ground leakage current should be determined to ensure minimal
current flows through the patient.
Biological assessment criteria include measuring the inactivation of microorganisms, the vi-
tality of cell cultures after plasma treatment, the detection of chemical species in liquids, and the
determination of pH changes. For sterilization applications, the inactivation of a wide range of
medically relevant microorganisms should be shown. This includes both gram-positive and gram-
negative bacteria as well as fungal spores. The cell culture vitality is particularly for in vivo treat-
ment. A wide variety of chemical species including nitrites and nitrates can be produced in water
due to plasma treatment, which need to be characterized for a plasma system that may produce
them on biological surfaces. Lastly, any change in the pH of a treated liquid should be measured.
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Though no specific standard for low temperature plasma devices has been adopted by any
medical device approving body (e.g. the FDA), showing that one is following a standard such as




Plasmas are notoriously difficult to characterize. They are a collection of particles moving
at vastly different speeds, with dynamics occurring over sub-nanosecond timescales, with large
amounts of energy being dissipated over extremely short timescales. This chapter introduces the
diagnostic techniques used to characterize the plasma systems described in the following chapters,
discussing their applicability and limitations. The subsequent chapters will refer back to sections
in this chapter for more information on the systems used. First, the electrical characterization
of the plasma is treated, observing how the plasma interacts as a circuit element as well as the
difficulties and trade-offs that occur when taking these measurements. Second, imaging techniques
are discussed. Next, optical emission spectroscopy of plasma discharges is discussed. The two
main uses of species identification and plasma temperature are highlighted.
3.2 Electronic Characterization
This section will discuss the various aspects of the electronic side of plasma generation and
diagnostics. Many of the systems used to generate or characterize the plasma systems discussed
in later chapters will be described in detail here so that they need only be referenced in the later
chapters. Initially plasma power supplies are discussed, followed by voltage, current, charge, and
electric field measurements; lastly Lissajous analysis for DBD systems will be discussed.
3.2.1 Power Supply Considerations
As explained in Section 2.2.1, a plasma is coupled to its power supply (and the rest of the
circuit powering it). As such, changing the power supply will affect the behavior of the plasma.
This can be as simple as changing the capacitance that the plasma is drawing charge from, yet this
can have profound impacts in plasma operation, such as a small change of increasing the length of
wire in the system can then influence the plasma dynamics.
















Figure 3.1: Schematic of the Three Primary Types of Plasma Power Supplies with Representative
Voltage Traces
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AC power supplies (see Figure 3.1). Current travels in only one direction for DC power supplies;
thus they do not work for DBD systems, since the dielectric stops the flow of charge. However, DC
power supplies can be used as charging power supplies for pulsed DC systems (see Section 4.4.1
and the first pulsed DC system in Figure 3.1). They are the simplest design from a basic circuit
characterization standpoint, since the direction of the current is known. Since the source of power
is typically a standard AC wall outlet, they must involve some relatively complex circuitry to
both step up the voltage and rectify the current. As such, they typically have a relatively large
output capacitance to ensure a relatively smooth rectified signal. Typically high voltage DC power
supplies are used to power corona or glow discharges.
Pulsed DC power supplies deliver current in pulses in a single direction; they achieve this by
having a single polarity voltage pulse, as shown in Figure 3.1. They can be constructed of a DC
power supply with a fast switch to deliver stored charge (e.g. a spark gap, as shown in Figure 3.1
for the first pulsed DC power supply) or they can involve complex circuitry, such as the FID power
supply (see Section 3.2.1.3). Pulsed DC power supplies can power nearly any type of plasma
discharge, including DBDs. They are characterized by their duty cycle and pulse duration. Since
pulsed DC power supplies only deliver short pulses, they tend to deliver lower average power than
the other two types of power supplies. They are increasingly being used to drive low temperature
plasmas, since one of the main ways to achieve a low temperature plasma is to have a low duty
cycle, delivering high current over very short timescales either before significant gas heating occurs
or so that the time-average gas temperature remains near ambient.
AC power supplies alternate the direction of charge flow, typically at fairly fast rates (10s of
kHz, but can be up to 100s of MHz). Since the power supplies typically use wall power, they
are relatively simple and can consist of simply a transformer to step up the low wall voltage to
a high enough voltage to generate a plasma discharge. Further internal circuitry is needed to
modify the frequency of the power supply. The main drawback of AC systems is that they need
impedance matching to be able to deliver substantial power. This is often done with a matching
network attached to the power supply for high power systems, but it can also be done by varying
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the frequency of the power supply.
Three of the power supplies used for this research are described below. They are a DC high
voltage power supply, an AC high voltage power supply, and a pulsed DC power supply system.
Two further systems were used: a Bovie, which will be discussed in Chapter 5, and a custom AC
high voltage power supply used in the FlashFuse system (see Section 7.5).
3.2.1.1 Spellman HV DC Power Supply
The high voltage DC power supply used in this work is a Spellman SL300 DC power supply. It
is capable of outputting voltages from 0–40 kV and currents from 0–7.5 mA. Its output capacitance
is on the order of 1 nF. It will operate in either a voltage or current controlled mode, depending
upon whichever control (voltage or current) is limiting the power draw from the circuit. This power
supply is used in conjunction with a double spark gap pulse-forming network in Section 4.4.1 to
deliver nanosecond voltage pulses.
3.2.1.2 Information Unlimited HV AC Power Supply
The most common high voltage AC power supply used in this work is the PVM500 power
supply from Information Unlimited (also known as Amazing1 from their website URL). This is
an inexpensive radio frequency (RF) power supply capable of delivering 0–40 kV (peak-to-peak)
over a frequency range of 20-70 kHz. This ability to adjust the frequency allows a resonance mode
to be found for driving capacitive loads that maximizes the power output. This avoids needing to
use a separate matching network to deliver maximum power to the load as is commonly used in
RF plasma systems. This is used in this work to drive a plasma (usually a DBD) jet (see Chapter 5
and Chapter 6).
3.2.1.3 FID Power Supply
Some of the power supplies with the shortest pulse duration on the market are the fast ionization
dynister (FID) power supplies from FID, GmbH. This work uses a model FPG 30-N, which delivers
5–30 kV high voltage pulses with a pulse duration of ∼3 ns. The frequency of pulses can be





















































(b) Zoom on Initial Pulse
Figure 3.2: Measured Voltage and Current Traces from the FID Power Supply
single pulse are possible. Due to the extremely short pulse duration, the electrical characteristics of
this power supply are difficult to measure. An attempt was made to measure the output voltage and
current in Figure 3.2, but the pulse duration is not adequately measured because the pulse is faster
than the voltage and current probes response times. There is also a significant amount of ringing
in the circuit, possibly from voltage reflections at numerous points in the circuit. Nevertheless,
this power supply has been measured to output ∼3 mJ/pulse into a plasma load, which is its rated
energy per pulse for a 200–500 Ω load. This power supply is used in this work in Section 4.4.2,
Section 4.5.1, and Section 7.4.
3.2.2 Voltage, Current, & Charge Measurements
Usually a number of trade-offs have to be balanced to adequately measure a plasma discharge’s
electrical properties. This is often due to the large range of timescales that processes occur over.
For example, current pulses can have a duration of only 10s of nanoseconds but the duty cycle of
them can be on the order of milliseconds, thus necessitating capturing data to adequately resolve
a 10 ns pulse while still attempting to capture multiple pulses to see the pulse-to-pulse variation—
6 orders of magnitude range in time! This is often impossible for systems since 10s of millions
of data points or more are necessary to measure a single signal. In addition to time, scaling the
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signal magnitude can be difficult. Particularly for current traces in AC systems, there can be a
low magnitude primary signal with large current spikes superimposed on it (e.g. the plasma bullets
described in Section 2.2.1.8 or microdischarges as shown in Figure 3.5a). As the oscilloscopes
used involve an analog-to-digital (A/D) conversion to acquire the signal, substantial data can be
lost. There are attenuators that can be used to ensure a signal is within the range the oscilloscope
can measure, but linear scaling may still cause important information in the signal to be lost. As
a result, some researchers have investigated more complex circuitry that scales the input signal in
a logarithmic fashion to not lose any important aspects of the data. [209] There are also a number
of other considerations for each type of measurement, which will be discussed in the following
subsections.
3.2.2.1 Measuring Voltage
The main difficulty in measuring the voltage drop across a plasma is due to the large voltages
occurring. A good rule of thumb is that a plasma requires 3 kV/mm to break down an air gap
(this value is the dielectric strength of air). As such, the voltage can easily be on the order of
10s of kilovolts. The easiest way to measure the voltage is using a high voltage oscilloscope
probe; however, these can easily cost $100s to $1,000s for a probe with a high enough bandwidth
(the range of measurable frequencies) and voltage rating. Even worse, at times probes cannot be
commercially purchased (without custom builds) that can achieve the high bandwidths and voltage
rating desired.
This brings up the second challenge in measuring the voltage drop across a plasma: they often
operate at high frequencies. The bandwidth needed to fully measure the dynamics is generally
beyond any probe, but high bandwidth probes (>100 MHz) are usually sufficient for most cases
(the exception being the FID power supply or similar systems). Note here that the lower bandwidth
is assumed to be 0 Hz so that a probe can measure DC voltages.
Another option to purchasing an expensive high voltage probe is to build your own high voltage
probe, using a basic resistor divider circuit (see Figure 3.3). The bandwidth will not be optimal (at
best on the order of 100 kHz, higher bandwidths require adding in a capacitive divider) and care
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Figure 3.3: Schematic of a Resistive Divider Circuit
must be taken to ensure the proper voltage is being read by an oscilloscope, but this is a very cheap
alternative to buying a high voltage probe. The resistors must be chosen so that very little current
will flow through them (R1 +R2 ≥∼ 10 MΩ, but higher resistances may be necessary if the circuit
element has a high resistance), and the output voltage is able to be input to an oscilloscope (Vout =
R1
R1+R2
Vin ≤∼ 40 V). Care must be taken for proper impedance matching with the oscilloscope.
(Often an oscilloscope has an input impedance of 1 MΩ, but R2 can also be the same order of
magnitude; a simple solution might be to use an op-amp to isolate the resistive divider from the
oscilloscope.) A custom-built voltage divider probe was used for initial diagnostics of the custom
RC pulse generator and in determining the voltage across the capacitor (see Section 4.4.1 for circuit
details) since this did not require a fast time response.
Placement of the voltage probe is important. The probe must be placed as close as possible to
the circuit element of interest to minimize possible time delays between the measured voltage and
the actual voltage across the circuit element (as noted in Figure 3.1). There ideally should be no
other circuit elements between the circuit element of interest and ground to accurately measure the
voltage (e.g. a shunt resistor may be used for current, but then the voltage difference can be used
instead). This is because the probe often has a ground reference; floating this ground reference
can potentially damage the oscilloscope, which often also has its own internal ground reference.
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(a) Shunt Resistor (b) Monitor Capacitor (c) Current Transformer
Figure 3.4: Schematic of Three Different Methods for Measuring Current or Charge
Differential probes can be used instead to avoid this, but they rarely are capable of measuring high
enough voltages for use in plasma diagnostics.
For the work reported in this dissertation, three high voltage probes were used. The first is
a Northstar PVM-4 with a bandwidth of 110 MHz, a maximum voltage rating of 40 kV, input re-
sistance of 400 MΩ, and input capacitance of 10 pF. The second is a LeCroy PPE20KV with a
bandwidth of 100 MHz, maximum voltage of 20 kV, input resistance of 100 MΩ, and input capac-
itance of <3 pF. A resistive divider probe (nominally R1 = 50 MΩ and R2 = 10 kΩ, measured as
R1 = 49.9 MΩ and R2 = 9.84 kΩ) was used to measure the breakdown voltage on a capacitor (see
Section 4.4.1), since this did not require a fast time response.
3.2.2.2 Measuring Charge and Current
Current (or charge) is possibly the most difficult part of a plasma system to measure. This
is because for a DBD, the discharges last only 10s of nanoseconds, while the overall excitation
(applied voltage sinusoid) is on the order of 10s of microseconds, and the pulses can sometimes
be as high at 100s of amperes (see Figure 3.5a). Note that current or charge can be measured as
a function of time. As long as there is sufficient temporal resolution, the other can be sufficiently
determined by either integration or differentiation of the signal.
There are three main ways to measure current—a shunt resistor, a monitor capacitor, or a
current transformer (see Figure 3.4). The downside for all of these systems is that the current (or
charge) is linearly proportional to the output voltage. Though simple, this requires the oscilloscope
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to have sufficient resolution to resolve both the low current and high current aspects of the system.
More complex circuitry can be used to achieve logarithmic dependence, thus reducing the need to
have a large resolution on the oscilloscope. [209]
A shunt resistor (Figure 3.4a) is a small resistance placed between the plasma load and ground.
(it can be placed elsewhere, but then two voltage probes, or a differential voltage probe is needed to
isolate the voltage drop across the resistor.) The voltage measured across the resistor is proportional
to the current (I = V
R
). The resistance must be small enough to not affect the circuit, but large
enough that a measurable voltage drop across it occurs; often, this is in the range of 1 to 10 Ω but
the values can range greatly depending upon the current magnitudes expected.
A monitor capacitor (Figure 3.4b) is similar to a shunt resistor, except that the voltage across
the capacitor is proportional to charge rather than current (Q = CV ). The charge must be dif-
ferentiated to obtain current; however, this can be useful if a Lissajous figure is being obtained
(see Section 3.2.3), since then there is no need to integrate a current signal. One difficulty of im-
plementing this method is that charge can build up on the capacitor. If this occurs, the voltage
across the capacitor continues to grow with each plasma discharge and will eventually affect the
discharge characteristics. If this occurs, a moderately large resistor in parallel with capacitor may
be necessary to remove the charge between discharge cycles, but the resistor must be large enough
to not allow significant charge to flow through it during a discharge event. Finding an optimum
value for this resistor may be difficult to impossible, thus this method of measuring current (after
differentiating the measured charge signal) is not always feasible.
A current transformer (Figure 3.4c) uses the magnetic field from the flowing charges to induce
a voltage. (It is a Rogowski coil with a integrating circuit on the output.) This voltage can then
be measured by an oscilloscope. This is often one of the easiest ways to measure current, since
the inductive loading on the circuit is typically small; however, it may be difficult (or expensive)
to find a current transformer with a high enough current and bandwidth rating for a DBD system.
An advantage of a current transformer over the other two methods is that the current transformer
does not need to be placed between the load and ground, but can be placed anywhere the current
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measurement is desired.
The primary method to measure current used in this dissertation was a Bergoz current trans-
former, model CT-D1.0, which has a maximum (peak) current of 1 kA, a rise time of 0.7 ns, and a
bandwidth of 200 Hz–500 MHz. A Pearson current monitor model 6585 was also used which has
a maximum (peak) current of 500 A, a rise time of 1.5 ns, and a bandwidth of 400 Hz–250 MHz.
3.2.2.3 Electric Field
For many applications, the voltage is not the desired result, rather the electric field. The electric
field, E,is the gradient of the voltage, V expressed as,
E = −∇V (3.1)
Space charge, ρ, however, develops in the discharge gap for any plasma system which greatly affect
electric field, as given by Gauss’s Law
∇ · E = ρ
ε
(3.2)
where ε is the permittivity of the medium.1 This leads to difficulty or (much more often) even im-
possibility of measuring the local electric field, which is often necessary for a full characterization
of many systems (such as an electroporation system described in Chapter 4). At a minimum, the
local electric field cannot be estimated by only knowing the applied voltage at the electrodes.
There are two methods of observing the electric field directly. The first is an electric field
probe. This is based off of the Pockel’s effect, a well established electro-optical effect, where the
index of refraction changes based on the applied electric field. [210] Though commonly used used
in lasers to control the pulse, similar devices can be used as sensors to measure the applied electric
field. [211] They, however, suffer from poor spatial resolution and can have a substantial impact
on the discharge if inserted directly into the plasma.
The second direct method of measuring the electric field is a dye measurement. A dye sensitive
1Not to be confused with the vacuum permittivity, ε0 = 8.854 × 10−12 F/m. The permittivity of the medium
is often given by ε = εrε0, where εr is the relative permittivity. Either εr or ε are experimentally determined and
tabulated.
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to the applied electric field can be selected. The details of this are discussed in Section 4.5.4, where
a rhodamine dye is used in an attempt to measure the electric field. The dye’s fluorescence changes
under the magnitude of the applied electric field. The challenge in this case is that the change is
quite small and thus difficult to observe.
Indirect methods of measuring the electric field are typically optically based. For example,
Stark polarization spectroscopy can be used to measure the electric field. [212] This measures the
location of a normally forbidden transition that becomes allowed due to the electric field; however
the line is very close to an allowed transition, making this measurement difficult. [212, 213] There
is also a new technique using a variant of coherent anti-Stokes Raman spectroscopy, whereby non-
linear mixing of three laser beams yields a signal that scales with the electric field. [214]
3.2.2.4 Oscilloscope Considerations
The behavior of the probes are meaningless unless a device, such as an oscilloscope, is used
to capture the signal traces. Common oscilloscopes today are digital rather than analog. This may
add some small complications with the A/D conversion, but a wide variety of other functions are
possible, such as peak finding, various mathematical transformations, etc. Oscilloscopes are rated
for the number of channels (2, 4, and 8 channels are the most common), bandwidth, sampling rate,
and memory (for digital oscilloscopes). For all of the work reported in this dissertation, a 4 channel
LeCroy 204MXi (2 GHz) oscilloscope with 10 GS/s.
3.2.3 Lissajous Analysis
A typical voltage and current trace for a DBD is shown Figure 3.5a, in this case from the
FlashFuse system characterized in Section 7.5. The voltage is sinusoidal with a slight deviation
at voltages greater than the breakdown voltage of the gas gap due to the plasma discharge. The
current is roughly a sinusoid phase shifted from the voltage (since the overall system is mainly
capacitive). However, there are large spikes superimposed on the current’s sinusoidal behavior.
These spikes are the plasma discharges; there is one spike for every filament. They come from
large increases in the current due to the breakdown process. Their duration is in the range of 10 to
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(a) FlashFuse Voltage and Current Traces (b) FlashFuse Lissajous Curve
Figure 3.5: Typical DBD Voltage and Current Traces with the Resulting Lissajous Curve
100 nanoseconds, and the number of current spikes can vary from a single spike (fairly typical in
DBD jets) to hundreds or more (common for planar DBDs as seen in Figure 3.5a). For a normal
capacitor, there is no net power loss over a full cycle; however, for a DBD the plasma is dissipating
some of the energy in the form of light emission and heat (Joule heating occurs, since a plasma
does have a small resistance, typically on the order of 100 Ω). Often the forward and reverse
polarity do not match because the discharge gap is not symmetric (e.g. the FlashFuse system has
a resistive additively manufactured part as one electrode), thus there is some difference in the
number of spikes or their magnitude for the two polarities. Since these current spikes are so large
in magnitude and so short in duration, accurately measuring them is very difficult, as discussed in
Section 3.2.2.2.
Due to the cyclic nature of a DBD’s voltage, it can be useful to use time as a parametric
variable, since ideally each cycle is identical to all others. Plotting the voltage and charge of a
DBD produces a Lissajous figure, which is an easy way to characterize the discharge. An ideal
Lissajous figure is shown in Figure 3.6. From this diagram, the capacitance of the system can
be determined. Capacitance is the slope on this diagram (Q = CV ), so the capacitance of the
dielectric (and any capacitance in the rest of the external circuit) is the slope during the discharge
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Figure 3.6: Annotated Ideal Lissajous Plot for a DBD System
event (steeper sloped lines in Figure 3.6). The system’s total capacitance without a discharge is
the slope of the curve not during a discharge event (shallower slopes in Figure 3.6) Note that
the system’s total capacitance is smaller than the dielectric capacitance due to this being a series
capacitance of the gas gap and the dielectric, namely
Ctotal =
CdielectricCgas gap
Cdielectric + Cgas gap
(3.3)
The breakdown voltage, Vb, is readily evident on a Lissajous figure as the voltage where the curve
crosses the voltage axis. Likewise, the amount of charge transferred during each half-cycle, qmax
is also easily noted on the Lissajous figure. [215].
In reality, the Lissajous figure for a DBD is rarely so clean. A Lissajous figure for the FlashFuse
system is shown in Figure 3.5b with a parallelogram fit to the experimental data. The rounded
corners on the figure come from resistance in the system, [216] and there is asymmetry denoting
differences in the discharge with the positive and negative half-cycles. This is expected due to
the asymmetry in the geometry of the FlashFuse system, which has a resistive part as one of the
electrodes. Nevertheless an approximate system capacitance, dielectric capacitance, breakdown
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voltage, and charge transferred can be determined from the Lissajous figure.
3.3 Imaging Systems
Imaging is one of the most basic methods for analysis, especially for a plasma discharge.
This is typically done using a charged coupled device (CCD) or complementary metal-oxide-
semiconductor (CMOS) sensor as a part of most standard cameras, which can also be attached to a
microscope as opposed to using a standard camera lens, although a subsection below will discuss
scanning electron microscopy, which images solid samples using electrons rather than photons and
thus uses a completely different type of system. Though there are a number of possible parame-
ters for imaging (f#, focal length, ISO value, etc.) this discussion will focus mainly on quantum
efficiency as a function of wavelength and exposure time.
The quantum efficiency is the ratio of the number of electrons generated by the incident light to
the number of incident photons. The higher the quantum efficiency the more sensitive the detector
is. This becomes useful for two reasons: color detection and photon counting. A typical CCD
for a camera has three types of detectors that are sensitive to different wavelengths of light. This
allows them to capture a color image. The color has some indication for the type of discharge.
In general, cooler discharges typically have the majority of the light coming from specific narrow
transitions, while hotter discharges become more broadband and thus white. However, a spectrom-
eter is needed for a more accurate and full analysis. In a well calibrated system, the exact number
of photons impinging on the detector (or their flux) can be determined, allowing for quantification
of the total number of photons emitted by the plasma.
The exposure time for typical cameras ranges from fractions of a second to∼30 s. This is often
substantially longer than the duration of a plasma phenomenon of interest, typically an ionization
wave in a pulsed plasma system. However, an electronic gated system as opposed to a mechanical
shutter is capable of extremely short exposure times that can temporally resolve these phenomena.
To achieve this, timing circuitry must be used to ensure the camera gate opens at the desired time
with as little jitter as possible, usually involving a timing circuit for the plasma discharge as well.
Two different imaging systems are treated in more detail in the first two subsections below
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as they are used to characterize some of the plasma systems discussed in future chapters. The
next subsection discusses optical microscopy, which used the Nikon cameras (Section 3.3.1) as the
imaging system. The last subsection gives a brief overview of scanning electron microscopy and
discusses the two scanning electron microscopes used in this work.
3.3.1 Nikon Camera
Three comparable cameras are used in our lab: a Nikon D90, a Nikon D3300, and a Nikon
D5600, all of which use a CMOS sensor. They have an ISO range of 100 to 6400 (to 25,600 for
D5600), and the exposure time can vary from 1/4000 to 30 s. Both cameras are able to accept
a wide variety of lenses, typically a 105 mm focal length micro Nikkor lens with variable f# or
similar. They are used for plasma imaging, in particular determining where a plasma discharge is
occurring, which may be difficult for the unaided eye if the plasma is extremely dim, as well as for
qualitative analysis between various discharge conditions.
3.3.2 Stanford ICCD
A Stanford Computer Optics 4Picos ICCD (intensified CCD) is used both for directly imaging
the plasma as well as a detector for the SPEX Spectrometer (see Section 3.4.1.1). It is a gated
ICCD capable of exposure times as small as 400 ps in a burst mode and 1 ns in normal operating
mode. It can accept a TTL (transistor-transistor logic) signal for a trigger or can be self-triggered.
This ICCD has a high quantum efficiency around 20% in the range of 200–450 nm, but it quickly
decreases at higher wavelengths. This is why is it useful for capturing the 2nd positive system of
N2 for spectral analysis, but it is not extremely useful for broadband spectra.
3.3.3 Optical Microscopy
Optical microscopy uses a light microscope to image small features. The microscope used in
this work, an AMScope, is a binocular stereo microscope with a magnification of 0.5 X–4 X along
with an additional magnification on the eye-pieces. It as a C mount for mounting a camera as well,
which was used extensively in Chapter 6 for imaging deposited films using a Nikon camera (see
Section 3.3.1).
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3.3.4 Scanning Electron Microscopy
Scanning electron microscopy uses electrons for imaging rather than photons. This is ulti-
mately possible by the wave-particle duality of electrons as explained by de Broglie, [217] where
the wavelength of electrons is varied by the accelerating voltage used. Electrons are emitted from
a fine tip, either by thermionic emission or field emission. These electrons are then accelerated as
a beam to the sample, which is rastered over the surface. The incident electrons cause secondary
electrons to be emitted from the sample surface, which are collected by a detector, ultimately
forming an image of the sample surface.
A number of factors affect the resolution of a scanning electron microscope (SEM). The most
fundamental is the accelerating voltage, where faster electrons can produce smaller wavelengths;
however, in practice other factors play a much larger role in the final image resolution. The pressure
inside the SEM affects the resolution, since more particles in the residual background gas results
in more collisions with the electron beam. This also limits what samples can be imaged with an
SEM, as the sample may outgas or degrade in low pressure. The magnification of the SEM is done
by a series of magnets (called lenses as an analog to light microscopy), which ensure the electron
beam is well collimated; deviations in the beam profile can have large effects on the image quality.
Important for some of this work is sample charging. The sample must be conductive to dissipate
the electrons impinging on it. If the sample is not conductive, it will charge and the electron beam
used for imaging will be repelled by the charge buildup on the sample surface.
Two different SEMs were used in this work. The first is a TESCON VEGA II LSU SEM, which
uses a heated tungsten cathode. It has a probe current of 1 pA–2 µA, using an accelerating voltage
of 200 V–30 kV; mostly an accelerating voltage of 5 kV was used in this work. Magnification up to
1× 106 X is possible. Due to the thermionic emission tip, this SEM is in general lower resolution
than the other SEM used.
The second, higher resolution SEM used in this work is a JEOL JSM-7500F. It uses a cold
cathode UHV field emission conical anode gun with accelerating voltages of 500 V–30 kV with
probe currents of 100 fA–2 nA. Magnification up to 650,000 X is possible.
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3.4 Optical Emission Spectroscopy
Optical emission spectroscopy uses the light emitted from a plasma to characterize it. The
light is coming from photon emission of the various species in the discharge, as described in
Section 2.2.2.2. Optical emission spectroscopy differs from other types of spectroscopy in that
the system is naturally emitting light, rather than requiring an energy input to excite the species,
as is done in a variety of laser techniques. As such, this is a completely non-intrusive technique;
however, the amount of light is dictated solely by the physics occurring in the system. As such,
the amount of light cannot be increased by varying the excitation process; the collection time
must be increased to increase the amount of light collected. This technique is also not easily
spatially resolved; the collection optics must be setup in such a way as to exclude certain areas for
spatial resolution. This is in contrast to excitation spectroscopy techniques such as laser induced
fluorescence, which are spatially resolved due to the excitation process that generates the signal.
3.4.1 Spectrometers
There are a number of types of spectrometers, but they all work on the same basic principals
of breaking light up into its constituent wavelengths. This is usually done with a grating (although
prisms can be used), commonly a diffraction grating (transmission gratings are also used at times).
The diffraction grating splits the light up into its constituent wavelengths that are then detected by
a light sensitive medium, such as a PMT or CCD.
The spectrometers used in this work are discussed in the following subsections. This will allow
the details of their operation to be discussed here so that later chapters can refer to these subsections
for more detail on the experimental setup.
3.4.1.1 SPEX Spectrometer
This is the main spectrometer used in this research. It is a SPEX 1 m focal length scanning
monochromater spectrometer, model 1000M. It is a Czerny–Turner type spectrometer, containing
a variable width entrance slit, two parabolic mirrors, and a reflective grating, such that the light
travels in a W shape with the parabolic mirrors on one side and the entrance and exit slits and
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grating on the other side. Two different detectors are used with this spectrometer, a Hamamatsu
R928 photomultiplier tube (PMT) and an ICCD camera (see Section 3.3.2). The PMT has a spectral
resolution of ∼0.2 nm, as measured by the FWHM of the helium 706.5 nm peak, whiel the ICCD
has a spectral resolution of ∼0.04 nm, as measured by the FWHM of the iron 360.3 nm peak. As
such, the resolution is substantially better (one order of magnitude) with the ICCD as the detector;
however, scanning over wavelengths is possible with the PMT but has not been implemented with
the ICCD. Thus the wavelength range is limited to∼5 nm when using the ICCD, which is sufficient
for temperature determination using the 2nd positive system of N2. The spectrometer wavelength
dispersion was calibrated using a mercury lamp; a range of visible lines from 253.7 nm to 546.1 nm
was used in the calibration.
3.4.1.2 B&W Tek Modular Spectrometer
The B&W Tek Inc. Glacier X thermoelectrically cooled CCD spectrometer is designed to have
0.5 nm spacing from 200–800 nm. The thermoelectric cooling allows for less thermal noise without
a more complicated cooling mechanism (such as one requiring a coolant). The advantage of this
system over the SPEX spectrometer is that the entire range is captured in a single acquisition
without the need to scan over the wavelengths. This gives the entire spectrum at a single point
in time, rather than relying on the assumption that the system is time-invariant, with the trade-off
of having poor wavelength resolution. The disadvantage is that extremely short exposure times
(<1 ms) are not possible.
3.4.1.3 Ocean Optics Modular Spectrometer
A second modular spectrometer (Ocean Optics Model HR4000) is used that has a narrower
wavelength range from 325–421 nm, with a spectral resolution of 0.03 nm, which is sufficient for
temperature determination using the N2 2nd positive system, since some rotational lines are able to
be resolved. It has a set 5 µm slit. This is an alternative to using the SPEX spectrometer, but is
not able to provide the nanosecond time resolution that system is capable of achieving, due to the
ability to gate the ICCD detector.
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3.4.2 Species Identification
Figure 3.7 shows a measured spectrum from the FlashFuse system (see Section 7.5). The gas
species present can be determined from the transitions (spectral lines) visible in the discharge. For
the FlashFuse system, mostly nitrogen is visible, which is overexposed in Figure 3.7. This is to
show some of the trace species, namely nitric oxide (NO), atomic carbon, and ionized nitrogen gas
(N2+). In addition, different systems within a given species can be excited. This is shown where
both the 2nd (C–B) and 1st positive system (B–A) of N2 are both visible. The notation A, B, and
C here correspond to different electronic transitions within a N2 molecule. These transitions have
different energies and thus appear at different wavelengths. The transition energy is given by the
equation




which relates the change in energy in the gaseous species (∆E) to the light emitted (frequency ν
or wavelength λ, where h is Planck’s constant and c is the speed of light).
Various species can be identified because the electronic state is different for every atom and
molecule, leading to differing spectra for each species. However, identification is not completely
straightforward, sometimes considered an art rather than a science, because there can be many
overlapping spectra which also can be excited in various ways leading to differing intensities or
even different lines being observed. As such, a priori knowledge of what species are present (or
likely to be present) in the system is crucial in making a determination of line identification.
In addition, understanding the method of excitation is helpful. For example, the dominant
mechanism in the spectrum (a discharge in air) in Figure 3.7 is electron-impact excitation; however,
O2 is not observed (nor monatomic oxygen) due to the electron affinity of those species, which
favors electron capture rather than electron excitation. Discharges with helium can also create
a number of other species through Penning ionization or similar processes (see Section 2.2.2.2),
since collisions with excited helium species can introduce a substantial amount of energy. There
can also be large differences in the relative intensities of the emitting lines, even in systems that
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Figure 3.7: Spectrum of the FlashFuse System
appear quite similar. This is determined by how the various levels are excited, and can often be
used to determine parameters about the discharge. For example, the ratio of various atomic lines
can be used to determine the electronic excitation temperature, Telex, which is often assumed to
be equal to the electron temperature, Te, since the free electrons are causing the excitation of the
various electronic states (see Section 3.4.3.1).
The stability of a state also is important. An excited species can lose energy via collisions rather
than photon emission. This is called quenching, and is most commonly discussed in fluorescence
applications, but can occur in plasma processes as well.
3.4.3 Temperature Determination
One of the primary ways to measure the temperature of a discharge is from the light emitted
from it. The following subsections will discuss the theory of this method, the implementation in
numerical software, and the practical issues in implementing it experimentally.
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3.4.3.1 Theory of Temperature Determination
The light intensity emitted from a specific transition from an upper state u to a lower state





where Iul is the measured light intensity of the specific u → l transition, Nu is the number of
emitters at the upper energy level of the transition, and kul is a proportionality constant. The pro-
portionality constant is a measure of the likelihood this transition will occur. It is described by
the Einstein coefficient for electronic transitions (tabulated in the NIST database [218]) and be-
comes more complicated for molecular species, using the Franck–Condon factor for vibrational
transitions and the Hönl–London factor for rotational transitions. [219–221] The number of emit-
ters is given by the distribution function, typically a Maxwell–Boltzmann distribution (see Sec-
tion 2.2.2.3), as described by quantum mechanics. For a single energy mode, say for the electronic











where Ntotal is the total number of particles (of a given species, such as helium or N2), gu is
the degeneracy of the upper level state, Z is the partition function of the energy levels, kB is the
Boltzmann constant, and T elex is the electronic excitation temperature.
For a simple system of a single atomic species (i.e. no vibrational or rotational energy modes),
the electronic excitation temperature can be explicitly solved for. The intensity of a particular
















where the first factor comes from integrating the transition energy (∆E = Eu−El = hνul ) over the
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solid angle of a sphere and Aul is the Einstein coefficient for this transition. Taking the ratio of this



























For a more complicated system such as a diatomic molecule like N2, the intensity of a particular
transition is a compilation of electronic, vibrational, and rotational energy modes that must be
solved simultaneously.2 Each energy mode is assumed to be in equilibrium internally, but not with
the other energy modes. The state of the system is described by three quantum numbers, n, v, and
J corresponding to the electronic, vibrational, and rotational energy modes, respectively. For a
transition from an upper to a lower energy level, n′, v′, J ′ → n′′, v′′, J ′′, the intensity is given by
In
′,v′,J ′



































This is much more complicated than the case with a single energy mode, where the temperature
could be explicitly solved for. Instead, it is easier to create a simulated spectrum, which can
then be compared to the experimental spectrum, where the difference between the two spectra are
minimized.
2The translational energy is normally treated separately since the quanta of energy are so small they are usually
treated as a continuum. Doppler broadening and/or some other method are used to determine the translational temper-
ature.
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3.4.3.2 Implementation of Temperature Determination
Rather than attempting to look up every rotational and vibrational level to calculate the tem-
perature by hand, it is convenient to use a computer program that has already implemented them,
including deviations from the ideal cases, such as anharmonicity in intermolecular bonds and cou-
pling between the energy modes. SpecAir [222] is a program that is capable of doing this, gen-
erating a spectrum of a variety of species including N2 and N2+ given the necessary inputs of the
various species and their fractions, the discharge temperatures (Ttrans, Trot, Tvib, and Te), and gas
density. However, this only produces a spectrum with a predetermined set of temperatures, rather
than finding the actual temperature of a discharge. Since the equations in Section 3.4.3.1 cannot
be solved explicitly, an iterative numeric approach is used to determine the temperature.
For this a MatLab routine is used to minimize the difference between the experimentally mea-
sured spectrum and the modeled spectrum from SpecAir. This code was developed by David
Staack as a part of his graduate work [223] and was shown to successfully determine the tem-
perature of atmospheric pressure glow discharges. [224] Some small changes were made to the
code by Matthew Burnette, but no large changes in its behavior were implemented in this work.
This is a highly nonlinear optimization for up to 9 dimensions: two spectral shifts (wavelength and
intensity), one spectral stretch parameter (since the data is normalized only a wavelength stretch pa-
rameter is needed), four temperatures (Ttrans, Trot, Tvib, and Te), a species number ratio (since only
N2 and N2+ are typically modelled), and an instrumental spread. The spectral shifts and stretch
account for small spectral spread and shifts between the experimental and modelled spectra. The
temperatures and species number ratio are accounted for in the simulated spectrum generated by
SpecAir. Typically the translational temperature does not affect the spectrum significantly (it is
implemented in SpecAir as Doppler broadening on the spectrum, which is typically too small to
affect the result); in particular for low temperature plasmas this can be set equal to the rotaional
temperature, as these two modes equilibrate quickly. The electron temperature can be set equal to
the vibrational temperature if there is no other information to better determine its value; it has a
much larger effect on the spectrum when both N2 and N2+ are both modelled, since this partially
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(a) Set Te = 1 eV (11604 K)































(b) Set Te = Tvib
Figure 3.8: Spectral Fitting Showing the Non-Independence of Te and Relative Concentration of
N2+ in Modeling the 2nd Positive System of N2 and the 1st Negative System of N2+
determines the amount of ionization occurring in the discharge. The ionization fraction (or species
ratio in the general case) determines the ratio of N2+ to N2, thus determining the amount of each
species spectrum in the overall result. Lastly, the instrument function, also called the slit function,
is the spread of a Gaussian curve that is convolved with the modelled spectrum to best match the
experimental spectrum. This is needed because the spectrometer does not have perfect resolution;
it broadens the lines from what is actually emitted by the plasma due to the instrument’s detector
resolution and the physical inlet slit (via diffraction). Though different instrument functions can be
used to better match the physical system (such as a Voigt profile or a trapezoidal profile), the sim-
plicity of a Gaussian profile is used in place of a measured slit function. These various parameters
are not necessarily independent of each other; in fact, in many cases they are not independent, as
shown in Figure 3.8. To remove this dependence, further information is needed; for example, the
electron temperature can be determined from Stark broadening of a hydrogen line in the spectrum.
The accuracy of modeling the temperature was shown to be up to 50 K for Trot and <500 K for
Tvib for the 2nd positive system of N2. An example fit of an experimental spectrum is shown in
Figure 3.9 for the FlashFuse system (see Section 7.5), where inserts are included to show the fit
for increasing or decreasing both Trot and Tvib by 200 K and 500 K respectively.
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Figure 3.9: Measured Experimental Spectrum with a Model Fit of Trot =598 K and Tvib =4244 K
Along with Model Fits (Grey Curves in Insets) of Trot ±200 K and Tvib ±500 K (+ Upper;− Lower
Grey Fits)
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(a) ICCD 357.7 nm Band (b) ICCD 380.5 nm Band
(c) PMT 357.7 nm Band (d) PMT 337.1 nm Band
Figure 3.10: Spectra of Various Wavelengths and Detectors for Bands in the 2nd Positive System
of N2 with Temperature Fits
3.4.3.3 Temperature Determination in Practice
In practice, a number of factors can affect the accuracy of the temperature determination. The
spectrometer resolution, band selection, and timing and light collection will be discussed.
The first is the resolution of the spectrometer and the resulting spectrum. The difference in
resolution is noted by comparing Figure 3.10a with Figure 3.10c. Though these are the same
system, band, and even the same spectrometer (including entrance and exit slit widths), the ICCD
detector is able to achieve a much better resolution than the PMT detector (see Section 3.4.1.1 for a
quantitative comparison). This is noted especially in the tail of the band heads, where the rotational
lines are resolved in the ICCD spectrum, while they are not resolved in the PMT spectrum. This
leads to more accurate Trot when using the ICCD compared to the PMT.
The second main factor affecting the accuracy of the measured temperatures for a plasma dis-
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charge is the band used for the temperature determination. The 357.7 nm band (Figure 3.10a)
and the 380.5 nm band (Figure 3.10b) of the 2nd positive system of N2 are roughly comparable to
each other, although the 357.7 nm band also has a small influence from N2+ which is absent in the
380.5 nm band. The main difference is with the 337.1 nm band (Figure 3.10d), where the addi-
tional vibrational levels are much smaller compared to the main band head. As such, an accurate
Tvib is nearly impossible since only one band head is investigated.
The last aspect that can affect the accuracy of the temperature determination is the combina-
tion of the spectrometer timing and light intensity. Sufficient light must be collected to obtain a
spectrum, but increasing the exposure time may have unintended consequences. The temperature
of a discharge may not be a constant, and for all of the discharges investigated in this dissertation
the temperature is highly time dependent. Thus the trade-off must be made between sufficient
light collection and time resolution. In general, all of the temperatures reported in this dissertation
are time averaged temperatures, because the dynamics of the discharge are occurring too quickly
(∼1–10 ns) for adequate light collection while maintaining any reasonable time resolution (i.e. ex-
posures on the order of 1 ns). The gas temperature that would cause issues in a medical setting is a
time averaged temperature, as well, further supporting this approach.
One way to work around the trade-off of light collection and time resolution is to assume that
all discharge events are identical. Thus a gated system could be used where the light is collected
many in short (∼1–10 ns) increments before it is read off of the detector. This has been done
with the ICCD, but not for any of the results reported in this dissertation. The main issue (beyond
the complications in creating the timing circuitry between the discharge and light detector) that
was found with this approach is that there is more noise for many short exposures of the ICCD
compared to long exposures. As such, some testing was done in a dark room to limit influence




This chapter introduces an electroporation system that is designed to apply a high electric field
to human skin with pulse durations ranging from ∼3 ns to >20 ns. This system is designed to
assist with drug delivery in dermal and epidermal applications. In addition to using a commercial
pulsed power supply system (∼3 ns pulse duration), a custom built RC pulse generating circuit,
capable of delivering 2–40 kV pulses with variable pulse widths of >20 ns, is also devised as
an inexpensive system to apply the fast electric field. An array electrode is developed of finely
spaced tips which allows for gas flow through the array as the high electric field applicator. The
system is characterized by high resolution imaging to observe uniformity across the array tips.
Three distinct discharge modes are noted for the system using the custom pulsed system. Optical
emission spectroscopy is used to determine some of the species created using this system, as well
as a method of determining the temperature of the plasma discharge. The plasma discharge is noted
to be substrate invariant for a range of conditions. The possible approval routes for marketing this
system are explored.
4.2 Electroporation Background
Electroporation is the application of an electric field on a cell to induce pore formation in
the cell membrane. Research began in earnest starting in the 1980s after transfection of plasmid
DNA was shown to occur using electroporation. [225] This has only been perfected in more recent
decades. [226] It was in the 1990s that it was determined that physical pores do form in cells as
a result of electroporation. This was done by rapidly freezing cells before performing electron
microscopy, which yielded images of 20–120 nm sized pores in the cell membranes. [227] These
pores were observed to start to close after several seconds, showing that electroporation is only a
transient effect (see Figure 4.1).
Electroporation is used to insert proteins into the cell membrane, introduce foreign matter into
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Figure 4.1: Electron Micrographs of Flash Frozen Cells Exhibiting Electroporation (Reproduced
under Fair Use from [228])
Electric Field
Figure 4.2: Schematic of Electroporation with Uses Including Protein Insertion, Foreign Matter
Introduction, and Cell Membrane Destruction
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the cell, or destroy the cell membrane, as shown in Figure 4.2. However if too high of a voltage
is used, the electroporation is irreversible, and the cell will not recover after the electric field is
removed. [229] Irreversible electroporation is not always undesired. It is one method of killing
cells, although other methods may be more useful or efficient for a given setting; in particular,
large areas of necrotic tissue often result if this is done in vivo. Often after electroporation a
number of cells are no longer viable, particularly for in vitro electroporation where it is difficult
to control the electric field magnitude for all cells. However newer electroporation techniques
are being developed that are more selective in the cells that are electroporated leading to higher
cell viability. Research shows that typically a transmembrane potential of around 1 V is sufficient
to induce electroporation. [225] For in vivo applications, reversible electroporation occurs for an
electric field around 350 V/cm and irreversible electroporation occurs around 600 V/cm, as found
using rat liver tissue with eight 100 µs pulses at 1 Hz. [229]
Clinical research is beginning to be done with electroporation; however it appears to solely be
in the field of electrochemotherapy, that is the application of electroporation for the insertion of
chemotherapy drugs directly into cancerous cells. Irreversible electroporation is not desired per se
due to creating large sections of necrotic tissue; however, small amounts of irreversible electropo-
ration may occur during electrochemotherapy. [230] The primary purpose is to assist in targeted
delivery of the chemotherapy drugs directly to the tumor. A number of drugs have been investi-
gated, predominantly bleomycin and cisplatin, which have been shown to have up to 1000 times
and 80 times cytotoxic enhancement, respectively, due to electroporation treatment. [231] Even
more, insertion of plasmid DNA is also being investigated for anti-cancer effect. [232] Though no
device is on the US market to date, advanced clinical trials are ongoing in this space. [233]
Conventional electroporation can be done in vitro in electroporation cuvettes using low voltage
pulses or in vivo where two electrodes are placed on opposite sides of a section of skin and a
voltage pulse is applied. Usually long (micro- or millisecond) pulses are used, but new research
has shown that nanosecond electroporation can also be used with some differing effects. Research
shows that nanopores are created using nanosecond-pulsed electric fields. [234] Other effects can
98
occur such as inducing apoptosis, damaging DNA, modifying caspase activity, and modifying
calcium functions in the cell. [7,234,235] Since the electric field is applied faster than the inherent
charge time of ∼100 ns for a cell, a higher electric field is possible before the charges migrate to
reduce the applied electric field. [236] This is one reason that though irreversible electroporation
was noted above 600 V/cm, [229] higher electric fields may still be used if they are applied over
nanosecond durations. However, more research needs to be done to understand what threshold
may exist for irreversible electroporation using a nanosecond pulsed electric field.
4.3 Device Life-Cycle Overview
The goal of this project was to develop and test a nanosecond-pulsed array and correspond-
ing pulsed power system that is capable of creating a uniform discharge with high electric fields
(100-150 kV/cm, note this is about 50 times the magnitude required for electroporation using mi-
crosecond pulses) and low current in ambient air that can also be operated using different working
gases. The system should be stable, safe, and robust within the operation range, such that anyone
with moderate training can use. This device seeks to be external to the patient, ideally without
direct contact, thus the electric field must also penetrate through the epidermis and into the living
cells in the dermis, a gap of ∼68.9 µm to the edge of the dermis. [237] Applying higher fields
nanoseconds in duration is one way to achieve the necessary high fields at depth, but inevitably
this will create a plasma, which is utilized in this project for device characterization. Plasma dis-
charges have also been investigated for their electroporation effect. [238] This system is intended
to be a novel nanosecond electroporation device for medical treatment.
As with most of the devices discussed in this dissertation, this device is very early in its de-
velopment. The need has been at least partially identified as epidermal electroporation to assist in
drug delivery through the skin and dermis (see Figure 4.3), but the market is a challenge due to the
nature of the FDA. This is because, as a combination drug/device, each new drug used will require
a separate approval process (see Section 2.4.1.7). As such, the need has to be further narrowed to a
specific drug, which will most likely narrow this to a specific application. One possibility is using







Figure 4.3: Schematic and Image of the Array for Epidermal Electroporation Applications
the most likely application as it has a large market, which also means many potential investors to
see this device through to marketing.
Significant work has been done in electrochemotherapy with other devices. An earlier clinical
trial was conducted in 2004, but it does not appear the FDA approved this device; most likely it has
stopped in clinical trials, [240] since no further information on it is publicly available. This may
be due to lack of funding to continue the project or may have occurred because poor results were
obtained and the project was cancelled. [241] It is unclear if this may be a similar device that has
been used successfully in Europe for electrochemotherapy. [242] There is a further clinical trial of
an existing, FDA-cleared irreversible electroporation device, called the NanoKnife, being used for
electrochemotherapy; [233] although it is unclear what FDA approach this system is taking, which
can affect the approach for this device. In addition, there is at least one clinical trial attempting
to use calcium, rather than bleomycin, as a device for electrochemotherapy, where calcium should
have fewer side-effects than the standard chemotherapy drugs. [243]
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4.3.1 FDA Approach
Most electroporation devices are designed for cell suspensions or similar setups rather than for
direct medical treatment. An example of this is the prevalence of electroporation cuvettes. [225]
This means that any device brought before the FDA will most likely be a novel device, requiring a
De Novo request. There is a small probability that the FDA would view this as a Class III system
and require a PMA, but this is unlikely, since the risks associated with an electroporation system
can be mitigated with special controls. Lacking a clear predicate device, the 510(k) pathway
does not seem to be a viable option, however a narrow use device may be possible via the 510(k)
pathway. This would require finding a need where an electroporation system has the same intended
use as the predicate device, but is operating with different technological characteristics; however
this is unlikely to be found.
Though there are a number of FDA cleared systems for operation as irreversible electropo-
ration devices [244, 245] (which all appear to be grandfathered into the FDA as derivatives of
older devices, possibly dating back to the Bovie power supply for electrosurgery), this device is
not designed for irreversible electroporation, and thus those existing systems cannot be used as a
predicate device. No device for clinical non-irreversible electroporation was found except those
used for electrochemotherapy (where small amounts of irreversible electroporation may occur);
however none of these systems are FDA approved. The NanoKnife system, though, may offer the
rare opportunity for a 510(k). If this system is cleared under a 510(k)1 or is granted a De Novo
request, this would allow further devices to seek a 510(k) clearance using it as the predicate device.
However, the use would most likely be limited depending upon the exact wording of the intended
use of the NanoKnife system predicate.
The main difficulty in this device is that it is designed to be paired with a drug to be delivered,
which opens the possibility of complex reactions, since not only is the reaction of the tissue to
the applied electric field needing to be considered but also the drug-tissue interactions, the drug-
1A 510(k) clearance is unlikely, since this should be viewed as a combination device, and no similar drug/device
combination is currently approved.
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electric field interactions, and even the possibility of a drug modified by the electric field interacting
with the tissue. This will require substantial study to show that there are no unintended results. As
such, the De Novo request may be the best option. This is the most probable course for any device
seeking a combination drug/device without a clear predicate, which is the most probable use for
electroporation devices in a clinical setting.
However, electroporation by itself may yield enough benefit it can be used without pairing
it with a drug or a drug may be applied after electroporating the tissue. In this case, a 510(k)
option may be available. This would allow a limited number of drugs to be used that could be
applied after the electroporation, thus avoiding potential plasma-drug interactions. This, however,
may still be considered a combination product, but the risks are lower since the electroporation
system and drug are applied in series rather than parallel. Later, the developer can begin trials
with other drugs that cannot be applied in series, while being able to market the device and ideally
turn a profit. This seems to be the general approach for AngioDynamics, Inc., the manufactures
of the NanoKnife system, who are currently using their 510(k) cleared device in clinical trials
for electrochemotherapy, most likely in support of a De Novo or similar combination product
(bleomycin, the drug, along with the device) submission. [233]
4.3.2 Device Outlook
For our device, the possibility of using nanosecond pulsed electric fields for electroporation of
the epidermis is desired, without the need to insert electrodes into the dermis as is commonly done
for electrochemotherapy systems. [230] Though we are not targeting a specific drug at this point,
we would most likely also use an anti-cancer drug, such as bleomycin or even just intracellular
calcium. [243] Thus we are considering how to ensure the safety of the device in our design such
that it could be used in a clinical setting. The testing is also designed to show at least from a bench
top scale, that this device is biocompatible and could be taken through further testing to become a
clinical device. Nevertheless, further verification studies should be conducted on this device.
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4.4 Device Design
The device consists of two main parts, a nanosecond pulsing circuit and an electrode to deliver
a wide area high electric field treatment. These two parts will be discussed in the following sub-
sections. Initially the FID power supply (see Section 3.2.1.3) was used as the nanosecond pulsing
circuit; however, this power supply is prohibitively expensive for widespread use, so a custom RC
pulse generating circuit is devised as detailed in the next subsection.
4.4.1 RC Pulse Generator Circuit Design
To maximize the desired high electric field (E), high voltage (V ) and fast voltage rise time are




where d is the distance between two electrodes, thus clearly higher voltage produces higher electric
fields. This gives an initial approximation to yield the desired electric field magnitudes of 100–
150 kV/cm; using an applied peak voltage of 30 kV an electrode-substrate gap of 2 mm is needed.
However if there are charges present in the form of free electrons or ions, these charges can build
up on dielectric surfaces which then negate the applied electric field. Therefore the rise time on
the voltage should be comparable to the ion transit time to allow for a high electric field before
the ions have time to migrate and decrease the electric field. Since cells have an inherent charge
time on the order of 100 ns, [234] a nanosecond pulsed system is required to maximize the electric
field. To achieve a nanosecond rise time in voltage, a fast switch (i.e. operating on a nanosecond
time-scale) is needed capable of supporting high voltage. The two main options are spark gaps or
solid state devices, such as insulated-gate bipolar transistors (IGBTs). One main drawback to such








where E is the energy delivered, C is the capacitance being discharged (normally a constant for
a given system, thus the energy applied scales with V 2), and Q is the charge transferred in the
discharge. This large amount of energy is often incompatible with biological substrates. The main
way to limit the energy delivered, while still maintaining the high voltage and fast voltage rise
time, is to have another fast operating device in parallel to the load which is able to take most of
the energy. This could be a resistor, inductor, etc. that is able to operate on the timescale of the
voltage pulse. For our design detailed below, a second spark gap that is in parallel to the load is
used to take most of the energy from the discharging capacitor.
For this project, an RC pulse generator was developed which consists of four switchable ca-
pacitors (5 nF, 500 pF, 50 pF, and stray capacitance), an optional secondary resistor to dampen the
pulses, two independently adjustable spark gaps, and a third spark gap used for triggering the main
spark gap. As this pulse generator was delivered to the project sponsor, a user guide for was de-
veloped to help ensure proper operation, which is included in Appendix A. The schematic of the
RC pulse generator is seen in Figure 4.4, and the inside of the box housing the RC pulse generator
is seen in Figure 4.5. The box is well insulated to ensure no undesired breakdown would occur in
it or to its outer shell. It has the ability to be locked to avoid any unauthorized users from gaining
access to it, as well as a top acrylic shield (not shown in the images) to allow basic diagnostics on
it without being exposed to the high voltage.
Until the main spark gap (MSG) breaks down, the circuit is a standard RC charging circuit. A
Spellman high voltage DC power supply (PS, see Section 3.2.1.1) initially charges the capacitor
(C) through a resistor (R1). Once sufficient charge has been built up on the capacitor to reach the
breakdown voltage of the MSG, a spark occurs bridging the gap and resulting in a fast voltage
rise downstream of the MSG. If the second spark gap (SSG) distance is small enough, it will
discharge as a spark, taking most of the energy from the discharging capacitor and shortening the
voltage pulse; if the SSG is too long, it will not break down resulting in significantly more energy
being delivered to the array and substrate load and a much longer pulse duration will result (∼1 µs
for the single spark gap configuration compared to∼20 ns for the double spark gap configuration).
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Figure 4.4: Schematic of the RC Pulse Generator
More details on this long pulse mode can be found in Appendix A. The voltage pulse travels down
a meter-long twisted pair high voltage cable (a transmission line because the differential impedance
is roughly constant along the wire due to a constant high voltage wire to ground wire distance with
no change in the dielectric material separating them) connecting the array and substrate load to the
RC pulse generator. If the load is conducting the current will travel through the array and substrate
directly to ground; if the load is non-conducting, the voltage pulse will get partially reflected back
to the RC pulse generator, resulting in a higher voltage across the load than the breakdown voltage
of the MSG for the duration of the voltage pulse transit time in the transmission line. The load
can still be non-conducting even if the substrate is conducting due to an array-substrate gap that
is too large for complete breakdown to occur. The secondary resistor (R2) is used to dampen any
oscillations in the voltage pulse by slowly draining off excess charge. R2 does not greatly affect the
voltage pulse unless its resistance value is quite small (∼100 Ω, see Appendix A). Two grounding
locations are noted (G1 and G2) even though they are both ground. This is because for the duration




R2 in insulating tube











Figure 4.5: Image of the RC Pulse Generator with the Lid of the Housing Open
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Figure 4.6: Comparison of Voltage Traces for Dielectric and Conductive Substrates with the RC
Pulse Generator for a VC = 9 kV and VC = 27.5 kV Breakdown Voltage Case
inductance. This also clarifies that the ground side of the transmission line is actually connected
directly to ground and not floating, relying on the ground reference inside of the box. The third
spark gap (EXT ) is operated by an external circuit board (CB, Ignitor10 power supply from
Information Unlimited) mounted on the side of the main box housing the RC pulse generator. The
EXT is able to trigger the MSG to fire when it is just below the breakdown voltage. It does this
by introducing a few seed electrons (primarily by photoionization however due to its physically
close location electron diffusion may also be significant) to initiate the breakdown process in the
MSG.
By varying the spark gap distances of the MSG and the SSG, the desired pulse voltage and
107
(a) Dielectric Substrate (b) Conductive Substrate
Figure 4.7: Comparison of Voltage and Current Traces for a VC = 9 kV Breakdown
duration are able to be specified for a given load. The pulses from the RC pulse generator appear
very repeatable, with a variance under 5%. Like any high voltage pulsed power supply, there is
some load dependence on the pulse characteristics. For lower voltages (for a 5 mm electrode-
substrate gap it was below 18 kV and 30 kV for a metal conductive and glass dielectric substrates,
respectively) the air gap acts as a dielectric and voltage reflection can occur, leading to pulse
voltages higher than the breakdown voltage on the capacitor, C. Some typical voltage pulses
are shown in Figure 4.6. Nevertheless, peak pulse voltages were generally close (within about
3 kV) to the breakdown voltage on the capacitor (generally only slightly higher if voltage reflection
occurred). This is because the characteristic impedance of the transmission line (the meter-long
twisted pair high voltage cable) is not well matched with most of the loads. There was roughly
a 1 kV/ns rise and fall on the voltage pulse if the SSG was set at or below an optimum value for
a given load; larger SSG distances did not reliably fire, leading to longer pulse durations with
substantially slower fall times. SSG distances below the optimum value reduced the peak pulse
voltage but still maintained the 1 kV/ns rise and fall speeds. This speed limit on the rate of the
voltage change is due to the characteristic impedance of the transmission line between the RC
pulse generator and the load.
The voltage traces in Figure 4.6 are plotted together to show the effect of the load and break-
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(a) Dielectric Substrate (b) Conductive Substrate
Figure 4.8: Comparison of Voltage and Current Traces for a VC = 27.5 kV Breakdown
down voltage of the MSG. Despite nearly identical behavior for the lower breakdown voltage
(measured across the capacitor as 9 kV), the two loads have very different voltage traces (both in
maximum peak voltage attained and later ringing in the voltage) for the higher breakdown volt-
age case (measured to be 27.5 kV across the capacitor). These voltage traces are also shown in
Figure 4.7 and Figure 4.8 for VC = 9 kV and VC = 27.5 kV breakdown voltages, respectively.
In addition to the voltage trace the corresponding current is also displayed along with the energy,
found by multiplying the instantaneous current and voltage (i.e. the instantaneous power) and then
integrating. The oscilloscope was limited to only displaying ±40 A, thus the current peaks for
the VC = 27.5 kV breakdown cases was cut off. Peak values were assumed (dashed lines) and
thus an estimate on the instantaneous energy was also determined for those cases as well. The
current traces and energy traces are comparable in the VC = 9 kV breakdown voltage case, but
there are significant differences in the VC = 27.5 kV breakdown case. For all cases, it appears
that the majority of the energy delivered occurred on the initial voltage and current rise (the higher
breakdown voltages cases are possibly skewed slightly due to the current not being adequately
measured), but further energy was delivered when the current fell; for the higher breakdown volt-
age case with the conductive substrate this current fall took longer to occur due to some ringing
in the current signal. The total energy was nearly equivalent in the lower breakdown voltage case,
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suggesting the air gap between the array and substrate did not completely break down; the stream-
ers formed apparently did not form a fully conductive path to ground. Substantially more energy
was delivered for the higher breakdown voltage cases. Counterintuitively, the dielectric substrate
had substantially higher energy delivered for the higher breakdown voltage case compared to the
conductive substrate. This occurred because the voltage and current magnitudes were higher for
this load, especially the large fall in the current. This is most likely explained by better matching
of the transmission line with this load than the conductive load.
The RC pulse generator is designed for a wide range of pulse frequencies from a single pulse
up to ∼100 Hz depending on the voltage and current supplied from the power supply (the power
supply was limited to 7.8 mA). The pulse voltage has a minimum value around 2 kV, due to issues
in reliably spacing the main triggering spark gap; the power supply was limited to 40 kV, serving
as an approximate upper voltage limit, although higher voltages are possible if voltage reflection
occurs. The EXT has some inherent jitter on the order of 1 µs in triggering the MSG to break
down, nor did it always trigger the main spark gap to break down since it had to be placed far
enough away to avoid the high voltage side of the MSG from discharging to the ground of the
EXT . For more detailed information on the operation of the RC pulse generator see the user
guide in Appendix A.
4.4.2 Electrode Array Design
To achieve a uniform high electric field, a high density of sharp tips is desired. This is because





where r is the radius of the tip. Sharper tips yield the higher electric fields. By creating an array
of tips, the electric field will be approximately uniform ∼0.5 mm from the tips, as determined by a
2D electrostatic model run in Comsol, shown in Figure 4.9.
This model (Figure 4.9) serves as a qualitative measurement of the effect that sharp tips have on
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Figure 4.9: Schematic of the 2D Electric Field Model for the Array Tip Electrode and Graph of
the Resulting Modeled Electric Field
enhancing the electric field. The model geometry has an array of 6 tips spaced 1 mm apart held at
1 kV (purple color) and ground 2.5 mm away at the bottom of the geometry (orange color). There
are 4 lines where the electric field along the length is determined (red, blue, black, and green lines).
The tips provide a local enhancement of the electric field, which becomes virtually non-existent at
a distance of 1 mm from the tips. As such, for very short gaps (<0.5 mm) the electric field will be
enhanced near the tips, leading to a more non-uniform electric field; farther away from the tips the
electric field becomes lower than near the tips but approaches a uniform value.
The array was developed by using electrical discharge machining (EDM). Thin sheets of 1 in
wide stainless steel were stacked together and portions were removed to create an array of tips
along the length of each stainless steel sheet. U-shaped spacers were inserted between the EDM
sheets to create a gas inlet, mixing chamber, and outlet near the tips by alternating their orientation,
such that one opens up at the gas inlet and the other points in the opposite direction to be a gas outlet
(see Figure 4.10). The array of tips was then placed in a block of Teflon to hold them together. The
Teflon also acts as a good electrical insulator to protect the operator from the high voltage. A gas
inlet was placed in the back of the Teflon block, and a high voltage wire was connected through
the side to the stainless steel array. The final design is seen in Figure 4.11.
Three arrays were developed with varying tip spacing as noted in Table 4.1. Images of the
different arrays are shown in Figure 4.12. Array #1 was used for all of the testing reported here
except for the array comparison testing.
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Figure 4.11: Image Showing the Design of the Array Electrode
(a) Array #1 (b) Array #2 (c) Array #3
Figure 4.12: Discharge Imaging Comparison of the Three Array Electrodes
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Table 4.1: Comparison of the Design Parameters for the Three Array Electrodes
Array # Tips/Sheet Sheets Number of Tips
1 25 19 475
2 51 19 969
3 51 48 2448
The three arrays were compared using the FID power supply at a voltage of 15 kV and a fre-
quency of 1 kHz with a 3 mm gap. Array #1 appears to be the most uniform, but the differences
may be due to slight alignment differences between the arrays. Nevertheless, all three arrays de-
veloped streamer discharges. Optical emission spectra was collected for two wavelength ranges
with an ICCD camera (352–358 nm and 375–381 nm, see Section 3.4.1.1). The 2nd positive system
of N2 along with the 1st negative system of N2+ was compared to modeled spectra from SpecAir to
determine the rotational (Trot) and vibrational (Tvib) temperatures of the nitrogen species in the gas
(see Section 3.4.3.2). The results are shown in Figure 4.13. No clear trend seems to exist in the
data, especially when one considers that the error in the temperature fitting is ∼50 K for Trot (see
Section 3.4.3.2 for temperature determination considerations). The slight increase in temperature
from Array #2 could be due to slight issues in alignment where the array was slightly closer to the
ground electrode.
4.5 Device Characterization
The basic experimental setup is shown in Figure 4.14 with images in Figure 4.15. The main
goals were
1. to observe uniformity of the tips lighting up on the array, which would suggest a fairly
uniform electric field across each tip,
2. to identify the various species created from the discharge,
3. to determine the temperature of the discharge, and
4. to estimate conditions that would maximize the electric field in the substrate.
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Figure 4.13: Temperature Comparison of the 3 Arrays (the Error Bars Shown Represent 1 Standard
Deviation)
All testing was done in ambient air, although the gas flowing through the array was varied. Imaging
was done with a Nikon D3300 camera (see Section 3.3.1 for details on the camera). Spectra was
collected from 200–800 nm using a scanning monochromater (see Section 3.4.1.1 for details on the
spectrometer) with a PMT detector for the FID testing and the ICCD (see Section 3.3.2 for camera
details) for the nanosecond RC pulse generator circuit testing. Initial testing was done with the
FID power supply before switching to the RC pulse generator.
4.5.1 Initial FID Testing
Initial testing was conducted using the FID power supply (described in Section 3.2.1.3) using
Array #1 discharging into ambient air. Optical images were taken along with spectra to determine
the species in the gas along with the temperature of the discharge.
4.5.1.1 Array Imaging
A parametric study was performed, with five gas flow conditions (air at 4.3 SLPM, argon at
3.61 SLPM, helium at 8.54 SLPM, nitrogen at 4.35 SLPM, and no gas all flowing into ambient
air), four power supply conditions (1 kHz, 15 kV; 1 kHz, 30 kV; 10 kHz, 15 kV; 10 kHz, 30 kV),
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Figure 4.15: Images of the Array Testing Setup with Dielectric and Conductive Substrates
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Figure 4.16: FID Discharges with Air Flow onto a Dielectric
and three substrates (metal plate, glass petri dish filled with grounded salt water to have a consis-
tent dielectric, and pig skin thawed from frozen pork bought at the local grocer ∼4 mm thick) to
determine uniformity across all of the tips in the array. The results are shown in Figures 4.16–4.20
for the glass substrate and in Figures 4.21–4.25 for the metal substrate. Figure 4.26 shows the
results for pig skin with no gas flow.
General trends were brighter and more uniform discharges at higher voltages. Helium created
the most uniform discharge (Figure 4.20 and Figure 4.25), having all of the tips on the array lighting
up; all other gases (and no gas flow) were comparable in uniformity. The color of the discharge
varies depending on the gas due to various species and concentrations being created. The metal
substrate generally led to brighter discharges (especially when it was grounded, though no floating
metal images are shown here) compared to pig skin and the glass dielectric substrate. The dielectric
glass substrate generally had a more uniform discharge across the tips. Uniformity on pig skin was
difficult mainly due to non-uniformities in the pig skin itself (Figure 4.26). The metal substrate
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Figure 4.17: FID Discharges with No Gas Flow onto a Dielectric
Figure 4.18: FID Discharges with N2 Flow onto a Dielectric
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Figure 4.19: FID Discharges with Ar Flow onto a Dielectric
Figure 4.20: FID Discharges with He Flow onto a Dielectric
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Figure 4.21: FID Discharges with Air Flow onto a Conductor
Figure 4.22: FID Discharges with No Gas Flow onto a Conductor
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Figure 4.23: FID Discharges with N2 Flow onto a Conductor
Figure 4.24: FID Discharges with Ar Flow onto a Conductor
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Figure 4.25: FID Discharges with He Flow onto a Conductor
Figure 4.26: FID Discharges with No Gas Flow onto Pig Skin
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was also very difficult to align, thus the right side is brighter due to being slightly closer to the
array. The metal substrate easily developed individual streamers that transition toward a spark
discharge. These are clearly seen in air (Figure 4.21 and Figure 4.22), N2 (Figure 4.23), and argon
(Figure 4.24) for the 1 kHz discharges, where one or two tips on the right side are brighter than
the others. This is explained by one or two of the tips having a slightly more negative differential
resistance. As the electron avalanche is initiated one or two of the tips will breakdown easier and
faster than the others. Since a more conductive path begins to form on those tips the majority of
the current flows through them, leading to a more intense discharge on them.
4.5.1.2 Spectra
Broadband optical emission spectra (OES) were collected from 200–800 nm with a PMT detec-
tor (see Section 3.4.1.1) for the dielectric substrate for five gas flow conditions (air (4.3 SLPM), Ar
(3.61 SLPM), He (8.54 SLPM), N2 (4.35 SLPM), and no gas all flowing into ambient air) and four
power supply conditions (1 kHz, 15 kV; 1 kHz, 30 kV; 10 kHz, 15 kV; 10 kHz, 30 kV). The gas flow
rates were chosen since they all have a consistent rotameter setting. OES were also collected for
temperature determination of these conditions using three wavelength ranges (325–339 nm (Trot
only), 347–359 nm (Trot and Tvib), and 363–382 nm (Trot and Tvib)). Spectra for the helium dis-
charge was not modeled since the light levels for the 2nd positive system of N2 were too low for
accurate modeling. Note that the temperatures reported are the gas temperatures, not the substrate
temperatures which can be much lower. An infrared (IR) thermometer was used to measure the
substrate temperature, and no increases over 5◦C were noted.
There was no observable change in the spectra other than increased light intensities for in-
creasing voltage and frequency, as seen in the N2 flow spectra in Figure 4.27, so the other reported
spectra (Figure 4.28) are only for the brightest condition of 10 kHz and 30 kV. In the spectra for
both no gas flow and air flow mostly only N2 (2nd positive system) was observed with a few trace
impurities. This is expected, since nitrogen is the dominant gas in air. Oxygen, being electroneg-
ative, does not emit light easily. In N2, a significant amount of NO (γ system) was also observed;
however no peak for atomic oxygen was noted. The additional NO lines are likely coming from a
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(a) 1 kHz 15 kV






























(b) 1 kHz 30 kV






























(c) 10 kHz 15 kV






























(d) 10 kHz 30 kV
Figure 4.27: Spectra of FID N2 Discharges for Various FID Power Supply Settings (Unidentified
Peaks are Second Order Artifacts from the Spectrometer)
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Figure 4.28: Spectra of FID Discharges for Other Gases at 10 kHz and 30 kV (Unidentified Peaks
are Second Order Artifacts from the Spectrometer)
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different electron temperature, Te, in the discharge due to fewer electronegative O2 molecules cap-
turing free electrons. [246–248] This different Te in turn changes the chemistry occurring in the
discharge since different excited states are being created. For argon, OH (A-X system) dominated
the spectra, with some N2 (2nd positive system) and argon visible. Since argon has a high ionization
energy (15.8 eV), an argon atom is able to store significant energy in its electronic states and then
release it upon colliding with other species in the gas. The O-H bond in water has an energy of
4.8 eV, which is much lower than the amount of energy an excited argon atom could carry. The
spectra indicates that the reaction between an excited argon ion and water, namely
Ar∗ +H2O → Ar +OH +H (4.4)
is significant. No hydrogen lines are visible though, possibly due to them not gaining sufficient
energy to subsequently emit or perhaps due to possible participation in further chemical reactions.
Trace amounts of NO (gamma system), O (777 nm), and H (656 nm) were noted in helium along
with various helium peaks. OH (A-X system) and N2+ (1st negative system) dominated the helium
spectra. Similar to argon, helium has a high ionization energy (24.6 eV), thus it can store a signifi-
cant amount of energy and release it upon collision with another species, such as water or nitrogen.
Since the ionization energy for N2 is 15.6 eV, which is comparable to the ionization energy of ar-
gon, it is observed in helium but not argon. If an argon atom had sufficient energy to ionize N2, it
would instead be ionized, rather than storing that energy until colliding with a nitrogen molecule.
The unlabeled peaks in the spectra are from the 2nd mode of the spectrometer, and thus correspond
to doubled wavelengths of the brightest transitions noted in the spectra.
From modeling the temperatures, air (and no gas flow with discharge into ambient air) had the
highest vibrational temperature and lowest rotational temperature (Figure 4.29). Argon had the
highest rotational temperature and the lowest vibrational temperature; however this analysis may
not be accurate since it does not account for excitation of the nitrogen species from collisions with
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Figure 4.29: Plot of Rotational and Vibrational Temperatures of the FID Discharges
argon metastable species, namely
Ar∗ +N2 → Ar +N∗2 (4.5)
The analysis that yields these temperatures assumes only excitation by electron impact. Otherwise
a non-Maxwellian distribution would result, which SpecAir cannot model. In general higher vi-
brational temperatures are correlated to higher electron temperatures which correspond to higher
E/n, thus it is likely that air has a higher electric field. [249] This is supported by the fact that air
is electronegative due to its relatively high oxygen content, making it harder to break down and
requiring a higher E/n. There was no large trend in the spectra for higher voltages or frequencies.
4.5.2 RC Pulse Generator Testing
Further study of the array was conducted using the RC pulse generator using the same sub-
strates previously discussed, namely a biological substrate (pig skin thawed from frozen pork
bought from the local grocer ∼4 mm thick), a conductive substrate (thin aluminum or stainless
steel sheet), and a dielectric substrate (a glass petri dish filled with salt water and grounded through
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a wire in the salt water). The main spark gap, second spark gap, electrode-substrate gap, and air
flow through the array were varied. Having observed from the FID testing that air is possibly the
best gas for enhancing the electric field further testing did not vary the type of gas flowing through
the array. All data was taken at a pulsing frequency of 5 Hz using a BK Precision 4063 function
generator to get the desired pulsing frequency via the external trigger spark (EXT ) and circuit
board (CB). The voltage pulse magnitude and duration (FWHM) were taken from oscilloscope
traces (LeCroy WaveRunner 204MXi oscilloscope with North Star PVM-4 high voltage probe,
see Section 3.2.2.4 and Section 3.2.2.1 for the oscilloscope and high voltage probe information,
respectively).
4.5.2.1 Array Imaging
Overall three main discharge modes were noticed with the RC pulse generator. The first mode
is streamers only visible on the edge of the array directed toward the substrate. This discharge
mode occurred for all three substrates. There are variations only in light intensity with varying
other conditions such as the pulse voltage, pulse duration, electrode-substrate gap distance, and air
flow rate. This discharge mode is seen for pig skin in Figure 4.30. This first discharge mode is seen
for the conductive metal substrate in Figure 4.31. Figure 4.31c shows a different angle as well to
note that there are no visible discharges in the center of the array. This first discharge mode is also
seen for the glass dielectric substrate in Figure 4.32. In Figure 4.32d a few streamers are visible in
the center of the array (the benefit of having a transparent substrate of glass) though not nearly as
densely occurring as at the edge of the array, where all of the tips are showing a streamer discharge.
This is most likely due to a slightly higher negative resistance in the outer tips that is less noticed
with the FID power supply due to the fast rise time of the voltage pulse. This is possibly analogous
to the “donut” shape of the ionization wave noted in helium plasma jets. [250,251] In this case, the
visible discharges may be travelling along the helium-air boundary, where breakdown is easier.
The second discharge mode was observed for the dielectric glass substrate with no gap between
the array and the substrate as seen in Figure 4.33 (this has some of the same power supply condi-
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(d) Varying Electrode-Substrate Gap
Figure 4.30: Images of the Array’s First Mode with the RC Pulse Generator for the Biological
Substrate Showing Streamers Only on the Edge of the Array with Only Variations in Light Intensity
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(d) Varying Air Flow Rate
Figure 4.31: Images of the Array’s First Mode with the RC Pulse Generator for the Conductive
Substrate Showing Streamers Only on the Edge of the Array with Only Variations in Light Intensity



















(d) Varying Pulse Duration (Different Angle)
Figure 4.32: Images of the Array’s First Mode with the RC Pulse Generator for the Dielectric
Substrate Showing Streamers Only on the Edge of the Array with Only Variations in Light Intensity
















8 SLPM Air 0 SLPM Air 
(c) Varying Air Flow Rate
Figure 4.33: Images of the Array’s Second Mode with the RC Pulse Generator for the Dielectric
Substrate Showing Spreading of the Streamers on the Substrate for a Variety of Conditions All
with an Electrode-Substrate Gap of 0 mm with Only Variations in Light Intensity for Changing
Discharge Conditions (All F#40, 30 s Exposure, and No Air Flow Unless Noted Otherwise)
different yielding different voltage pulse magnitudes and durations). In this second discharge mode
the streamers, instead of being directed toward the substrate, spread out across the substrate. This
occurs because the surface becomes charged, thus the streamers must spread out to find ground
(i.e. a potential of zero). Similar to the first discharge mode, there are no visible streamers in the
center of the array.
When the voltage was increased above a threshold or the electrode-substrate gap reduced be-















5 s exposure 20 s exposure
Figure 4.34: Images of the Array’s Third Mode with the RC Pulse Generator for the Conductive
Substrate Showing Brighter Discharges for Certain Conditions Where the Streamers Have Transi-
tioned to Higher Energy Spark Discharges with Changes in the Applied Voltage (Increasing SSG
in This Case) and Electrode-Substrate Gap Distance (All F#25)
Figure 4.34. The discharge would begin like the first discharge mode, but then one or two of the
streamers from individual tips would become a preferential path for current and thus grow much
brighter as that streamer begins transitioning to a full spark discharge (note that the middle image
in Figure 4.34 is actually 25 distinct discharge events, thus multiple spark discharges are seen).
4.5.2.2 Spectra
No broadband spectra was collected for the RC pulse generator. It is assumed to be similar
to the FID power supply for the no flow or air conditions (see Figure 4.29). Broadband emission
would have been much more difficult to acquire, since the array was only pulsed at 5 Hz, compared
to 1–10 kHz for the FID spectra. Significantly longer exposure times would have been required.
Optical emission spectra were acquired for temperature data using two wavelength ranges
(352–358 nm and 375–381 nm) with an ICCD detector (see Section 3.4.1.1). The emitted light
was collected for around 10 minutes (usually 60 exposures each 10 seconds long to allow enough
light to adequately expose the ICCD). The 2nd positive system of N2 along with the 1st negative
system of N2+ were compared to modeled spectra from SpecAir (see Section 3.4.3.2). Overall for
all substrates the rotational temperatures are low, suggesting the discharge is not transitioning to a
glow mode but remains as a streamer discharge (Figure 4.35). For a glow discharge in air, Staack
et al. found a rotational temperature of 1320 K, which is much higher than the 389 K for the metal
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Figure 4.35: Temperature Comparison Using the RC Pulse Generator for Varying the Substrate
with Vmax = 25±2 kV, FWHM = 26±1 ns, Gap = 7 mm, and No Air Flow
another mode, irrespective of the substrate used. The conductive metal showed a slightly higher
rotational temperature and a corresponding lower vibrational temperature than the dielectric glass
and pig skin substrates (Figure 4.35). This is most likely due to higher current (a slight transition
toward a spark discharge compared to the other substrates) for the metal substrate, which is slightly
heating the gas.
This low rotational discharge temperature holds true (see Figure 4.36) for varying the applied
voltage (i.e. maximum peak pulse voltage) from 12.4 kV to 26.3 kV, varying the pulse duration
(FWHM) from 15.9 ns to 33.8 ns, varying the air flow rate from 0 SLPM to 8 SLPM, and varying
the electrode-substrate gap from 4 mm to 9 mm. No large effect of varying the gap distance is
expected, since the variation in the gap size only affects the overall electric field (note: E = −V
d
).
However the streamer head produces a local electric field (which is initiated by the voltage pulse
at the small radius of the tips which does not change), which does not vary with changing the
electrode-substrate gap; thus overall the electric field is mostly constant. The effect of higher
convection due to the air flow rate happens on a time scale much larger than the voltage pulse, thus
the flow does not affect the plasma temperatures or electric field.
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Figure 4.36: Temperature of Array Discharges for Varying the Applied Voltage, Pulse Duration,
Air Flow Rate, Substrate, and Electrode-Substrate Gap
It was noticed that the 378 nm peak family consistently showed lower temperatures (both Trot
and Tvib) than the 356 nm family. This could be due to the greater effect of N2+ concentration on the
modeled spectra in the 356 nm family, while no N2+ peaks appear in the 378 nm family. Overall,
the temperatures were Trot = 310±35 K and Tvib = 4208±717 K. Some rotational temperatures
were observed to be lower than ambient. This is due to some error in the modeling; however it was
consistent and should not affect any trends visible in the data.
A measurement of the temperature of the second discharge mode was also attempted, where
there was sparking on every second or third pulse to the conductive substrate. As seen in Fig-
ure 4.37, there are a number of iron peaks in the N2 spectrum, indicating electrode ablation, as
this is the main constituent of the stainless steel array electrode. As the discharge changes mode,
the electrode heats up and some of the electrode is ablated, introducing enough iron to obscure the
spectrum. There also appears to be some continuum in the background, which also makes temper-
ature determination nearly impossible for this spectral range. For another band in the 2nd positive
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Figure 4.37: Spectrum of 2nd Positive System of N2 for the Second Mode of the RC Pulse Generator
Showing Many Iron Peaks and Some Continuum Emission, Making Temperature Determination
Impossible (Model Spectrum Is for Trot = 300 K and Tvib = 4500 K, and Was Not Fitted to the
Spectrum




















Figure 4.38: Temperature of the Second Mode for the RC Pulse Generator With Small Gaps (Gray
Boxes) Not Modelled Due to Iron Peaks in the Spectrum
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system of N2, there were fewer iron lines that could be removed from the spectrum for temperature
determination (see Figure 4.38). However, in addition to the iron peaks removed (gray boxes in
Figure 4.38), there is an iron peak (3d6(3G)4s4p(3P ◦)→ 3d7(2H)4s) at 357.4 nm, which lines up
near the band head of nitrogen (C3Πu → B3Πg, ∆ν = 0 → 1) at 357.6 nm which was not ac-
counted for, possibly increasing the apparent height of the N2 band head and incorrectly matching
the temperatures.
4.5.3 Computational Model of the Electric Field in Skin
This section provides a basic computational model of the electric field in skin. This illustrates
the benefit of using a streamer to apply the electric field closer to the skin and provides a rudimen-
tary analysis of the depth of penetration of the electric field into the skin. At the request of the
project sponsor, this model was done for a planar DBD rather than exactly matching the geometry
of this setup. Nevertheless, the basic trends will stay the same. In addition, the modeling with a
streamer is nearly the same as would be done without the dielectric barrier.
The electric field was modeled using Comsol (version 4.3) under four conditions:
1. With a 100 µm streamer head and a circular ground electrode on top of the substrate,
2. With plasma with 100 µm streamer head and a far away ground,
3. Without plasma but with a 2 mm air gap between the DBD electrode (1 mm thick quartz) and
substrate and a circular ground electrode on top of the substrate, and
4. Without plasma but with a 2 mm air gap between the DBD electrode (1 mm thick quartz) and
substrate and a far away ground.
Conditions 1 and 2 are seen schematically in Figure 4.39a, where condition 2 lacks the copper
ground electrode. Conditions 3 and 4 are seen schematically in Figure 4.39b, where condition 4
lacks the copper ground electrode.
The model was conducted as a 2D axisymmetric system with the electrostatics package as a
stationary (time independent) study. A zero potential was applied 4 mm deep into the skin and on
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(a) With Streamer (Conditions 1 & 2)















(b) Without Streamer (Conditions 3 & 4)
Figure 4.39: Schematics of the Comsol Model for the Electric Field in Skin with and without a
Plasma Streamer (Note the Images are Not to Scale)
the copper ring ground electrode. A potential of 40 kV was applied to the high voltage electrode
and to the plasma streamer. A boundary condition of dielectric shielding was applied to the air and
far edge of the skin. Charge conservation was applied to all areas with an initial zero voltage. Ac-
cording to Sunaga et al. the relative permittivity of skin varies greatly, even for an individual. [252]
For this study, the value of 120 was used, which is in relatively close agreement with both Gabriel
et al. and Penn and Bell; [253,254] this is approximately the permittivity of human skin at 20 MHz
(i.e. a pulse with a 50 ns period).
The magnitude of the electric field has been plotted below along two lines: the central axis for
depth into the skin (Figure 4.40a) and radially through the skin halfway to ground at a depth of
2 mm (Figure 4.40b). Overall the ground electrode has nearly no effect on the electric field since it
was too far away; instead, the ground 4 mm deep into the skin determined the voltage and electric
field. The electric field was locally higher with the plasma streamer. This is seen in Figure 4.40a
where the electric field directly under the streamer is ∼1.2 times higher (∼1700 V/cm compared
to ∼1400 V/cm) than the electric field without a streamer, but the field drops to a value very close
to the electric field without a streamer as depth into the skin is increased. This locally higher
electric field from the presence of the streamer also decreases quickly with radial distance away
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(b) Radially 2 mm Deep
Figure 4.40: Plot of the Modelled Electric Field Magnitude into the Skin Along Multiple Directions
from the streamer, lasting only ∼4 mm when 2 mm deep into the skin, as noted in the inset graph
in Figure 4.40b.
Since this model does not account for moving charges (i.e. plasma, other than the presence of
a streamer), the air and skin act as distributed capacitances; a simple 1D series capacitor equation
describes the results fairly accurately. Assuming equal and constant cross-sectional areas (Across)
for the skin and air (with thicknesses lskin and lair, respectively) and a uniformly applied electric
field (E = V
l
), the capacitor equation (C = εAcross
l








This equation shows that the electric field in the skin, Eskin, is roughly proportional to the applied
voltage, V , assuming the voltage drop through the quartz dielectric (Vquartz) is small (no dielec-
tric can also be used as is the case for the array). Decreasing the air gap distance will increase
the electric field in the skin. This is observed in the model, where the presence of the streamer
effectively halves the air gap. However the air gap, lair, has a practical minimum value for a non-
uniform substrate such as skin (which has a characteristic roughness value). The plasma, as well,
has a minimum distance, on the order of 4–20 Debye lengths (the characteristic length scale of the
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plasma, typically on the order of 100 µm). Though the permittivity of skin is frequency dependent,
the frequency is set by the pulse duration, which does not vary greatly (it varies within one order
of magnitude unless the second spark gap, SSG, in the RC pulse generator does not discharge).
The ratio of permittivities, εskin
εair
≈ 120, is approximately a constant; thus the denominator has
a practical minimum value, yielding a maximum for the electric field in the skin at the smallest
practical air gap.
4.5.4 Electric Field Measurement
Rhodamine-640 perchlorate dye (4.985× 10−4 mol/L in methanol) was used in an agarose sus-
pension (with mass fractions 6.845× 10−3 agarose and 9.47× 10−3 dye solution in DI water) to
attempt to measure the electric field in the substrate by changes in the fluorescence from a 532 nm
laser. Rhodamine dye was chosen as both easily available and due to its known fluorescence varia-
tion in an electric field; [255] while agarose was used to be a solid that better matches the dielectric
properties of skin, rather than a water-methanol liquid alone. The agarose suspension was heated
in a microwave for 3 minutes until nearly boiling, placed in a mold, and allowed to solidify. The
resulting block of agarose and dye was placed under a glass slide (the agarose suspension had a
resistance ∼1.5 MΩ since it is mostly water). A high DC voltage was applied to the agarose block
and glass slide. The setup is seen in Figure 4.41.
The fluorescence from the laser was measured as a function of applied voltage (Figure 4.42).
Some variation was noted, but a large change was not noted, thus possibly limiting the use of this
technique as a measure of applied voltage or electric field. Further, this system was noted to be
extremely sensitive to optical fiber placement; small changes in the fiber placement would cause
larger effects in the resulting signal than the applied voltage.
In an attempt to better quantify the changes of the electric field in the agar substrate, two dif-
ferent methods of measuring the peak intensity were used. The first method employed was to find
the highest point in a 5 pixel range of the supposed peak. Two wavelengths were chosen, 600 nm
and 624 nm, the location of the main fluorescence peak and the shoulder peak. This method is









Figure 4.41: Image of the Fluorescent Dye Setup for Electric Field Measurements in an Agar
Substrate

































(a) Wide Spectrum View





































(b) Zoomed Spectrum View
Figure 4.42: Fluorescence Spectra from the Rhodamine-640 Perchlorate Dye Varying the Applied
Duration
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(a) Highest of 5 Points Results




























(b) Pseudo-Voigt Fitting Results
Figure 4.43: Ratio of Peak Intensities Plotted Against the Applied Voltage for the Dye Fluores-
cence Spectra
















Figure 4.44: Deconvolution of Dye Fluorescence Spectrum (Blue Curve) Using Three Pseudo-
Voigt Profiles (Red, Black, and Magenta Yielding Cyan Curve; Linear Offset Not Shown)
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Figure 4.45: Time-Resolved ICCD Imaging Setup Schematic
are unfortunately fairly arbitrarily chosen and can be greatly affected by noise in the signal, thus
calling into question the validity of this method. The second method employed was to fit two
pseudo-Voigt profiles to the data. Poor fittings resulted until both a baseline correction and a third
pseudo-Voigt profile were included, as shown in Figure 4.44, suggesting that the fluorescence is a
combination of three different transitions. The clearest trend was found to be the ratio of the sum
of the two shoulder peaks to the main fluorescence peak as shown in Figure 4.43. This may have
become an option to adequately determine changes in the applied electric field, but was abandoned
due to time constraints and anticipated further challenges in developing it to have sufficient spatial
and temporal resolution for this system.
4.5.5 Time-Resolved Discharge Imaging
The ICCD camera was used to directly image the discharge over a grounded metal substrate
(see Section 3.3.2 for camera information). A function generator (BK Precision 4063) was used to
trigger both the camera and the discharge, and an oscilloscope (see Section 3.2.2.4 for oscilloscope
details) was used to capture the voltage pulse at the high voltage electrode (i.e. the array) and the
camera gate (that is the camera shutter). A schematic of the setup is shown in Figure 4.45, and
Figure 4.46 shows the actual setup. The discharge was pulsed at 0.5 Hz with an electrode-substrate
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Figure 4.46: Time-Resolved ICCD Imaging Setup Image
gap of 5 mm, MSG = 0.187 in, and SSG = 0.092 in, yielding Vmax = 20 kV and FWHM = 24 ns.
350 images were taken with an exposure time of 2 ns. Since there is some jitter in the triggering
of the discharge, the images were sorted in post-processing by the time delay measured on the
oscilloscope traces (a 9 ns adjustment was based off of the cable lengths, which also agreed well
with the data), where the zero point in time is taken when the voltage pulse is at 1 kV (above
the noise in the measurement). The images without a discharge (41 in total) were used to get an
average background, which is then subtracted from the other images.
Initially the discharge is visible at the tips of the arrays, as seen in Figure 4.47 for a delay time
of−1.2 ns and−1.1 ns. The next image captured shows a full discharge approximately 1.6 ns after



















Figure 4.47: Select ICCD Images Showing the Time-Resolved Discharge with 2 ns Exposures
full gap distance of 5 mm in 1.6 ns, thus it is traveling around 3.1× 106 m/s, which is ∼1% of the
speed of light. Though the electrons and ions may not be traveling this fast, the ionization wave is
traveling around this speed, which is consistent with literature on fast ionization waves. [256–258]
The plasma begins to decrease in light intensity after the initial brightness at the voltage rise and
ultimately it fades out. The discharge is visible for only around 60 ns, but it is very bright for only
a fraction of that time (∼20 ns) as seen in Figure 4.48, which shows the brightness superimposed
on the voltage pulse as a function of the delay time of the ICCD. There is no returning streamer
observed (shown in Figure 4.47 at tDelay = 45.8 ns), despite having a measured voltage around
−8 kV in the voltage pulse.
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Figure 4.48: Voltage Trace and Background Subtracted Image Brightness as a Function of Time
(5 mm Gap, t = 0 ns at V = 1 kV, Delay Adjustment Based Off of Cable Lengths)
4.6 Electroporation Efficacy
This system (both the array and the nanosecond RC pulse generator) was delivered to the
project sponsor who shared some preliminary results of the electroporation efficacy of this array.
The results are shown in Figure 4.49, comparing two different control cases (no electroporation
but with and without plasmid DNA added) to a conventional electroporation and electroporation
using the array electrode. The treatment with the array shows the most uptake of the plasmid DNA,
observed by noting green fluorescence in the images.
4.7 Chapter Summary & Future Work
This chapter introduced a plasma system for inducing electroporation in biological substrates,
with a focus on epidermal and dermal electroporation. A device such as this would most likely
be paired with a drug for enhancing the uptake of the drug into cells, such as is done in some
preliminary electrochemotherapy systems. This creates a more difficult pathway for marketing as
this becomes a combination drug/device, which would most likely require a De Novo request (or
the equivalent if assigned to the drug approval side of the FDA), since there are no existing systems
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No Electroporation, No Plasmid DNA
Array Electroporation 
25 pulses— 20kV, 80 ns
No Electroporation, Plasmid DNA
Conventional Electroporation
16 pulses—200 V/cm, 150 ms
Figure 4.49: Fluorescence Gene Uptake Comparing Conventional Electroporation to Electropora-
tion Using the Array Electrode [Credit: Private Communication with EP Technologies, LLC.]
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similar enough to serve as a predicate device.
The system was characterized to determine if all of the tips would develop a plasma to show
good uniformity. This was sometimes observed with the FID power supply (depending upon uni-
formity of the substrate), but not with the custom RC pulse generator, most likely due to the
difference in the individual tips’ differential resistance having a larger effect with the longer pulse
durations. A variety of gaseous species were noted to be generated depending upon the gas flow
through the array, but few species were noted with air, which also appeared to have the highest
electric field. Overall, the temperature of the discharge was noted to be quite low, owing to the
short duration of the applied voltage pulse. The most interesting finding was that the array was sub-
strate invariant for a wide range of conditions, including changing the substrate from a conducting
one to a dielectric substrate.
Further work needs to be done to determine the electric field generated from this system. In
particular, whether the electric field is roughly uniform underneath the entire array is of interest for
wide area medical treatments. Further medical development needs to be done to validate the effect
of electroporation, particularly in vivo.
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5. MODIFICATION OF AN ELECTROSURGICAL SYSTEM
5.1 Introduction
Electrosurgical generators have been used in the medical industry for nearly 100 years; how-
ever, they produce a “hot” plasma that is used for destruction of tissue. This chapter introduces a
method for converting an existing “hot” electrosurgical plasma into a “cold” plasma jet. This cold
plasma jet can then be used for a variety of new uses, most obvious being sterilization applications
in wound treatment such as the newly developed European plasma systems previously discussed
(see Section 2.5.2). This plasma jet is compared using discharge imaging, electrical characteristics,
and optical emission spectra to an existing system used for generating a low temperature plasma jet
in laboratory applications. Two different electrical configurations of the existing laboratory plasma
jet system are used. A preliminary inactivation study is shown to compare the efficacy of this new
plasma jet to the laboratory plasma jet.
5.2 Electrosurgery Background
The first electrosurgery occurred on October 1, 1926, when Dr. Harvey Cushing and Dr.
William Bovie removed a lemon-sized brain tumor. [4] The surgery was a success due to the newly
developed electrosurgical generator developed by Dr. Bovie, who later patented the device. [259]
Due to this success, the device quickly became synonymous with its inventor and all future devices
are now known as “a Bovie”. [4]
Electrosurgery is particularly useful for its ability to maintain hemostasis. This is because high
frequency currents to not penetrate the body but rather become dissipated in the form of heat. [260]
This heat is able to quickly cauterize tissue, in particular sealing blood vessels as the surgeon is
cutting them. A number of different terms are used to describe the type of mechanism that is oc-
curring for a desired effect during electrosurgery, mainly cutting, desiccating, and fulgurating. All
of these, however, operate on the same basic principle of supplying enough energy to vaporize the
water in the tissue. [261] The water vapor along with other tissue fragments leave in the generated
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“smoke”. Cutting occurs when the electrode touches the tissue and generates enough heat in the
tissue to completely destroy it, passing through the tissue like a scalpel. This is done with a lower
voltage sine wave, typically delivering 50–80 W into the tissue. A second type of waveform, called
coagulation or coag for short, uses a higher voltage, often up to 9–10 kV, but with a much lower
duty cycle. This waveform delivers 30–50 W of power into the tissue. The coagulation waveform
does not heat up as large of a volume of tissue, so it is often used to seal blood vessels by locally
cauterizing them, rather than cutting through bulk tissue. This is used in a contact method called
desiccation to desiccate a local area of tissue. This can also be used in a non-contact method called
fulguration, which is used to spray a region of tissue that is oozing blood, sealing any small cap-
illaries in the region. [262] Between the cut and coagulation waveforms can be a variety of blend
waveforms that have a moderate duty cycle (less than 100% and more than ∼6%) and a moderate
voltage.
There are also two different methods of applying this electromagnetic waveform to the body.
The first is called monopolar configuration, where a large dispersive electrode is attached to the
body to act as the ground electrode as a return path for current. The high voltage electrode is at-
tached to the handpiece that the surgeon uses. The second is called bipolar configuration where for-
ceps are used for the surgery, one of which is the high voltage electrode and the other is grounded.
This localizes the deposited energy to the region of the handpiece, but requires a larger handpiece
that has both the high voltage and ground electrodes along with sufficient high voltage shielding.
This is much more difficult for laparoscopic surgery, where space is limited.
Electrosurgery is differentiated from electrocautery by the mechanism of heat application.
Electrosurgery passes the electrical current through the tissue, while electrocautery uses the elec-
trical energy to heat a filament which is then applied to the tissue to cauterize it.
5.3 Device Life-Cycle Overview
The initial motivation behind this project was that a new CAP device can be expensive to create
and ultimately get FDA approval for, however an existing device can be modified with little effort
and hopefully receive clearance quickly by using the 510(k) process. To that end an existing FDA-
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cleared electrosurgical device is compared to an existing laboratory power supply. This is done
by adding a small tube on the end of the electrosurgical generator with a helium gas flow. Helium
is used since it has been well characterized in our lab, produces the lowest temperature plasma
discharge, and is non-reactive as a noble gas. [29–31, 39] However, in researching the 510(k)
submission pathway, it was noted that this pathway requires the same intended use for the new
device. Since a CAP has very different effects on tissues, the intended use would not be the same
as current, marketed electrosurgical systems, thus the 510(k) pathway would not be a viable option.
However the De Novo pathway is a possible option, since the safety of the device has already been
established; this would only extend its intended use to include CAP uses such as sterilization or
wound treatment.
This then sets up an interesting situation, where the initial device is already done, since an
existing device is being slightly modified. However, due to the drastic change in the nature of the
plasma discharge going from a “hot” plasma to a “cold” plasma, substantial development is still
needed. This is especially so since the entire intended use of the device is changing.
5.3.1 J-Plasma System
In the course of conducting this project, it was found that a newer Bovie system called the
J-Plasma already has a tube with helium flow and a retractable electrode, essentially mimicking
this setup. [263] However, this system is only being used as a “hot” plasma source for electro-
surgery. This is observable in a promotional video of the J-Plasma system (the video appears to
have recently been taken down, since it appears the J-Plasma system has been sold to another com-
pany), [264] where it initially generates a cold plasma in contact with an egg; only after decreasing
the electrode-substrate gap does the plasma transition to a “hot” mode where it ends up “cooking”
the top layer of the egg (see Figure 5.1). This is an interesting situation where an existing device
can be used for a different intended use without any modification because the plasma already oper-
ates in multiple modes. However, like the modifications done on the Bovie system in this research,
the intended use has changed, possibly requiring further development for the new intended use.
One study using the J-Plasma system has been conducted for its viability in killing cancer
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(a) Cold Plasma (b) Hot Plasma
Figure 5.1: J-Plasma Operating in Cold and Hot Plasma Modes (Reproduced under Fair Use
from [264])
cells. [265] This showed that the J-Plasma system could be used as a low temperature plasma
source when operated with a low duty cycle. It was more successful in inactivating the cancer cells
when they were in a liquid medium compared to plated in growth media. This is not explained
by a pH change of the medium, rather this is due to biological effects resulting from the plasma
treatment, most likely from long-lived reactive species created in the liquid medium. This suggests
the J-Plasma system can be used as a post-operative treatment after removal of a cancerous tumor
to help ensure any residual cancerous tissue is inactivated.
5.3.2 Other Electrosurgical Systems as a Cold Plasma
In addition to the J-Plasma system, a Maxium electrosurgical unit from Gebrüder Martin GmbH
has been used as a cold plasma source specifically for sterilization of multidrug-resistant bacte-
ria. [266] It appears that a low power was used for this in a coagulation mode, hence it is an
argon beam coagulator as well. It appears a larger distance than for standard treatment was used,
namely 0.5–1 cm to ensure the plasma did not transition to a “hot” mode. Eleven patients with a
total of twenty-two wounds were treated; samples were taken directly before and after treatment.
Eight wounds had a bacterial reduction by at least 3-logs; fourteen wounds were measured to have
been completely sterilized, though this may also be due to a bacterial count too small to count
(hence a reduction factor of less than 3-log for many wounds since fewer than 1× 103 CFUs were
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counted before treatment). All wounds showed some decrease in the bacterial load. Nevertheless,
the design of this system is potentially suspect, since it requires the surgeon to maintain the high
voltage electrode a safe distance away from the tissue to avoid it transitioning into a “hot” plasma
discharge.
5.3.3 FDA Approach
In particular for the J-Plasma, this is an interesting situation where the device is already on the
market, just under a different intended use. Since the Bovie electrosurgical generators are FDA
cleared for “the removal and destruction of skin lesions and the coagulation of tissue,” [267] it
seems unlikely that any effect of a cold plasma would be similar enough to use the same intended
use. As such, the 510(k) pathway is not a viable option for a modified Bovie (or even the existing
J-Plasma system) as a cold plasma device, unless a different device with the same intended use as
the cold plasma system is found. Since these devices are already cleared as Class II devices, a De
Novo request is a logical move to allow a modified device to become marketable under the FDA
as cold plasma source.
5.3.4 Device Outlook
The main applications for a cold plasma device such as this would be for sterilization. In
particular this is the use for similar devices currently marketed in Europe (see Section 2.5.2),
particularly the sterilization of biofilms that have built up in chronic wounds. For this specific
project, the Bovie is characterized as a cold plasma source and an initial bacteria inactivation study
is done. However to have any hope of FDA classification as a Class II device (or even Class I
device, but unlikely due to the Bovie already being a Class II device), substantially more work
needs to be done to characterize the Bovie power supply for a wider range of conditions, and
to prove the results of bacteria inactivation achieved with an already existing laboratory power
supply can also be achieved with the Bovie. [30, 31] In addition, at least one robust clinical study
(a suitable animal model study may also be sufficient, but the FDA has become stricter for De
Novo requests, so a clinical study may still be required) would be required to show this device
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does behave like the various European devices for treating chronic wounds. However, in addition
to showing efficacy, this system would also have to show superior performance to the existing,
state-of-the-art treatments for wounds to be successful from a marketing point of view.
Though the system discussed here is not used for removal of cancerous tissue, a second ap-
proach for another system, such as the J-Plasma or a similar system, could be for cancer treatment.
This opens up a market for systems that can operate in both a “hot” mode used for removing can-
cerous tissue and then switch to a “cold” mode for treating the nearby tissue that may have residual
cancerous cells.
5.4 Bovie Modification
This project seeks to determine the similarities and differences between two power supplies
listed in Table 5.1. The first power supply (Aaron 940) manufactured by Bovie Medical Corpora-
tion is used for thermal plasma treatment, i.e. electrosurgery. Specifically this unit is “intended for
the removal and destruction of skin lesions and coagulation of tissue,” [268], which is solely done
with a coagulation mode, that is with a lower duty cycle but higher voltages compared to the cutting
mode of electrosurgery. As such, it is designed for high current and low voltage (Vpp ≤ 8 kV) oper-
ation. The second power supply, the laboratory AC power supply, is manufactured by Information
Unlimited (also known as Amazing1 from their website URL, a PVM500 model), which is used
for research. The laboratory AC power supply has been well characterized for plasma operation in
a FE-DBD jet configuration for non-equilibrium plasma generation previously in our lab. [15, 29]
This project seeks to determine if the Bovie power supply is also capable of generating a controlled
non-equilibrium plasma jet, which is typically done with higher voltages.
To make the Bovie power supply into a low temperature plasma jet, a small plastic tube was
placed over part of the electrosurgical tip electrode. A T-shaped tube connector was then placed
on the small plastic tube to make a seal around the electrode and tube. A gas inlet line was then
connected to the tube connector and varying lengths of glass tube were attached to the third side to
vary the electrode-to-ground distance. The modified electrosurgical tip was then inserted into the
Bovie handpiece to be powered. The Bovie handpiece, the part of the power supply that houses
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Table 5.1: Comparison of Bovie and Laboratory AC Power Supplies
Bovie (Aaron 940) Amazing1 (PVM500)
Voltage ∼0–6 kV ∼0–40 kV (peak-to-peak)
Power 40 W (max) 300 W (max)
Frequency 550 kHz (nominally, measured 455 kHz),
21 kHz repetition (pulse) rate (see Figure 5.8)
20-70 kHz








Figure 5.2: Image of the Modification to the Bovie Electrosurgical Tip Electrode
the control knobs and has a location to insert the high voltage electrosurgical tip electrode, was
then connected to the setup. This modification is shown in Figure 5.2. For all testing done here,
the blade electrode was used, rather than an electrode with a different geometry (such as a ball or
needle tip).
5.5 Device Characterization
A glass tube (OD 0.25 in, ID 0.16 in) of varying lengths were used in testing. A helium gas
flow was supplied around the electrode, usually at a flow rate of 3.97 SLPM. The electrode was
suspended above a ground electrode plate. The Bovie handpiece was then connected to the setup.











Figure 5.3: Schematic of the Bovie Power Supply Setup
the laboratory power supply could be connected in lieu of the Bovie power supply, thus the only
difference would be the excitation waveform between the two devices; the electrode and all other
connecting parts, such as the gas tube, would be the same.
Unfortunately, the Bovie power supply turns off if it overvoltages, thus there is a narrow operat-
ing range that it is able to create a low temperature plasma jet in; increasing the power or decreasing
the tube length would cause it to enter a “hot” mode, and decreasing the power or lengthening the
tube would cause it to overvoltage and turn off. This is due to a fail-safe in the power supply to
avoid excessive power assumed to be due to failure of the insulation around the electrode. [269]
Initially the various modes of the two power supplies are investigated. Two different and pos-
sibly useful modes are identified for each power supply, a diffuse and concentrated mode, and
these modes are further characterized by their voltage-current traces, broadband spectra to deter-
mine gaseous species present in the discharge, and discharge temperature. Lastly a brief bacterial









Figure 5.4: Image of the Bovie Power Supply Setup
5.5.1 Discharge Mode Imaging
The Bovie power supply was operated while varying the power and distance between the high
voltage electrode and ground. A number of modes were observed at various conditions as shown in
Figure 5.6. The circles represent measured data points; the background color is to demonstrate how
the modes blend into each other. Modes of interest are the diffuse plasma (green, see Figure 5.5(a)
with a 1.7 mm glass tube, 16 power setting), and the concentrated mode (purple, see Figure 5.5(b)
with a 1.7 mm glass tube, 22 power setting). The preceding modes (red to orange, with a lower
power settings) do not extend beyond the length of the tube, having either no discharge (red) or
only a partial discharge (orange). The final mode (blue, a pulsing discharge) does not allow for
continuous plasma since the power supply is being overvoltaged and turns off intermittently with
short pulses of plasma occurring at a frequency of ∼1 Hz.
The laboratory AC power supply was operated in two different electrode configurations, in a
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(a) (b) (c) (d) (e) (f)
5 mm
Figure 5.5: Bovie Power Supply Operating in (a) a Diffuse Mode and (b) a Concentrated Mode;
Laboratory AC Power Supply FE-Direct Jet Operating in (c) a Diffuse Mode and (d) a Concentrated















































Figure 5.6: Different Operating Modes for the Bovie Power Supply as a Function of Electrode-
Substrate Gap and Power Setting for a Flow Rate of 3.97 SLPM (Circles are Measured Data Points
with the Background Color Approximating the Operating Mode Between Data Points)
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floating electrode direct jet configuration the same as the Bovie power supply and in a FE-DBD
jet configuration, where the high voltage electrode surrounds the dielectric tube rather than being
inside it. The laboratory FE-direct jet was observed to operate in two main modes, a diffuse mode
(Figure 5.5(c) with a 1.7 mm glass tube, 6% low power setting, 8.08 SLPM He flow) and a con-
centrated mode (Figure 5.5(d) with a 1.7 mm glass tube, 15% low power setting). The laboratory
FE-DBD jet was also observed to operate in two main modes, a diffuse mode (Figure 5.5(e) with
a 1.7 mm glass tube portion extending below the high voltage electrode, 10% low power setting,
13.8 SLPM He flow) and a concentrated mode (Figure 5.5(f) with a 1.7 mm glass tube portion be-
low the electrode, 20% low power setting, 13.8 SLPM He flow). This is similar to what was found
previously in our lab, [29] showing at least qualitatively that the modes exist for FE-direct plasma
jets in addition to FE-DBD jets.
5.5.2 Voltage and Current Characterization
It was noted that the initial current and voltage pulse from the Bovie power supply was sub-
stantially higher than the subsequent pulses. This is seen in Figure 5.7. This is most likely due
to the subsequent pulses having some preionization from earlier pulses, thus requiring a lower
breakdown voltage to initiate the plasma discharge. This also explains the pulsing mode noted in
Figure 5.6, where the gap is too large, requiring too large of a voltage to initiate the discharge. The
first pulse creates a plasma discharge, but then the power supply turns off due to being overvolt-
aged. This process then repeats with only the initial pulse creating a plasma discharge, pulsing at
the frequency the overvoltaging control system allows (∼1 Hz).
The steady state current and voltage traces are shown in Figure 5.8. The Bovie voltage traces
between the two modes are similar; the diffuse mode has more decaying oscillations after the pri-
mary voltage pulse. The current, though, is two orders of magnitude larger for the concentrated
mode compared to the diffuse mode. Similar to the voltage, the diffuse mode has significant ring-
ing after the primary pulse, which is absent in the concentrated case. For the diffuse mode, the
laboratory power supply behaves very similarly for both the laboratory FE-direct jet and the lab-
oratory FE-DBD jet. The voltage and current traces are fairly sinusoidal; the laboratory FE-DBD
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Figure 5.7: Initial Voltage and Current Pulses for the Diffuse and Concentrated Modes with the
Bovie Power Supply
jet only requires slightly higher voltages due to the dielectric barrier, which in turn is causing a
slightly higher current. No current spikes are noted, most likely being too small to notice. The
concentrated mode for the laboratory FE-DBD jet is similar, with a few current spikes becoming
noticeable. This is different than the very pronounced current spikes noted previously, [29] how-
ever this jet is running a substantially higher gas flow rate (13.8 SLPM compared to 2.9 SLPM).
The concentrated mode for the laboratory FE-direct jet is quite different. The current spikes have
consolidated into a single large spike (similar to previously noted FE-DBD jets [29]), that draws a
large amount of power skewing the otherwise sinusoidal voltage trace. The large current spike (i.e.
ionization wave) frequency is comparable to the repetition frequency of the Bovie power supply.
5.5.3 Broadband Spectra
Optical emission spectra were taken using a CCD spectrometer (see Section 3.4.1.2 for the
spectrometer details). All spectra showed OH (A2Σ → X2Π), N2 2nd positive system (C3Πu →
B3Πg), He, He21, H (Hα and Hβ as well as very small Hγ in the Bovie spectra), and O (777 nm).
The spectra for the various conditions are seen in Figure 5.9 corresponding to some of the condi-
1Unlike what is commonly taught in undergraduate chemistry, helium is capable of making bonds, albeit normally
van der Waals bonds, which can nevertheless be considered molecules [270]. In this case, it is most likely from the
collision of two helium atoms, where at least one is excited to a metastable state. [271]
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(a) Diffuse Bovie FE-Direct Jet













































(b) Concentrated Bovie FE-Direct Jet
































(c) Diffuse Laboratory FE-Direct Jet






























(d) Concentrated Laboratory FE-Direct Jet





























































(f) Concentrated Laboratory FE-DBD Jet
Figure 5.8: Current and Voltage Traces for the Bovie FE-Direct Plasma Jet, the Laboratory AC
Power Supply FE-Direct Jet, and the Laboratory AC Power Supply FE-DBD Jet for Both Diffuse
and Concentrated Modes
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(a) Diffuse Bovie FE-Direct Jet

















































(b) Concentrated Bovie FE-Direct Jet
















































(c) Diffuse Laboratory FE-Direct Jet














































(d) Concentrated Laboratory FE-Direct Jet
Figure 5.9: Broadband Spectra for the Bovie and Laboratory AC Power Supply FE-Direct Jets for
Both Diffuse and Concentrated Modes
tions in Figure 5.5. Overall the spectra were similar other than differing relative intensities between
lines, which was to be expected since all are discharges in a helium gas flow. The laboratory FE-
direct jet produced more OH compared to the Bovie, which has a larger concentration of N2 excited
states. The Bovie also created N2+ (B2Σ+u → X3Σ+g ), which was barely observed in the laboratory
FE-direct jet’s spectra, especially compared to the relative intensity of the OH and He peaks. Some
of the non-flat baseline noted in the diffuse laboratory spectrum may be due to broad H2 lines.
To attempt a more quantitative comparison, a Boltzmann plot (Figure 5.10) can be created for
each condition. The Boltzmann plot is plotting the distribution of line intensities to their energy by
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Figure 5.10: Boltzmann Plots Derived from the Broadband Spectra of the Bovie and Laboratory










Ei + k (5.1)
where Ii is the intensity of a specific transition i, λi is the wavelength, gi is the degeneracy of the
upper level, Ai is the Einstein coefficient, Ei is the energy, kB is the Boltzmann constant, and k
is a constant (see Section 3.4.3.1 for more details on the theory). [272] This allows the electronic
excitation temperature, Telex, to be determined from the slope of the line in the Boltzmann plot.
The electronic excitation temperature is assumed to be similar to the electron temperature, Te,
since the primary mechanism of generating these excited states is from electron impact excitation
processes (at least for helium, the excitation of the hydrogen can also be attributed to dissociation
processes with water vapor). However various deexcitation processes are possible, such as photon
emission as well as collisional losses, such as Penning ionization with neutral N2 atoms, which
can skew the resulting Telex determination. Two different Boltzmann plots are generated, one from
various helium lines (388.9 nm, 501.6 nm, 587.6 nm, 667.8 nm, 706.5 nm, and 728.1 nm) and the
other from the hydrogen lines (Hα, Hβ, and Hγ, namely 656.3 nm, 486.135 nm, and 434.0 nm).
The parameters gi, Ai and, Ei came from NIST. [218] Since the Hγ line was extremely dim (and
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non-existent in two cases), Telex is found with (dashed lines) and without its inclusion.
The electronic excitation states are not described by a Maxwellian distribution (and a single
Telex value2), since the electronic excitation temperature determined from the helium lines is signif-
icantly lower than the temperature determined from the hydrogen lines; although the concentrated
Bovie case is close. That is because this system is tending towards an equilibrium discharge both
within an energy mode (electronic excitation in this specific case) and across energy modes (see
Section 5.5.4 for the rotational and vibrational temperatures). The hydrogen lines may give an
approximate electron temperature for the N2 excitation, since the C-state of N2 (the upper state in
the 2nd positive system) is approximately 11 eV above the ground state, which is close to the en-
ergy required to excite the hydrogen. This, however, is complicated by the fact that the hydrogen
lines may not be electronically excited due to an electron impact excitation process but rather from
a dissociation process from a water vapor molecule colliding with an excited helium atom, as is
described by the equation
He∗ +H2O → He+OH +H∗ (5.2)
In this case, the electronic excitation temperature determined from hydrogen is not a good indicator
of the electron temperature, Te. Nevertheless, these different electronic excitation temperatures for
the four measured cases result in the different relative intensities noted in the broadband spectra
and are caused by the differing excitation mechanisms of the electrical systems. Interestingly, the
two diffuse cases are comparable despite having vastly different intensities in OH, N2, and N2+.
Some of this could also be due to differing flow rates in helium, leading to a lower concentration
of the ambient air species in the discharge.
5.5.4 Temperature Determination
Optical emission spectra were collected for 352–358 nm using an ICCD camera (see Sec-
tion 3.4.1.1 for the spectrometer details). The 2nd positive system of N2 along with the 1st neg-
2Some authors in the literature will use two Telex values (typically broken into high energy and low energy fittings)
to fit the entire distribution, which technically breaks from the strict definition of temperature as derived from an
equilibrium Maxwellian distribution.
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(a) Diffuse Bovie FE-Direct Jet





















(b) Concentrated Bovie FE-Direct Jet





















(c) Diffuse Laboratory FE-Direct Jet





















(d) Concentrated Laboratory FE-Direct Jet
Figure 5.11: Various Wavelengths for the 2nd Positive System of N2 with Temperature Fits for the
Bovie Power Supply and Laboratory AC Power Supply FE-Direct Jets
ative system of N2+ was compared to modeled spectra from SpecAir to determine the rotational
(Trot) and vibrational (Tvib) temperatures of the nitrogen species in the gas (see Section 3.4.3.2 for
information on the temperature fitting algorithm). Spectra for the various conditions are seen in
Figure 5.11 corresponding to the conditions in Figure 5.5. Both power supplies are non-equilibrium
plasmas for both the diffuse and concentrated modes as determined by their rotational and vibra-
tional temperatures. The diffuse mode for the Bovie has a very low gas temperature (approximately
the rotational temperature), while both modes for the laboratory FE-direct jet have very low gas
temperatures. Though in the concentrated mode the Bovie power supply is still a non-equilibrium
plasma, it is closer to an equilibrium state than the other conditions, showing a higher rotational
and lower vibrational temperature. For both power supplies in the concentrated mode, N2+ was
noted in the spectra; however, the concentration of N2+ was negligible in the temperature fitting for








Figure 5.12: Setup Schematic for the Plasma Jet Sterilization Treatment
trated mode, with a relative number concentration of species [N2+]/[N2] = 4.7× 10−6 compared to
3.83× 10−10 for the Bovie power supply. Nevertheless, this analysis was done assuming T e = T vib,
rather than using the electronic excitation temperature found in Figure 5.10, since that temperature
is assumed to better reflect the dissociation process rather than the true electron temperature.
5.5.5 Inactivation Study
A bacterial and fungal inactivation study was conducted to compare the Bovie (run at 21 W)
and the laboratory FE-DBD jet (powered at Vpp = 6 kV and 23.8 kHz). The FE-direct plasma
jet using the laboratory power supply was not used. This experimental work was performed by
Rhys Michna, an undergraduate student; data processing was conducted by the author, Matthew
Burnette. The setup is shown in Figure 5.12. The plasma jet, run with 15 SLPM industrial grade
helium (99.95%), was placed ∼1 cm over a petri dish with agar contaminated with 300 CFU of
one of three strains, E. Coli, Bacillus, or Aspergillus Flavus. Three different treatment times were
used, 30 s, 90 s, and 180 s, along with a control of 180 s treatment without a plasma discharge (i.e.
just a helium gas jet). The samples were plated minutes before treatment, and images and counts
were taken after 1 day of incubation. Three replicates of each trial were used.
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Examples of the plated and incubated samples are shown in Figure 5.13. Cell count results
for the entire petri dish are shown in Figure 5.14 for E. Coli, Figure 5.15 for Bacillus, and Fig-
ure 5.16 for Aspergillus Flavus. Results were compared using a t-test at a 5% significance level,
all compared to the 180 s no plasma trial. No significant differences were noted for the laboratory
FE-DBD jet with E. Coli or Bacillus compared to the control, suggesting that the laboratory FE-
DBD jet is not effective at inactivating the bacteria, except for the 90 s treatment of Bacillus which
was statistically significant (p = 0.0286). It is assumed this single case is due to a small variance
from the small sample size, especially since neither shorter nor longer treatments were statistically
significant. The 30 s and 90 s treatments of Aspergillus Flavus with the laboratory FE-DBD jet
were both significant (p = 0.0466 and p = 0.0260, respectively). All of the E. Coli trials with the
Bovie were significant (p = 0.0044, p = 0.0061, and p = 0.0030 for the 30 s, 90 s, and 180 s trials,
respectively). The 30 s and 180 s trials of Bacillus (p = 0.0293 and p = 0.0201, respectively) were
significant, and the 30 s treatment of Aspergillus Flavus was significant (p = 0.0446).
These results suggest that the Bovie is more effective at inactivating E. Coli than the laboratory
FE-DBD jet. In particular, a much larger area in the center of the plates is bacteria free for the
Bovie jet. The 180 s case for the laboratory FE-DBD jet and the control both show a small area in
the center without colonies, suggesting this is most likely due to drying out of the agar. Neither
jet was successful in inactivating Bacillus, where all trials were higher than the control. Both
jets had moderate effectiveness against Aspergillus Flavus, although the fungus did not appear to
thrive in any situation, experiencing the majority dying off in all cases. The laboratory FE-DBD jet
actually shows a larger area in the middle of the plate that does not have any fungal growth. This
is particularly pronounced at lower treatment times. This could be due to aqueous species being
generated in the agar that are responsible for the anti-fungal effect, while longer times dry out the
agar permitting growth of the fungus over the 1 day incubation. The Bovie shows only a small area
of no fungal growth, suggesting it did not create as many aqueous anti-fungal species.
However, this is only a preliminary test and much more needs to be done. For example, better
controls need to be conducted, rather than a single control at 180 s treatment time. A larger treat-
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Figure 5.13: Plates After 1 Day Incubation of E. Coli and Aspergillus Flavus for Both FE-DBD Jet
and Bovie Jet for 30 s, 90 s, 180 s Trials and 180 s No Plasma Control Condition























Figure 5.14: Number of E. Coli Colonies Counted After Various Plasma Treatments
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Figure 5.15: Number of Bacillus Colonies Counted After Various Plasma Treatments
























Figure 5.16: Number of Aspergillus Flavus Colonies Counted After Various Plasma Treatments
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ment area should also be used, rather than treating the center of the petri dish. This could be done
by using smaller petri dishes or a longer treatment time with a moving plasma jet, such as is used
in Chapter 6. Since not all images were properly documented, further analysis on investigating a
subset of the petri dish area as a better representative of the treatment area could not be obtained
with statistically relevant results. Various incubation times could also be used, as well as treating
samples that have already been partially incubated to better simulate wound treatments as well.
5.6 Chapter Summary & Future Work
In this chapter an existing FDA cleared electrosurgical device has been modified to create a low
temperature plasma jet. The device is compared to an existing laboratory plasma system. Similar
discharge modes were noted for the two devices, each having a diffuse mode and a concentrated
mode. The generated species were noted to be spectographically similar, though differences were
noted in their relative intensities. The diffuse modes had comparable temperatures near ambi-
ent for the rotational temperature, while the concentrated mode for the Bovie power supply was
substantially hotter than the laboratory power supply. Inactivation of E. Coli was noted for the
Bovie power supply, but further results are needed to show significant reduction of bacterial load
to warrant further development of this as a device.
When first approached, it was desired to find a fast approval method for a low temperature
plasma jet through the FDA. Though using an existing FDA cleared device may alleviate some
concerns about the safety of the device, this does nothing to prove the efficacy of the device using
a new intended use. As such, this is not likely to affect the speed of approval for such a device,
since the intended use is a major driving factor for the approval of a device through the FDA. In
addition, changes to the power supply may increase the efficacy, while not greatly affecting the
safety of the device, thus changes to the device may be warranted. Nevertheless, this is a prime
example of a medical system that could use the De Novo pathway for moderate approval speed
(slower than a 510(k) but faster than a PMA).
Development on this specific design may not be carried forward, but the idea of using an
electrosurgical generator for cold plasma treatment is now in the literature, including in clinical
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trials in Europe. It is possible this may lead to further development of these devices in the US for
cold plasma treatment.
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6. DIRECT WRITE OF FILMS USING A DIELECTRIC BARRIER PLASMA JET
6.1 Introduction
A direct write plasma system is devised by replacing the printer head of a 3D printer with a
floating-electrode dielectric barrier discharge jet. Various methods are employed to deposit the pre-
cursors, including vaporizing the precursor into the gas stream or spraying a liquid precursor into
the plasma. Various materials can be deposited including metals (copper using copper (II) acety-
lacetonate and iron using ferrocene), polymers (a polymer from tris(2-methoxyethoxy)(vinyl)-
silane), and hydrocarbon compounds (using isopropyl alcohol). A variety of substrates are used
ranging from conductive to dielectric and even to biological substrates, as the low temperature of
the discharge allows patterning onto temperature-sensitive substrates. Factors affecting the deposi-
tion are explored, such as how higher concentrations of the precursor can be combined with faster
motion to increase the deposition rate without overheating the substrate. The design constraints for
fill pattern selection for the plasma printer are influenced by substrate heating, deposition area, and
precursor consumption. Higher concentration of the precursor can be combined with faster motion
and also higher discharge voltages and powers to increase the deposition rate without overheat-
ing the substrate. This is proposed as a method for a sprayable bandage or deposition of sensors
directly onto skin or other tissue.
6.2 Project Background
The background is broken into three parts. The first section briefly discusses what direct writing
is. Next, plasma enhanced chemical vapor deposition is discussed, which is the specific technique
used here for direct writing of films. Finally, applications of this specific direct writing technique
are examined, with emphasis given to two medically relevant applications.
6.2.1 Direct Writing
Direct writing, also known as maskless lithography, is a processing technique of laying down
a patterned functional material onto a substrate. The thickness of the deposition can vary from
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nanometers to millimeters in size. [273–275] As such, direct writing is typically differentiated
from 3D printing by having a smaller length scale particularly in the height of the material being
deposited, although there is overlap between the two techniques. Direct write techniques are gen-
erally classified under four main types based on how they deposit material: droplet, energy beam,
flow, and tip. [275]
Droplet based techniques are often limited in resolution by the ink used; specifically the surface
tension dictates the size of the droplets that form. [275] Aerosol direct write is one type of droplet
technique that atomizes an ink which is then sprayed on to the substrate as an aerosol. The aerosol
can be a variety of materials from metals, dielectrics, or even biological materials. [273] Energy
beam techniques use a modified form of chemical vapor deposition, such as laser chemical vapor
deposition and focused ion beam. These techniques cause the local excitation of a gas to create a
chemical vapor that deposits onto the substrate. [273] The main downside of these techniques is
that the substrate must be vacuum compatible. Flow techniques use a continuous flow of material
rather than a series of droplets. An example of this is fused filament fabrication (FFF), a type of
3D printing, which will be discussed further in Chapter 7. Dip techniques use extremely fine tips,
such as those used for atomic force microscopy, to deposit a small amount of ink. [276] As such,
they are able to achieve extremely fine feature sizes on the order of 10 nm. [275]
However, there are other types that are difficult to classify into those four main groupings.
For example, a glow discharge can be used to sputter a small diameter source electrode, which can
then be moved over a conducting surface leaving a pattern of the sputtered material. [277,278] This
system could also be implemented as a jet, spraying the sputtered material onto the substrate. [279]
Direct write techniques are used to fabricate sensors, such as thermocouples or strain gages
directly onto a substrate. [273] They can also print a wide array of antennas for various sensors.
Particularly, the energy beam techniques have shown great promise in the semiconductor industry
leading to patterning off of the chip. [280]
172
6.2.2 Ambient Plasma Enhanced Chemical Vapor Deposition
Plasma enhanced chemical vapor deposition (PECVD) is a process that transforms a gas to
a solid surface coating by use of a plasma process, using electrical energy rather than thermal
energy to initiate the chemical processes. [281] Though historically a low pressure process, there
has been a trend to increase the processing pressure of PECVD up to ambient conditions. Though
this has the added benefits of being able to treat pressure sensitive substrates, such as biological
substrates, and higher deposition rates due to higher concentrations of the reactive agents, high
pressure PECVD suffers from gas contamination, higher power requirements, arcing risks, and
difficulties in treating large areas. [282] A variety of plasma sources can be used, from DBDs to
various plasma jets (microwave, RF, DBD, etc.) or even corona discharges. [281]
A variety of printed materials are also possible using an atmospheric pressure plasma system,
with many available from earlier research on low pressure PECVD. These include hydrocarbons
(using acetylene [283,284]), silicon (using silane [285]), silicon carbon nitride (using tetramethyl-
disilizane, hexamethyldisilizane, and triethylsilane [286]), silicon dioxide (using hexamethyldis-
iloxane [60, 61, 284]), and titanium oxide (using titanium tetrachloride [287], titanium isopropox-
ide [288], or titanium tetraisopropoxide [289]). These examples show that a variety of precursors
can also be used to create the same film material. The precursor also does not need to be a complex
compound from PECVD. For example, metal nanoparticles (cupric oxide nanoparticles [290]) or
nanowires (silver nanowires [291]) can also be used. The substrate can also be coated in a metal-
containing solution and selective areas can be plasma treated. [292]
Our lab has also previously shown polymeric and metallic (copper) deposition using a float-
ing electrode dielectric barrier discharge (FE-DBD) jet (polymethyl methacrylate using the liquid
monomer [30, 31], and copper(II) acetylacetonate [14, 31]). This system has also been shown
to operate on temperature-sensitive biological substrates, such as onion skin, agar, and finger-
nails. [14, 30, 31]
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6.2.3 Applications of PECVD
PECVD has a wide range of applications, since there are a wide range of possible coatings that
it can create. These include optical coatings (e.g. anti-reflective coatings), wear and corrosion re-
sistant coatings (e.g. diamond-like carbon), electrical insulation (e.g. SiO2) and material synthesis
(e.g. carbon nanotubes). [59, 293, 294] Two specific applications with direct medical relevance are
sprayable bandages and epidermal electronics.
6.2.3.1 Sprayable Bandages
Paint-on liquid bandages (see Figure 6.1 for a schematic) are already FDA approved, [295] but
sprayable bandages are not included per se. They are however approved for veterinary use. [296,
297] They are being considered in cases where a typical bandage is insufficient, mainly due to pain
in the wound that would be exacerbated by current bandages and topical creams as well as cases
where cross contamination could occur. [298] They are also combined with a drug for wound
healing [299] or antimicrobial properties to prevent infection. [300, 301] The most commonly
investigated materials for sprayable bandages are silane/siloxane polymers, cyanoacrylates, and
hydrogels. [302]
6.2.3.2 Epidermal Electronics
A new field is growing of placing electronics directly onto skin for end use applications (see
Figure 6.1). These epidermal electronics have mostly stemmed from work done by Rogers [303,
304] and Bao [305]. Kim, et al. [303] showed that fairly complex circuitry (antennas, LEDs,
transistors, and a variety of other sensors) could be applied in a small package that can be applied
directly to skin and even deform with the skin. This allows a variety of useful sensors to have
access to the changing conditions of the epidermis. [304] Wang, et al. [305] has scaled this up
to 347 transistors/cm2. Small amounts of computational ability have even been demonstrated in
some of these electronic systems. [306] Complex sensors can be made and integrated into small
wearable devices (such as “smart” watches) that can give feedback during daily activities on a
















Figure 6.1: Schematic of Both Sprayable (Paint-On) Bandages and Epidermal Electronics Showing
Conventional Systems and a Direct Write Plasma Jet System
also be created to measure a person’s pulse or the amount of pressure applied to a surface. [308]
Often these circuits are not printed directly onto the biological tissue but are printed onto a sur-
rogate material that is adhered to the skin or are transferred onto the skin, such as by hydrographic
transfer. [309] Ink based solutions have also been used, where conductive ink can be drawn directly
on a variety of surfaces to create sensors. [310] However care has to be taken that the substrate does
not move, or at least have its movement tracked during the writing process for live patients, to en-
sure the pattern is properly printed. [311] The properties of these inks also become important, as
they need to dry quickly (ideally within seconds) while still maintaining good conductivity through
large bending, all the while ensuring biocompatibility of the ink materials. [312] These inks have
been based on liquid metals such as gallium [312] or based on silver particles (nanowires [313] or
small flakes [311]) in an alcohol solution.
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6.3 Device Life-Cycle Overview
For development, a specific indication needs to be decided upon. The sprayable bandage may
not be a viable option due to a number of cheap alternatives operating in that space; however, a
niche in the field of sprayable bandages could be found leading to investors willing to support this
device’s development. In particular, if a drug is going to be included in the spray, extensive testing
will be needed to ensure the plasma does not break it down.
The epidermal electronics application runs into the issue of other devices such as those out of
Rogers’ group using a less invasive method to create their electronics. They deposit the metal onto
a flexible substrate which is then applied to the body as a sticker or removable tattoo, with fewer
issues of biocompatibility concerns. As such, investors would be hard to attract to this method of
electronics implementation. However, this method could fill a niche of connecting other electronic
connections to the body, whether on the skin or inside of the body, such as for pacemaker leads.
This requires extensive testing for biocompatibility as well as long-term operability.
6.3.1 FDA Approach
The two expected applications of sprayable bandages and epidermal electronics have different
intended uses, requiring different considerations for approval pathways. The sprayable bandage
is designed for wound care and could be paired with a drug that would help with pain, improve
healing, etc., which would then require a combination drug and device application. This would
warrant substantial testing to show it is safe, ensuring there are no adverse changes in the drug due
to the plasma. Unless there is a similar predicate device, this would most likely require a De Novo
request.
Without an additional drug, this system would most likely be similar enough to other existing
bandage systems, in which case a 510(k) clearance would be viable. This becomes more diffi-
cult, however, particularly from a marketing standpoint, since there are similar devices under a
Class I approval as liquid bandages. [295] This could even apply to some that are closer toward
an aerosol. [314] A substantial improvement over the current state-of-the-art systems would be
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needed to warrant the added complexity and cost of the plasma system. As such, some further
benefit would need to be identified or utilized for successful marketing of this system (such as the
addition of a drug). An example of this is a spray on system for burn treatment, which required
a PMA. [315] A PMA was used because this is used for severe burns in which skin cells of the
patient are sprayed on, thus requiring skin grafts from other areas on the body. A CAP system
for depositing a bandage would most likely be deemed as a lower risk and could use a De Novo
request pathway.
Epidermal electronics pose some unique challenges. If they are using antenna, then the devices
need to ensure they do not have any Federal Communications Commission (FCC) regulations
they also have to follow and are not emitting any hazardous radiation, which is under the FDA’s
purview. The biocompatibility of the materials needs to be considered; for example, a number of
systems in the literature used silver, [311,313] thus argyria (silver poisoning) needs to be avoided.
Nevertheless, these hurdles can be overcome as shown in the pilot clinical studies for monitoring
neonatal patients. [304] A system like this could choose any of the main pathways depending upon
the exact intended use. A 510(k) pathway would be viable for printing a simple circuit on the
body, such as a strain gauge to monitor the heart rate, as this would have a clear predicate device
in other heart rate monitors. A De Novo request may be required for more complex circuitry and
monitoring, unless there is a clear predicate device. There is also the possibility of using a system
not just on the epidermis but for printing leads inside of the body. These could be used as a part of
a pacemaker or some other electronic system, which would necessitate fairly stringent testing and
lifetime requirements. The FDA has already established some performance standards for electrode
lead wires that would need to be followed. [316] Any deposition inside the body would almost
certainly require a PMA due to the high levels of risk.
6.3.2 Device Outlook
This particular design is merely a proof of concept, requiring extensive development for a
particular indication. The particular indication will most likely be a niche market, since other
systems are treating the proposed indications (bandages requiring a spray covering and epidermal
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electronics) at a much lower cost than this device could attain. Nevertheless, this system does show
a number of useful developments. This uses a floating electrode system, showing that deposition is
possible without using a second ground electrode. The dielectric barrier also helps avoid the risk
of large currents to the patient. Lastly, the variety of films possible show that as a single system
a number of possible treatments are possible. A unique combination of conductive, dielectric, or
other types of depositions may yield novel uses that cannot be obtained individually.
6.4 Experimental Setup
The physical setup of the system showing the various deposition methods is first introduced.
Following that, the changes required to the 3D printer patterning is discussed. As the need for
these changes was noted during the course of testing, many of the depositions reported later do not
have all of the changes implemented into them, resulting in less than ideal films.
6.4.1 Physical Experimental Setup
The experimental setup consists of a 3D printer (3DStuffMaker Evolution Gen 1) that has had
the heater and extruder removed from the printer head and an FE-DBD jet is mounted in their place
(Figure 6.2). The z-axis has been disabled to avoid undesired changing of the jet length. The FE-
DBD jet consists of an alumina tube with a high voltage copper electrode surrounding it. Helium
is used as the working gas (flow rate controlled by a rotameter). Sufficient high voltage insulation
is required to avoid discharging between the high voltage electrode and the printer chassis; in this
case a custom acrylic mount was made to hold the alumina tube and provide electrical insulation.
A high voltage AC source is used to excite the plasma (see Section 3.2.1.2 for power supply
information). The power supply frequency is tuned for each condition to achieve the most stable
discharge. The sample (usually either a silicon wafer or pig skin) is placed on the stage of the 3D
printer under the DBD jet. This entire system is enclosed in a ventilation chamber (the framing of
this chamber can be seen in the edge of Figure 6.2) with a removable side for access to the system.
Three different methods are employed to deposit the precursor into the plasma, as shown in






















Figure 6.3: Schematic of the Direct Write Setup Showing the Heated Sublimation Cell for Solid
Precursors and the Nebulizer and Syringe Pump for Liquid Precursors with Inset Images of the
Heated Sublimation Cell Partially Unwrapped from the Heating Tape and the Nebulizer Spraying
into the DBD Jet
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referred to as CuAcac, and ferrocene) are sublimed into the gas stream. This requires heating
of the percursor for a sufficient concentration to be vaporized. A small amount of hydrogen gas
is mixed into the gas stream to etch away the ligands on the metal; without the hydrogen no
material is deposited. High vapor pressure precursors are placed in a bubbler through which a
controlled amount of helium is bubbled. This is used for initial testing with isopropyl alcohol (IPA)
to determine the patterning requirements needed for the 3D printer (see Section 6.4.2) and for the
methyl methacrylate (MMA) testing in Section 6.6.1. The low vapor pressure liquid precursor
(tris(2-methoxyethoxy)(vinyl)silane, referred to as TMEVS, or ethylene glycol dimethacrylate) is
sprayed by a nebulizer into the plasma region on the substrate. Each deposition method affects the
voltage-current characteristics of the discharge, especially due to the presence of precursors in the
gas stream.
6.4.2 3D Printing Pattern Considerations
Thicker edges with little infill are commonly used for 3D printing, but are not desired for direct
write applications, thus necessitating a custom GCode pattern, rather than a pattern generated by
conventional 3D printer software, that achieves uniform coverage for the DBD jet (Figure 6.4).
For a circular deposition a spiral pattern was chosen that provides much more uniform coverage
(approximately equal area treatment) compared to the conventional 3D printing pattern. The Mat-
Lab code used to generate this pattern and control the 3D printer are in Appendix B. This spiral
pattern also ensures the film is deposited fairly uniformly, rather than one side receiving substantial
deposition before another side, which could create edge effects from the plasma discharge. This
non-uniformity in film thickness is noted in the hydrocarbon film in Figure 6.5. This was printed
using the built-in slicer software (Slic3r) to generate the GCode, rather than a custom GCode, as
evident in the thicker depositions for the outline and centerline. Normally these thicker areas would
be needed for structural support in an additively manufactured part. For this print, a helium flow of
6.9 SLPM was used with an additional 0.7 SLPM helium flow through the isopropyl alcohol (IPA)
filled bubbler.
Other considerations that can affect the printing pattern are the treatment area of the plasma
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(a) Conventional 3D Printer Path











(b) Custom Spiral Path
(c) Conventional Pattern Area Coverage (d) Spiral Pattern Area Coverage




Figure 6.5: Image of Hydrocarbon Deposition Using IPA Without Controlling for Equal Area
Treatment Yielding a Thicker Outline, Thin Infill, and Thick Centerline
jet, the speed of the printer head (residence time), and the temperature of the discharge. These
may not be independent of each other. For example, if a dielectric material is being deposited
onto a conductive substrate, the plasma will preferentially move to areas with a thinner coverage,
possibly leading to hot spots developing in the discharge region which will affect the deposition.
This appears to be the case in Figure 6.6, where a much thicker hydrocarbon deposition is used
(325 passes compared to 4 passes in Figure 6.5). Black spots are noted in the film, most likely
due to hot spots forming and changing the nature of the deposited film, producing more of a
charred deposition; however this film has not been properly characterized to determine a difference
between the brown and black areas. These hot spots can be mitigated by reducing the residence
time of the plasma to avoid a thick layer being deposited, but then more passes of the jet will be
required for a specified film thickness. This was one goal of using a spiral pattern (Figure 6.4b), so
that no area builds up faster than any other. This becomes more complex to determine an optimal
path for other geometries, since the deposition rate from the plasma must also be accounted for.
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Figure 6.6: Image of Hydrocarbon Deposition using IPA of an Equal Area Treatment with Black
Spots from Hot Spots in the Plasma Discharge and Plume Deposition
Also of note in Figure 6.6 is the large plume noted extending away from the discharge area. This
plume is coming from a small flux of radicals leaving the plasma and depositing onto the substrate
in undesired locations due to a a small ambient air current during the deposition process. Better
ambient air flow control could mitigate this issue.
Faster printing head speeds also effect the deposited film, which complicates the ability to move
faster so less material is deposited per pass as a method to reduce hot spot formation. As noted
in Figure 6.7 for a micro-DBD jet (created by pulling glass to achieve a smaller diameter tube),
the speed of the printer head changed the width of the deposited film. This seems counterintuitive
that a faster print would produce a wider deposition; however the height of this deposition is not
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Figure 6.7: Images of Hydrocarbon Deposition Using a Micro-DBD Jet for Small Feature Sizes
Varying with the Printer Head Speed
hydrocarbon deposition is likely conductive, thus a taller deposition may grow more rapidly than
the area around it as it becomes closer to the plasma discharge. This also shows that smaller
features can be created simply by changing the speed of the printer head. Further optimization is
required to determine the smallest feature size that can be printed using this method.
6.5 Metal Film Results
Significant work has already been done previously on copper deposition. [14,15] This includes
characterizing the voltage and current traces of the DBD jet during operation [29] as well as charac-
terizing the copper film. [14] The copper film was determined by X-ray photoelectron spectroscopy
(XPS) to be >60% copper for a long distance away from the jet and >80% copper near the center
of the deposition. The film’s resistivity is between that of bulk copper and bulk iron. Though not
directly measured, good adhesion of the films onto the substrate was noted, such that bending of
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Figure 6.8: Voltage and Current Traces for the Copper (II) Acetylacetonate Deposition
material did not cause any visible film delamination. As such, this work seeks to extend it to a
direct-write system.
Metal is deposited using the heated sublimation cell. A 1.85 SLPM helium gas flow mixed
with 0.09 SLPM H2 is flowed through the sublimation cell kept at 90◦C for the copper deposition
(using copper (II) acetylacetonate, referred to as CuAcac), while a mixture of 2 SLPM helium
and 0.09 SLPM H2 with 9.9 SLPM N2 as a shielding gas is used for the iron deposition (using
ferrocene). The small admixture of hydrogen is necessary to create the film via hydrogen reduction
of the compound. [317, 318] The majority of the experimental work in this section was done by
Brittany Spivey under supervision of the author.
The voltage and current traces are shown in Figure 6.8. The voltage trace is a distorted sine
wave, which is expected given the large current draw exceeding the power supply’s power output.
The current trace shows large spikes every half cycle, which is consistent with previous measure-
ments. [15] There is a single large ionization wave per cycle, with possible smaller ones after a
large one on the other half cycle. These are not noted on the first half cycle, suggesting they are
only occurring due to a substantial amount of preionization. There is also a decrease in the volt-
age and current magnitude, suggesting that the average power is dropping from the power supply.
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Figure 6.9: Image of Copper Direct Write Deposition onto Glass Creating a Copper Film
There could be a secondary duty cycle frequency, where an initial large ionization wave occurs
with large subsequent ones every cycle and smaller ones every half cycle in between, but that the
average power drops after a few cycles such that no discharge occurs, which then allows the aver-
age power to increase, precipitating another initial large ionization wave. This behavior is due to
an unusual coupling between the power supply and the plasma, where the plasma is attempting to
draw more power than the power supply can supply over a short time.
The copper deposition in Figure 6.9 is done with a tube-to-substrate length of 2.5 mm. The
relatively slow rate of metal deposition is due to the small concentration of the metal in the plasma
effluent. Increasing the compound’s temperature to increase the rate of sublimation would yield
faster deposition but would also increase the operating temperature of the jet. The various colors
noted on the edges of the deposition in Figure 6.9 are due to variation in the percentage of copper
in the deposition. [14,15] Further exploration is necessary to determine if there is still good plasma
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Figure 6.10: Image of Iron Oxide Direct Write Deposition onto Glass Using Ferrocene as the
Precursor
stability at significantly higher concentrations of the organometallic compound along with metallic
film deposition. Another way to increase the metal concentration to reduce printing time could also
be to switch from using an organometallic compound to small metal particles. [290, 292]
An attempt is also made to deposit iron using ferrocene. The pattern in Figure 6.10 is created
using a 16.7 mm/s raster with tube-to-substrate gap of 6.9 mm. However, despite trying a variety
of conditions it appears that only iron oxide was deposited. This is most likely due to iron’s
greater affinity of producing oxides than copper, which naturally will form a passivization layer
that protects the bulk copper, unlike iron which continually rusts.
6.6 Silane Film Results
This project intended to deposit thick (∼1 µm) films using a non-thermal plasma DBD jet as
a sprayable bandage system. The goal is to optimize the discharge parameters for the thickest
yet still uniform film as well as ensuring coverage over potentially non-uniform substrates. Fast
deposition rates are also desired, with a goal to coat a 1 ft2 area 1 µm thick within 10 minutes.
A variety of chemicals were initially tested using drying in air to determine the best chem-
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Table 6.1: Four Monomers Tested For Direct Write Film Deposition
Abbreviation Chemical Name Structure
TMEVS Tris(2-methoxyethoxy)(vinyl)silane
EGDMA Ethylene Glycol Dimethacrylate
VTMS Vinyltrimethoxysilane
MMA Methyl Methacrylate
ical for a surrogate bandage. The most promising candidate, tris(2-methoxyethoxy)(vinyl)silane
(TMEVS), was then carried forward into a small optimization study to determine the best condi-
tions for film deposition. Later testing was then conducted on a biological substrate (pig skin) to
determine if this could act as a bandage.
6.6.1 Initial Material Selection
Four chemicals (as listed in Table 6.1) were tested for their volatility and film creation by
exposure to ambient air and plasma treatment. These were selected due to their potential ability to
create films and/or easy manufacturability for large-scale use. Overall, the best choice from this
testing was TMEVS, which is carried forward in further testing.
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(a) Untreated and Air Dried (b) Untreated and Heat Gun Dried
(c) Plasma Treated and Air Dried (d) Plasma Treated and Heat Gun Dried
Figure 6.11: Images of Initial Droplet Tests Using TMEVS
6.6.1.1 TMEVS Initial Testing
Initial testing for tris(2-methoxyethoxy)(vinyl)silane (TMEVS) consisted of two tests, placing
a droplet on a silicon wafer and allowing it to dry and placing a droplet on a silicon wafer, plasma
treating it (5 min treatment, 40% low power, 1.04 SLPM He) to crosslink the monomers, and then
allowing the film to dry to to remove the residual monomer. The droplet was left for 24 hrs and
then dried using a heat gun to accelerate the drying process. This is seen in Figure 6.11. The
untreated droplet appears to have mostly evaporated away due to the excess heat from the heat
gun. The plasma treated droplet left behind a thin film; removing the excess monomer resulted in
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a brittle film that easily cracked. Nonetheless, this shows that polymerization occurred as a result
of the plasma treatment warranting further exploratory testing.
An initial nebulizer deposition was attempted using a 4 min treatment at 35% low power on the
power supply with 13.4 SLPM He and a nebulizer flow rate of 50 µL/min (10% TMEVS and 90%
methanol solution, with 1.43 SLPM He through the nebulizer). Figure 6.12 shows the resulting
deposition before and after being dried with a heat gun as well as two SEM images of the film
(using the TESCON SEM, see Section 3.3.4 for more information). Overall the film appears fairly
uniform, with some potential streaks in it due to the liquid flow being blown toward the outside of
the deposition region by the helium jet flow.
Further testing was conducted with the nebulizer using the 3D printer head in a circular pat-
tern with the 10% TMEVS 90% methanol solution at a higher power (10 min treatment, 50% low
power, 12.6 SLPM He, nebulizer at 10 µL/min with 2.51 SLPM He). This yielded a black-specked
deposition (Figure 6.13a), possibly from some hot spots developing in the plasma. However, at
lower power (35% low power) a white-specked deposition was noted on a silicon substrate (Fig-
ure 6.13b). It is unclear if these are also hot spots in the discharge or possibly areas with a slightly
higher film thickness.
Another test was conducted using a silicon wafer and masking half of the circle with a micro-
scope slide to show the film thickness (Figure 6.14; 10 min treatment, 35% low power, 12.6 SLPM
He, nebulizer run at 10 µL/min of 10% TMEVS 90% methanol solution with 2.51 SLPM He). SEM
images were taken of the film (Figure 6.15, using a JEOL JSM-7500F SEM, see Section 3.3.4 for
more information on the SEM). Agglomerations were noted in the film, with larger agglomerations
occurring near the masked edge of the film. It would appear that the plasma treatment creates small
∼1 µm “balls” of the polymer that can become aggregated where the plasma is more intense, such
as by the mask.
Depositions were attempted on various meshes to determine if the deposited film would be
able to fill the gaps of the mesh. If so, this would serve as a better sprayable bandage as it would
be less sensitive to the non-uniformity in the skin substrate. A nylon mesh was used initially
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(a) Plasma Treated (b) Plasma Treated and Dried
(c) Wide View SEM Image (d) Narrow View SEM Image
Figure 6.12: Optical Images and SEM Images for Initial TMEVS Nebulizer Tests
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(a) Higher Powered Treatment on Stainless Steel
Substrate with Black Specs
(b) Lower Powered Treatment on a Silicon Wafer
with White Specs
Figure 6.13: Images of Further TMEVS Depositions on Various Substrates with Specs Appearing
in the Deposited Film
(a) Immediately Post Treatment (b) After 3 Days to Dry
Figure 6.14: Optical Images of the Half-Masked TMEVS Deposition
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(a) Wide View SEM Image (b) Narrower View SEM Image
(c) Narrow View SEM Image
Figure 6.15: SEM Images of the Half-Masked TMEVS Deposition
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(a) Low Power Nylon Mesh Deposition (b) High Power Nylon Mesh Deposition
(c) High Power Metal Mesh Deposition
Figure 6.16: Images of TMEVS Depositions onto Various Meshes
showing some slight deposition (15 min treatment, 15% low power, 2.84 SLPM He, nebulizer run at
40 µL/min with 10% TMEVS 90% methanol solution with 0.583 SLPM He), but mostly wetting of
the nylon (Figure 6.16a). Higher powers usually caused melting of the nylon (Figure 6.16b; 15 min
treatment, 20% low power, 2.84 SLPM He, nebulizer run at 30 µL/min with 10% TMEVS 90%
methanol solution with 0.724 SLPM He). Similar results with significant wetting were obtained for
a stainless steel mesh (Figure 6.16c), but higher powers were able to be achieved (15 min treatment,
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25% low power, 2.84 SLPM He, nebulizer run at 10 µL/min with 10% TMEVS 90% methanol
solution with 0.466 SLPM He). No cases were found where significant deposition occurred to
begin closing the holes in the mesh, though.
6.6.1.2 EGDMA Initial Testing
Like the TMEVS’s testing, initial testing for ethylene glycol dimethacrylate (EGDMA) con-
sisted of two tests, placing a droplet on a silicon wafer and allowing it to dry and placing a droplet
on a silicon wafer, plasma treating it to crosslink the monomers (5 min treatment, 40% low power,
1.04 SLPM He), and then allowing the film to dry to to remove the residual monomer. The droplet
was left for 24 hrs and then dried using a heat gun to accelerate the drying process. This is seen
in Figure 6.17. The untreated droplet appears to have mostly evaporated away due to the excess
heat from the heat gun. The plasma treated droplet showed some possible polymerizing (i.e. white
specks visible in the liquid) compared to simply letting the sample air dry. These became more ev-
ident with heat gun drying of the sample. SEM imaging was conducted on the plasma-treated film,
showing the white specks appear to be larger structures compared to the bulk film (Figure 6.18,
using the TESCON SEM, see Section 3.3.4 for more information on the SEM). Further testing on
stainless steel (10 min treatment, 25% low power, 12.6 SLPM He, nebulizer run at 20 µL/min with
10% EGDMA 90% methanol solution with 2.51 SLPM He) did not yield any significant visible
deposition (see Figure 6.19a) even after drying with a heat gun so no further testing was conducted
(see Figure 6.19b).
6.6.1.3 VTMS Initial Testing
Like the TMEVS’s testing, initial testing of vinyltrimethoxysilane (VTMS) consisted of two
tests, placing a droplet on a silicon wafer and allowing it to dry and placing a droplet on a silicon
wafer, plasma treating it to crosslink the monomers (5 min treatment, 40% low power, 1.04 SLPM
He), and then allowing the film to dry to to remove the residual monomer. The droplet was left for
24 hrs and then dried using a heat gun to accelerate the drying process; in this case, the heat gun was
only used to briefly heat up the substrate to determine if a thin film may exist that would become
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(a) Untreated and Air Dried (b) Untreated and Heat Gun Dried
(c) Plasma Treated and Air Dried (d) Plasma Treated and Heat Gun Dried
Figure 6.17: Images of Initial Droplet Tests Using EGDMA
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(a) Bulk Film (b) Spots in Film
Figure 6.18: SEM Images of Initial EGDMA Tests
(a) Immediately After Deposition (b) Deposition Post Drying
Figure 6.19: Images of Stainless Steel Substrate Tests Using EGDMA
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(a) Untreated and Air Dried (b) Untreated and Heat Gun Dried
(c) Plasma Treated and Air Dried (d) Plasma Treated and Heat Gun Dried
Figure 6.20: Images of Initial Droplet Tests Using VTMS
more visible by heat. This testing is seen in Figure 6.20. Neither sample left any significant film,
so no further testing was done. The main issue with VTMS appears to be its high vapor pressure,
allowing it to evaporate before any significant treatment is conducted. Even the plasma did not
sufficiently polymerize it to leave behind any significant deposition of a polymer.
6.6.1.4 MMA Initial Testing
Since methyl methacrylate (MMA) was successfully used before in our lab, [30, 31] a short
test on two different meshes was attempted. As before, helium was bubbled through the MMA to
produce a vaporized monomer for plasma-induced crosslinking and deposition. MMA was tested
on silk above a quartz substrate (Figure 6.21a; 15 min treatment, 68% low power, 6.06 SLPM He
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(a) MMA Deposition on Silk (Lower Right) (b) MMA Deposition on Metal Mesh
Figure 6.21: Images of MMA Depositions on Various Substrates
with ∼0.01 SLPM through the bubbler). A clear deposition is noted, but no closing of the mesh
occurred. MMA was also deposited onto a metal mesh (Figure 6.21b; 15 min treatment, 40%
low power, 2.84 SLPM He with 0.25 SLPM through the bubbler). MMA penetrated the mesh and
deposited on the substrate as well, but no closing of the mesh holes was noted. The deposition was
also a light brown in color, although previously reported depositions were mostly clear. This is
most likely due to a more intense discharge (in this case a metal substrate) which has changed the
nature of the deposited film.
6.6.2 Optimization Study
TMEVS was identified as the best candidate for producing a thick and uniform film. Initially
eight samples were used to understand the parameter space, varying the DBD jet’s power, he-
lium flow rate, and concentration of TMEVS in the deposition solution. Based off of the results
from these eight samples, further iteration was conducted to ensure reproducibility and for further
optimization of the film for thickness and uniformity.
Due to issues with the nebulizer becoming clogged or broken, no helium flow through it was
used for this or further experimentation. Nevertheless, the inner tube of the nebulizer was still
small enough (ID < 0.2 mm) that it could still be used to spray drops of solution onto the sample
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Table 6.2: Testing Conditions for Initial Eight TMEVS Samples
10% TMEVS, 50% TMEVS,
DBD Power Helium Flow Rate 90% Methanol 50% Methanol
15% 2.51 SLPM Sample 1 Sample 8
15% 12.6 SLPM Sample 2 Sample 7
30% 2.51 SLPM Sample 3 Sample 6
30% 12.6 SLPM Sample 4 Sample 5
without the gas flow, being run at a constant average flow rate of 50 µL/min using the syringe
pump.
6.6.2.1 Initial Eight Samples
Eight samples with a variety of conditions were used to probe the parameter space, with condi-
tions noted in Table 6.2. A small portion of the wafer is masked using a microscope slide to allow
for easier film thickness measurements. The parameters held constant for the initial eight samples
to initially understand the sample space include the substrate (Si wafer), the DBD treatment time
of 15 min, the ambient conditions (as much as possible; the tent flap to the hood was closed for all
cases; samples 1 to 4 were run on a day earlier from samples 5 to 8, where the ambient temperature
decreased from ∼26◦C to ∼24◦C for the second day, while the humidity decreased from ∼70%
to ∼50% the second day), the pattern used for the 3D printer, and the time waited between the
depositing and imaging the samples.
A representable voltage and current trace are shown in Figure 6.22. A relatively small voltage
is required to ignite the discharge due to a fairly small jet length of ∼16 mm from the electrode to
the substrate and ∼1.5 mm outside of the alumina tube. This is comparable to previous work, [29]
albeit with a slightly smaller jet distance and electrode substrate gap, leading to the slightly lower
voltages required. The current spikes observed are significantly smaller, but the substrate is fully
conducting for this research as opposed to being a dielectric. Multiple discharge events are noted
for each half-cycle.
All samples yielded thin films. Images of each film taken shortly after creating them are seen
in Figure 6.23. Note that Samples 7 and 8 have different lighting conditions, since the films were
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Figure 6.22: Voltage and Current Traces of the DBD Jet with the Nebulizer Spraying TMEVS
not otherwise visible by the ambient lighting. Optical micrographs of each film are shown in
Figure 6.24 and with higher magnification in Figure 6.25. The film’s appearance changed upon
drying. After drying for 1 (samples 5 to 8) or 2 days (samples 1 to 4) the films are more visible as
seen in Figure 6.26.
Increasing the concentration of TMEVS made the films appear more uniform but also created
thinner films. In particular samples 7 and 8 were extremely thin films that were difficult to image or
see until after they had dried for 24 hours. These were deposited using the lower discharge powers.
The flow rate of helium did not seem to have any significant influence on the film. There may be
a slight trend in increasing deposition with lower helium flow rates (compare Samples 5 and 6 or
Samples 3 and 4) but the effect is not substantial; no profilometer data was acquired to verify this
as well. As such, the lower flow rate was deemed better since it reduces the amount of helium used
for depositing a thin film. Increasing the discharge power created thicker films (compare Samples 1
and 3 or Samples 6 and 8). However, Sample 3 shows what appear to be bubbles that have formed
underneath the film or inside of it, possibly leading to a more porous film.
SEM imaging was attempted (using the TESCON SEM, see Section 3.3.4 for details on the
SEM); however the SEM overheated after imaging only one sample, (Sample 2). The SEM images
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(a) Sample 1 (b) Sample 8
(c) Sample 2 (d) Sample 7
(e) Sample 3 (f) Sample 6
(g) Sample 4 (h) Sample 5
Figure 6.23: Images of the Initial Eight TMEVS Samples Shortly After Deposition
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(a) Sample 1 (b) Sample 8
(c) Sample 2 (d) Sample 7
(e) Sample 3 (f) Sample 6
(g) Sample 4 (h) Sample 5
Figure 6.24: Low Resolution Micrographs of the Initial Eight TMEVS Samples
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(a) Sample 1 (b) Sample 8
(c) Sample 2 (d) Sample 7
(e) Sample 3 (f) Sample 6
(g) Sample 4 (h) Sample 5
Figure 6.25: High Resolution Micrographs of the Initial Eight TMEVS Samples
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(a) Sample 1–4 (b) Sample 5–8
Figure 6.26: Images of the Initial Eight TMEVS Samples After Drying in Ambient Air
are seen in Figure 6.27. The film appears very uniform; however imaging was difficult due to
charging of the film during image acquisition, which caused the image to become overexposed. It
appears to be a piece of dust in the image near the center of the film, but the overexposed nature of
the image makes it difficult to confirm.
To determine the thickness of the depositions, a profilometer was used, dragging the tip from
a cleaner area on the silicon substrate across the edge of the film. Only three of the initial eight
samples were tested (Samples 2, 3, and 6). The results are seen in Figure 6.28, where the images
note roughly where the profilometer test was conducted. Sample 6 is noticeably thinner than the
other two samples. Noticeable ridges exist apparently matching the rings of the printing pattern.
This further supports the need to use a different pattern, such as the spiral pattern for direct write
rather than conventional 3D printing patterns. Similarly, Sample 3 has a thin edge where the
masking was done before increasing to a much thicker bulk film. Since mostly only the edges of
the films were sampled, no hard conclusions can be made to the average thicknesses of the films,
however they appear to be at least a micron thick, possibly much thicker to be on the order of
50 µm or more.
205
(a) Near Center of Film (b) Near Film Edge
Figure 6.27: SEM Images of the Inital TMEVS Sample 2
Table 6.3: Sample Conditions for Further Testing of TMEVS Film Deposition
Sample DBD Power Helium Flow Rate TMEVS Concentration Nebulizer Flow Rate
1A 15% 2.51 SLPM 10% 50 µL/min
3A 30% 2.51 SLPM 10% 50 µL/min
6A 30% 2.51 SLPM 50% 50 µL/min
8A 15% 2.51 SLPM 50% 10 µL/min
4A 30% 12.6 SLPM 20% 50 µL/min
6.6.2.2 Further Iteration
Some further iteration on the printing pattern and other parameters was conducted. The testing
conditions are shown in Table 6.3. All of these tests were run with the spiral pattern (Figure 6.4)
for equal area treatment.
Samples 1, 3, and 6 were repeated without masking the silicon substrate with a piece of glass
(called Samples 1A, 3A, and 6A), using the spiral pattern geometry that should be more uniform
in covering all areas, and run for approximately 19 min instead of 15 min. The results are seen in
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(a) Sample 2















(b) Sample 2 Profile
(c) Sample 3

















(d) Sample 3 Profile
(e) Sample 6













(f) Sample 6 Profile
Figure 6.28: Profilometer Results For Samples 2, 3, and 6 of the Initial Eight TMEVS Samples
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Figure 6.29, where all appear roughly the same as the previous trials, showing good repeatabil-
ity. Optical micrographs are seen in Figure 6.29 where all conditions show a fairly uniform film,
especially Sample 1A, where no pattern traces are easily visible.
Sample 3A was also further imaged using an SEM (JEOL JSM-7500F, see Section 3.3.4 for
specifications on the SEM) that has better resolution and lower available probe currents to help
reduce charging of the sample, which occurred previously. Overall the film appears moderately
uniform with some surface roughness and agglomerations on the order of 10–50 µm in size (Fig-
ure 6.30). No significant pores are apparent in the film, nor were any bubbles visible as noted in
Sample 3.
Another sample was created to determine if there may be more influence of TMEVS concen-
tration on the films than initially noted. Sample 4A was run with 12.6 SLPM He, 30% power, and
20% TMEVS solution deposited at 50 µL/min using the spiral pattern for 16 min. Micrographs of
the deposition are shown in Figure 6.31. The film appears consistent with Samples 3A and 6A,
suggesting less sensitivity as initially expected with the variation in the concentration of TMEVS.
Another sample (called Sample 8A) was run with the same conditions as Sample 8, except the
solution deposition rate was lowered to 10 µL/min to reduce the excess liquid buildup noted on
the sample. Again, after 15 min, no significant deposition was noted, so the solution deposition
was turned off, but the DBD jet was left on for a further 15 min treatment. The resulting film is
seen in Figure 6.32. The deposition appears thicker than Sample 8, but the film still appears very
thin, confirming that the solution concentration is still a major factor, not the amount of excess
solution left on the substrate during testing. Thus a large change occurs between a 20% solution
(Sample 4A) and a 50% solution (Sample 8A).
6.6.3 Testing on Biological Substrates
Testing was done on a pig skin as a biological substrate similar to human skin. Nevertheless,
this is only to serve as a basic proof of concept and not as a proper measure for biocompatibility.
Methanol was kept as the solvent for ease of use in testing, although it is known to not be bio-
compatible due to the risk of methanol poisoning. In addition, no histological studies are done to
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(a) Sample 1A (b) Sample 1A Micrograph
(c) Sample 3A (d) Sample 3A Micrograph
(e) Sample 6A (f) Sample 6A Micrograph
Figure 6.29: Images and Micrographs for TMEVS Repeatability Trials
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(a) Location 1 (b) Location 2
(c) Location 3 (d) Location 4
Figure 6.30: SEM Images of TMEVS Sample 3A
(a) 1 X Magnification (b) 4.5 X Magnification
Figure 6.31: Optical Micrographs of TMEVS Sample 4A
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Figure 6.32: Image of TMEVS Sample 8A Using a Lower Nebulizer Flow Rate
determine if there was non-visible damage done to the skin.
An initial test on pig skin was conducted with a few droplets of 10% TMEVS 90% methanol
solution placed directly on the skin and then treated with the FE-DBD jet. The results are seen
in Figure 6.33, showing the pig skin before during, and after treatment, as well as after drying of
the skin briefly using a heat gun. A shinier area is seen where the skin was treated, especially in
Figure 6.33d. Part of the deposited film was able to be exfoliated from the pig skin by scraping
tweezers across the surface, as seen in Figure 6.34. This is desired for film porosity testing.
Three further tests on pig skin were attempted. The first was an attempt to replicate Sample 3A
(2.51 SLPM He, 18% power, 10% TMEVS solution deposited at 50 µL/min, and the spiral pattern
run for 10 min). The skin was noted to deform at higher powers, so a lower power of 18% (rather
than 30%) was used. After 10 min of testing the skin was removed and imaged. It was noted that
the deposition had substantial liquid components. Upon drying the excess liquid, there appeared to
be no deposition as seen in Figure 6.35. The skin was noted to be dry and discolored post testing,
suggesting the either the power was too high or the treatment time was too long suggesting possible
thermal damage to the pig skin.
A second and third further attempts at using pig skin were made using higher He flow rates
to cool off the skin. Both a low (10% TMEVS) and a high (50% TMEVS) concentration of the
solution were used for two different runs (12.6 SLPM He, 30% power, TMEVS solution deposited
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(a) Before Treatment (b) After Treatment
(c) During Treatment (d) After Treating & Drying
Figure 6.33: Images of the Initial Pig Skin DBD Jet Treatment with a Droplet of TMEVS
212
Figure 6.34: Image of the Removal of the TMEVS Deposition from Pig Skin
(a) After Testing (b) After Deposition and Drying
Figure 6.35: Images of the Initial Test Spraying TMEVS onto a Pig Skin Substrate for Film Depo-
sition
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(a) 10% TMEVS Micrograph (b) 10% TMEVS Film Scrapings
(c) 50% TMEVS Micrograph (d) 50% TMEVS Film Scrapings
Figure 6.36: Optical Micrographs of Pig Skin with TMEVS Deposition and the Scrapings of the
TMEVS Films for Higher Helium Flow Rates
at 50 µL/min using the spiral pattern for 18 min). Both yielded films that were able to be scraped
off of the surface of the pig skin using metal tweezers, seen in Figure 6.36; however the film was
not able to be removed intact for film characterization, such as porosity testing.
6.7 Chapter Summary & Future Work
In this work, an existing fused filament fabrication (thermoplastic) 3D printer is modified to
serve as a direct write system by mounting an FE-DBD jet in place of the printer head. Due
to the change in application, different constraints on the printed pattern are needed to ensure
optimized film depositions. A variety of deposition methods and precursors are used, with the
primary goal of developing a system that can direct write onto biological substrates. Metal pat-
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terns were attempted with the goal of using this as a method of printing epidermal electronics. A
variety of materials were tested as possible sprayable bandages. The most likely candidate, tris-
(2-methoxyethoxy)(vinyl)silane) (TMEVS), was carried forward with an initial optimization study
on a silicon substrate. In general, the helium flow rate in the DBD jet had little effect on the system;
however higher flow rate helped cool the substrate, which was especially helpful in later deposi-
tions onto pig skin. Higher DBD powers tended to produce thicker films. The solution’s flow
rate did not seem to have a large effect on the films; any excess liquid would be blown off of the
substrate by the jet. Lower concentrations produced thicker but less uniform films. The optimum
conditions for a silicon substrate were found to be around 20% TMEVS solution (by volume in
methanol) at a flow rate around 50 µL/min with DBD jet parameters of 30% power and 2.51 SLPM
helium flow rate. However, these conditions are not optimal for pig skin deposition, as this lower
helium flow rate and higher DBD jet powers cause thermal damage. More research needs to be
done on depositions on pig skin to determine optimal conditions for deposition.
In addition, the deposition rate is fairly slow. For this to be used in a medical device, faster
deposition rates is desired, so that a patient does not have to lie still for minutes waiting for the
deposition. Lastly, a clear market is needed for this device to warrant further targeted development.
As it currently stands, existing technologies are cheaper and easier to use, so this device would not
warrant funding from investors to get it through an FDA approval process.
215
7. IMPROVEMENT OF ADDITIVE MANUFACTURING
7.1 Introduction
This chapter investigates two different systems that use a plasma for improving the strength
of additively manufactured parts. The first, uses a nanosecond pulsed plasma discharge. Due
to the EMI-generating nature of the discharge, this plasma treatment was done external to the
printer, however this also demonstrates that the effect is purely based on the plasma functionalizing
the polymer surface and not based on a thermal effect. This treatment yielded >100% strength
improvement in the bonding strength between layers. The second system is a commercial product
called the FlashFuse system, which uses a DBD to treat polymers coated in carbon nanotubes.
Since this system uses lower frequencies, EMI is less of a concern and parts are treated in situ
during the printing process. The primary mechanism appears to be Joule heating in the additively
manufactured parts where the plasma is coupling the power supply to the carbon nanotubes in the
polymer. This heating allows sufficient time for the layers to weld together creating parts with the
same strength as injection molded parts. The clearest path of using these processes for medical
applications is in printing custom prosthetics, which is currently being done with the FlashFuse
system.
7.2 Background of Additive Manufacturing
Starting from stereolithography systems developed in the late 1980s and thermoplastic extru-
sion printing in the early 1990s, additive manufacturing (AM), also known as 3D printing,1 has
become a huge field of research and innovation. [52] AM builds a part by selectively adding layers
of material; this is in contrast to conventional “subtractive” machining, where parts of a mate-
rial are removed to produce the finished part. There are many types of AM, from laser sintering of
1Though the two terms are treated as synonymous by most authors, [319] some disagree [320] stating that additive
manufacturing is more encompassing than 3D printing, emphasising the entire manufacturing process including, for
example, support structure design, part post-processing, and process considerations to ensure reproducibility in the
design. This dissertation will follow the standard convention of treating them as synonyms and will primarily use the
term additive manufacturing.
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metallic powders to laminate based methods for paper; this work will focus on thermoplastic extru-
sion, namely fused filament fabrication (FFF), also known by the name fused deposition modeling
(FDM), a name trademarked by Stratasys. [321]
FFF uses a thermoplastic that has a low glass transition temperature. When the material is
heated up to or above its glass transition temperature it can be extruded out of a heated nozzle.
Upon leaving the heated nozzle, the plastic will cool and reform into a solid, binding to the material
nearby. By controlling the rate the material is extruded out of the nozzle as well as the location
of the nozzle, a layer of material can be deposited in a controlled fashion. Successive layers can
be laid down building a part layer by layer. This entire process can easily be automated by a
computer, allowing the user to design a custom part in CAD software and quickly send it to a
slicing program, which will create the commands to send to a printer for creating the part layer by
layer. Though FFF may never quite meet the low cost of injection molding as a bulk manufacturing
process, the advantages lie in that parts can easily be customized (without needing to create a new
mold), various infills can be selected leading to varying material properties throughout the part,
and a variety of materials can be printed simultaneously.
The biggest challenge for FFF is creating a strong interlayer bond. Along the filament direction,
the strength is nearly identical to injection molded parts; however it is substantially weaker along
the y and z directions (see Figure 7.1).This is because the bond is formed between the cooling
filament as it leaves the nozzle and an already cooled thermoplastic layer. As a result, many
groups have investigated methods of heating the printed layers to improve bond strength including
using lasers [322], using infrared lamps [323], and microwaves [49].
The “gold standard” that is sought is to have additively manufactured parts with isotropic
strength the same as that of injection molded parts. Since plasmas have demonstrated the ability to
show surface modification of polymers (see Section 2.2.3), this is a viable method to improve the
strength of additively manufactured parts as we have demonstrated. [16] In addition, Essentium,
Inc. has shown adding a plasma to the printing process is a commercially viable option, which is











Figure 7.1: Schematic of Strength Variation in a 3D Printed Part
In addition to printing directly onto a biological substrate as done in Chapter 6, plasmas can
be used to assist the 3D printing process for parts that will used in the medical industry, such
as creating customized parts for prosthetics or implants. Using plasma’s ability to functionalize
surfaces, a variety of potential uses exist, such as binding the layers together in a 3D printed part,
adhering various surface coatings, and making other surface chemistry possible.
7.3 Device Life-Cycle Overview
This dissertation will focus on two systems: a nanosecond pulsed plasma system developed in-
house in conjunction Dr. Bruce Tai’s lab and the FlashFuse system developed by Essentium, Inc.
In particular, this dissertation will focus on the plasma characterization aspects as the mechanical
characterization has been reported in the papers [16, 17] and coworker dissertations [325, 326] on
these respective projects.
The nanosecond pulsed system requires substantial development to become a usable system.
Two main issues currently exist: combining the current system into a single unified system rather
than two disjointed parts of 3D printing and plasma treatment and greatly reducing or ideally
eliminating the EMI generated from the system. If these can be solved, this will result in a method
of creating parts with greatly enhanced strength compared to standard (i.e. non-plasma assisted)
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FFF.
The FlashFuse system is by far the most developed system discussed in this dissertation. It is
currently being used in commercial operation for a wide range of additively manufacturing pro-
cesses to create parts with the injection molded strength. The most relevant is TriFusion Devices,
a subsidiary of Essentium, Inc., which is using the FlashFuse system to produce prosthetic devices
for amputees. The only last step in development for the FlashFuse system is to show a wider
range of materials that can be used with the system, which is already claimed by the company’s
website. [324]
7.3.1 FDA Approach
The FDA has released non-binding guidance, which currently reflects the FDA’s thinking in
the area of 3D printed parts, to assist in company decisions. [71] Any patient-specific device cre-
ated by a 3D printer is still subject to normal requirements; there is simply more of a focus on the
process rather than the end product. As a result, following good manufacturing practices (GMP) is
key, which may require some more scrutiny for a plasma-assisted printed device. This is because
the plasma adds some additional controls over the printed part that need to be demonstrated to not
adversely affect the end product. For example, the additional chemistry provided by the plasma
may warrant additional testing to ensure no adverse chemicals were created. [55] However, these
would most likely only need to be documented in the design file rather than requiring a new ap-
proval, just as changing out any other material source may be required to note in the device design
file.
Essentium, Inc. and its subsidiary company TriFusion Devices are already operating in the area
of custom prosthetic devices. [327] These devices are exempt from the 510(k) process as Class I
devices, meaning no FDA approval is required for the device; however general controls such as
proper labeling and GMP still apply. [83]
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7.3.2 Device Outlook
Further work is being put into both of these designs. The nanosecond pulsed system is being
more fully characterized to understand the mechanism for the improved strength. Though this is
not developing it substantially as a potential medical device, it is planning to show that multiple
3D printers and materials can be used. In determining the mechanism a new plasma source may
be able to be used that can be integrated easier into the printing process, especially one that does
not generate so much EMI.
The FlashFuse system is already a marketed product. The only goal is that through the business
side of Essentium, Inc. and TriFusion Devices this device can become wide-accepted and used in
more systems.
7.4 Nanosecond Pulsed System
This system was developed in conjunction with Dr. Bruce Tai and his student, Chin-Cheng
Shih, as a part of his master’s work. [325] The plasma aspects of the system will have more of a
focus in this dissertation as the other aspects of the project (running the 3D printer, bond strength
testing, SEM, etc.) were Chin-Cheng Shih’s contribution to this joint endeavor. Some results will
only be mentioned in passing such as water contact angle changes and stress whitening noted on
fractured samples, as these were done by Chin-Cheng Shih.
7.4.1 System Description & Experimental Setup
The system consists of two parts: a 3D printer (Dreamer, Flashforge) and a nanosecond pulsed
power supply (FID power supply, see Section 3.2.1.3). Initially, small blocks of polylactic acid
(PLA) are printed, measuring 20 mm by 12.5 mm by 12.5 mm so that they fit under the arrays
previously described in Section 4.4.2 (Array #1 was used for all testing here). The printing process
is then paused for treatment, and the printing platform is removed from the printer. Removal was
necessary to avoid electromagnetic interference (EMI) during the plasma treatment. The blocks
are then treated using the the FID power supply using two different treatment times of 30 s or 300 s









Figure 7.2: Schematic and Image of Plasma Treatment for the Nanosecond Pulsed System
Table 7.1: Various Treatment Conditions for PLA Samples
Notation Name Treatment Description
C Untreated Control (no treatment)
CPT30 Short Treatment 30 s plasma treatment
CPT300 Long Treatment 300 s plasma treatment
P Polished Polished with #180 grit sand paper
P+CPT300 Polished & Treated Polished with #180 grit sand paper and then 300 s
plasma treatment
Figure 7.2. The FID power supply was run at 20 kV and 2 kHz, with a 2.5 SLPM helium gas flow
through the array; the discharge gap was maintained to be approximately 1 mm. In addition to a
plasma treatment, a polishing treatment was given to some samples in lieu of a plasma treatment
(manually polished with #180 grit sandpaper). A third treatment group was also conducted which
included being polished and then having a 300 s plasma treatment. The different treatments are
summarized in Table 7.1.
The two plasma treatment times were chosen to determine if there is any effect on the duration
of treatment, assuming that longer treatments may have a greater effect on the surface. The pol-
ished samples were used to provide a control that has surface modification done on a macroscale
level. In addition the polished surface showed itself to have the most wettable surface in wa-
ter droplet tests, having a substantially smaller water contact angle (∼10◦) than both the control
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Figure 7.3: Schematic of Test Part for Testing the Nanosecond Pulsed Plasma System
(∼80◦) and the 30 s plasma treatment (∼45◦).
After treatment, the printing platform was reinstalled and allowed to come back to thermal
equilibrium with the bed temperature. Then a thin second layer measuring 10 mm by 12.5 mm
by 0.9 mm is printed over half of the original block, as shown in Figure 7.3. The purple colored
surface of the substrate is the plasma treated surface. This thin layer is then sheared off to measure
the bond strength using a custom designed shear bond strength test apparatus (Figure 7.4), which
measures the force applied as the layer is sheared off at a constant shearing rate of 12.5 mm/min.
The work (or minimum energy expended, E) required to remove the top layer is given by
E =
∫
F · v dt (7.1)
where F is the instantaneous measured force, v is the velocity of the shearing tip, and t is time. This
allows not only the force (strength) of the part to be measured, but also the work in removing the
top layer of the material, showing how brittle the material is. This test is intended to be similar to
the shear bond strength test used for dental composites. [328] This is done in place of the standard
tensile test due to the small sample treatment area available using the array electrode.
In addition to the testing for the shear bond test, the plasma was characterized spectroscopically
using the Ocean Optics modular spectrometer (see Section 3.4.1.3 for spectrometer details). No
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Figure 7.4: Image of the Custom Designed Shear Bond Test Apparatus (Reprinted with Permission
from Shih, et al. [16] © 2018 Elsevier B.V.)
current or voltage measurements were taken due to the inability to measure the fast pulsing of the
FID power supply (see Section 3.2.1.3 for power supply details).
7.4.2 Device Characterization Results
All of the interpretation of these results presented here is the author’s work. Further data and
results are presented in the paper, most notably microscopic observations of the various treatments,
which show stress whitening (crazing) of the plasma treated surfaces. “Stress whitening occurs
when thermoplastic polymers are under an excessive tensile load, which causes the formation
of microvoids due to the movement of molecular chains, thus changing the material refractive
index.” [16] This supports the hypothesis that the plasma treatment increased the surface bonding
between the layers, especially as this did not occur in the polished and control cases.
7.4.2.1 Mechanical Results
All trials for each case are plotted in Figure 7.5. Not only is there a substantial increase in
the maximum force required to remove the top layer for the unpolished plasma treated samples
(see Figure 7.6), the force is also much greater at longer times as well. The fast drop in the
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Figure 7.5: Force vs. Time Plots from the Shear Bond Test for All Test Conditions
required force for the untreated and polished cases suggests that brittle fracture occurred with a
fast crack propagation along the interface. The plasma treated cases showed higher toughness,
requiring a larger force throughout the duration of the test. The peak force required is shown in
Figure 7.6, where the unpolished plasma treated samples have a significantly higher peak force
compared to the untreated control samples (p = 3.3662×10−5 and p = 0.0068 for the 30 s and
300 s treatments, respectively), while neither of the polished cases are statistically different from
the untreated control.
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Figure 7.6: Bar Chart of the Required Shear Force to Remove the Top Layer (Error Bars are
Standard Error)
Two other interesting results were noted. First, longer treatment times did not improve the
bonding strength; rather longer treatment times resulted in worse results. The effect for this is not
readily evident and is the subject of further ongoing research and hence not in this dissertation.
The second interesting result was the effect of polishing the surface. Polishing showed similar
peak forces as the untreated control, but had a faster fracture, suggesting that polishing may reduce
the bonding toughness. Even further, combining the two effects (polishing and plasma treatment)
had no significant effect.
There is considerably more variability in examining the total work done on the block until
fracture occurred compared to the peak force. This work is shown in Figure 7.7, where only the
30 s plasma treatment is statistically different from the untreated control case (p = 0.0052). This
mostly has to do with the time until fracture occurred. For the polished samples fracture occurred
very quickly, while for a few of the unpolished plasma treated samples fracture only occurred after
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Figure 7.7: Bar Chart of the Work Done Until Fracture of the Top Layer (Error Bars are Standard
Error)
the tip had sheared the entire top layer off. As noted in Figure 7.5, all of the polished samples
either fractured off early (all polished samples) or had very little required force at later times (most
polished and treated samples) suggesting only a small area had not fractured. There was greater
variability in the other three cases, where one or more samples fractured significantly early, while
some samples did not, requiring substantially more force at later times, suggesting a much higher
surface energy. Further work is needed in this area to better characterize the initial surface energy
as well as the effect of the plasma on increasing the surface energy, mostly to reduce the error or
better characterize its source in the data of Figure 7.7.
7.4.2.2 Plasma Characterization
Due to the fast rise time of the power supply, all plasma characterization is optical in nature,
since no equipment is able to adequately capture (i.e time resolve) the waveform of the FID power
supply (see Section 3.2.1.3 for more details). Broadband spectra is shown in Figure 7.8 (see Sec-
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Figure 7.8: Broadband Spectrum from the Nanosecond Pulsed System for AM
tion 3.4.1.3 for details on the spectrometer). Only N2 and N2+ lines are noted. Interestingly the
bright helium line at 389 nm is not noted, but the spectrum is primarily dominated by N2+. Broader
spectra would most likely show other helium lines, just as a broader spectrum in Section 4.5.1.2
for a very similar setup showed many other species, including He, OH, and NO. Two different
mechanisms could explain the large presence of N2+, Penning ionization with helium and electron
impact ionization (see Section 2.2.2.2 for explanation of these processes). It is assumed that Pen-
ning ionization is the dominant mechanism due to the large presence of helium (∼100% of the
gas exiting the array is helium). Although it is also possible that electron impact ionization due
to a large Te caused by the fast application of the electric field is present, which would also cause
ionization of N2. Without other evidence, such as multiple helium lines from which Te may be
approximated, the mechanism cannot be determined.
The spectra was also modeled for temperature fitting of the discharge, which is shown in Fig-
ure 7.9 (see Section 3.4.3.2 for information on the temperature fitting code). The gas temperature
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(b) 379 nm Band
Figure 7.9: Spectra with Temperature-Fitted Modeled Spectra from the Nanosecond Pulsed System
for AM
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(approximately Trot) is quite low, which is to be expected for such a short pulsed DBD discharge
primarily in helium to a dielectric substrate. The vibrational temperature (Tvib) is substantially
higher showing the discharge to be highly non-equilibrium. This choice of wavelength range in
Figure 7.9b was deliberate to ignore the contribution of N2+, as no N2+ lines are in this range. The
second range used in Figure 7.9a has peaks corresponding to N2+. It is quite possible that the N2
is not at the same temperature as N2+ due to different excitation methods between them; N2 is
predominantly excited by electron impact ionization, while N2+ is created by Penning ionization
with helium. Since SpecAir cannot assign different Trot and Tvib to the different species, it is best
to use the wavelength range where there are not N2+ peaks. Nevertheless, in this case the two result
in temperatures that do not differ from each other, being within the error of this method. This is
due to the small influence of N2+ in the 356 nm band; other wavelength ranges with larger peaks of
N2+ would differ more significantly.
7.5 The FlashFuse System
The FlashFuse system was developed at Essentium, Inc. in conjunction with Texas A&M Uni-
versity, from which the company was created. This system is an example of a production-ready
system of integrating a plasma with a 3D printer for strength improvement of additively manufac-
tured parts.
7.5.1 System Description
The FlashFuse system uses a DBD mounted to the head of a 3D printer to heat up polyamide
(PA) filaments that have carbon nanotubes (CNTs) added to them. A schematic of the system is
shown in Figure 7.10 and an image is shown in Figure 7.11. The system uses a custom-designed
high voltage AC power supply that is integrated into the control system of the 3D printer. This
system is designed to minimize the EMI generated to avoid disruption to the 3D printer’s elec-
tronics. The goal is to generate a “warm” DBD discharge to keep the printed part heated near or
above the glass temperature of the polymer so that sufficient time is allowed for increased mobility
of the polymer chains to cross the boundary between the previously printed layers and the new
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Figure 7.10: Schematic of the FlashFuse System
layers just extruded onto the part. If the DBD is too hot this can lead to undesired warping of
the part from excessive melting of the polymer; if the DBD is too cold insufficient polymer chain
movement in the welding process will occur leading to a weaker printed part. To ensure more even
heating the polymer is mixed with a small amount of carbon nanotubes that will couple with the
high frequency electric field leading to volumetric heating of the part via Joule heating. Higher
heating will occur in the region with the highest electric field, as expressed by the equation for
Joule heating
dQ̇ = j · E dV– = 1
ρ
E2 d V– (7.2)
where dQ̇ is the differential volumetric heat generation in the differential volume d V– of the printed
part, j is the local current density, E is the local electric field, and ρ is the local resistivity of
the printed part caused by the carbon nanotubes. It should be noted that the small amount of
carbon nanotubes does not impact the overall material properties (yield strength, elastic modulus,
etc.). [49]
The high voltage electrode is an annular electrode that fits around the nozzle of the 3D printer
and is fully encased to minimize the risk of electrical shock. For the purposes of characterization,
a minimum setup was used, as shown in Figure 7.12. A high voltage feedthrough was created to
allow voltage measurements. Current measurements were taken by a current transformer on the
ground return path. Care was made to ensure a single ground path through the printed part existed,







onto a 3D Printed Part
Printer Nozzle
Figure 7.11: Image of the FlashFuse System Running In Situ
to the grounded printer nozzle, through the printed part and the print bed, or through the filament
that is being extruded. Optical access was available via a fiber optic cable.
7.5.2 Device Characterization Results
The plasma characterization was done by the author; the material results were done by the
coauthors on the resulting paper [17], namely members of Dr. Micah Green’s lab or employees of
Essentium, Inc.
7.5.2.1 Voltage and Current Characterization
The measured voltage and current for the FlashFuse system are shown in Figure 7.13. Note
that some of this voltage is dropped across the additively manufactured part in addition to the
plasma; nevertheless, care was taken to avoid an excessive distance through the part before the
ground electrode to minimize the additional resistive drop through the part. As is characteristic









Figure 7.12: Image of the FlashFuse System as a Bench Top Setup
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Figure 7.13: Voltage and Current Traces of the FlashFuse System
seen near the peak in the upper half of the sine wave. This is most likely due to an excessive power
draw from the circuit beyond what the power supply is able to provide, leading to distortions in
the waveform. Some asymmetry is expected since there is asymmetry in the geometry; there is a
dielectric on one side of the gas gap, while there is a resistor on the other side, thus this system is
partially a DBD and partially an RBD. Many current spikes are noted superimposed on a roughly
sinusiodal current trace. The spikes are the individual microdischarges noted in the image of the
setup (Figure 7.12).
The current trace can be integrated to yield the charge. Plotting the charge against the voltage
yields a Lissajous figure, as shown in Figure 7.14. This figure allows for easier interpretation of a
number of system parameters. The Lissajous figure is a parallelogram, where the rounded corners
are more characteristic of a resistive discharge. [216] Since this discharge has a resistive barrier as
one electrode (the printed part) some rounding is expected. The system total capacitance without a
discharge (series capacitors of the dielectric barrier and the air gap) is the slope of the curve on the
233
Figure 7.14: A Lissajous Diagram of the FlashFuse System, Corresponding to the Voltage and
Current Traces in Figure 7.13
top and bottom of the parallelogram, measured to be 13.4 pF; the slopes of the left and right side
of the parallelogram are the system’s capacitance with a discharge (primarily from the dielectric
barrier), measured to be 40.2 pF. The energy dissipated per cycle is found by the area enclosed
inside of the parallelogram, measured to be 1.92 mJ, yielding a power of 29.6 W when multiplied
by the frequency of the power supply. It is expected that the power density of 1.29 W/cm2 (the
power divided by the electrode area) will remain constant during the printing process, but this has
yet to be verified. In addition, the power supply is designed to deliver a specified power, thus the
voltage and frequency will be modulated by a microcontroller with a feedback loop to ensure the
average power remains constant.
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Figure 7.15: Broadband Spectrum of the FlashFuse System
7.5.2.2 Spectroscopic Results
The broadband optical emission spectra is shown in Figure 7.15 using a broadband spectrom-
eter (see Section 3.4.1.2 for details on the spectrometer). Since this is a discharge in air, it is not
surprising that the main constituent noted is N2. No N2+ was noted, although NO γ was seen.
Interestingly both sodium and potassium are observed, but these are assumed to be an impurity
from excessive handling of both the additively manufactured part and the dielectric barrier.
The rotational temperature (Trot) was determined spectroscopically (see Section 3.4.1.1 for
the spectrometer details and Section 3.4.3.2 for the temperature fitting algorithm details) to be
598 K, and the vibrational temperature (Tvib) was determined to be 4244 K. The fitting for these
temperatures is shown in Figure 7.16. To show the goodness of fit, the grey spectra plotted in
the insets are modeled spectra with Trot±200 K and Tvib±500 K. These show that increasing or
decreasing the temperatures by those amounts leads to a clearly poorer fit. To better quantify the
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Figure 7.16: Spectrum (Blue) with Temperature Fit (Red) of the FlashFuse System, Noting the
Temperatures of the Discharge are Approximately Trot =598 K and Tvib =4244 K (Model Fits in
Grey of Trot ±200 K and Tvib ±500 K are also Shown)
error, the root mean squared error of the fit is plotted in Figure 7.17 as a function of the rotational
and vibrational temperatures. This gives bounds on the fit that are on the order of 50 K for the
rotational temperature and on the order of 400 K for the vibrational temperature, which is the
approximate error of this technique. [224]
7.5.2.3 Material Property Results
X-ray photoelectron spectroscopy (XPS) was performed on a sample from the FlashFuse sys-
tem. The results are shown in Figure 7.18. The main change was the increase of the nitrogen
(N1s) concentration from ∼0 to 5.7% due to the plasma. Oxygen (O1s) also increased slightly
from 11.8% to 12.7%, while carbon (C1s) correspondingly decreased from 88.2% to 81.6%. This
is interesting as PA is partially composed of nitrogen (the amide component of the structure, which
is of the form RC(=O)NR′R′′), but no nitrogen component is noted in the control sample. The
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Figure 7.17: Plot of the Error Associated with the Temperature Fit Shown in Figure 7.16
plasma likely modified some surface bonds to allow nitrogen to appear in the treated spectrum.
Using the IR cameras, the temperature of the print was measured as a function of the z height.
Figure 7.19 shows that the temperature of the printed part is substantially higher than glass temper-
ature of PA (40–60◦C) and close to the melting temperature of the polymer (189◦C) for the DBD
heated case. Since the degree of welding increases with increasing temperature, this large increase
in temperature at least partially, if not wholly, explains why there is improved bonding between
layers.
The material properties were enhanced compared to a control part, as shown in Figure 7.20.
The tensile strength and elastic (Young’s) modulus are nearly identical. The only material property
that was not achieved to be the same as an injection molded part is the elongation at break, sug-
gesting a more brittle fracture. Interestingly, this is the opposite result from the nanosecond pulsed
system, which found a less brittle break after plasma treatment (see Figure 7.5). Nevertheless, two
different materials (PA vs. PLA) and systems were used.
237
Figure 7.18: XPS Survey Spectrum of the Polymer Surface with (DBD Plasma) and Without (Con-
trol) the FlashFuse (DBD) Treatment and the Relative Atom Percentage of the Observed Species
(Reprinted with Permission from Sweeney, et al. [17] © 2020 American Chemical Society.)
Figure 7.19: Temperature Plot of the Partially Printed Part as a Function of Z Height with Flash-
Fuse Treatment (Reprinted with Permission from Sweeney, et al. [17] © 2020 American Chemical
Society.)
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Figure 7.20: Stress-Strain Curve and Radar Chart Showing Some Material Properties of the DBD
Welded Part Compared to a Control and Injection Molded Part (Reprinted with Permission from
Sweeney, et al. [17] © 2020 American Chemical Society.)
7.6 Chapter Summary & Future Work
This chapter investigated two plasma systems that improve the strength of additively manufac-
tured parts. Both systems show a large improvement in the strength of the parts, which can be used
for prosthetics among a variety of other applications. This application is already being used for the
FlashFuse system.
The exact mechanism for plasma improving the adhesion between the layers is unknown; this is
the subject of ongoing research for the nanosecond pulsed system, while substrate heating appears
to be one of the dominant mechanisms for the FlashFuse system.
From a design point of view, these systems are the easiest for medical devices since the plasma
does not directly contact the patient; as such prosthetics are Class I devices not even requiring a
510(k) for approval. Nevertheless, further development is needed in these systems. Fully under-
standing the mechanism for strength improvement can lead to a more tailored plasma to optimize
the strength improvement. For the nanosecond pulsed system, the plasma process needs to be
integrated into the 3D printer as the FlashFuse system is to create a single process.
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8. CONCLUSIONS & FUTURE WORK
8.1 Conclusions
Developing a low temperature plasma medical device is a complex initiative, requiring knowl-
edge of how the plasma behaves and how that behavior can be leveraged for medical benefit. In
addition, any given design must undergo extensive testing from the bench top to clinical trials to
verify the system works as intended and validate that the design is achieving the desired medical
results. Currently there are five devices in Germany that have received a CE marking and are thus
approved for medical use. However, there are currently none approved by the US FDA. This is due
in part to the stricter approval process of the FDA compared to the CE marking, which requires
substantial proof of efficacy in addition to safety leading to more extensive clinical trials being
required, as well as the number of universities in Germany that are at the forefront of the field
of plasma medicine. Nevertheless, there are a number of companies attempting to produce a low
temperature plasma medical device for the US market.
This dissertation addressed how to design low temperature plasma devices for the medical
field, attempting to answer the question: How can a low temperature plasma medical device be
developed effectively in the US? The biological aspects of the design were not the focus, which are
nonetheless crucial to the overall development; rather an engineering approach and a more holistic
view were taken. Four different aspects introduced for plasma medical devices were specifically
examined in some detail:
1. Device development was examined at a more holistic level for the various devices consid-
ered. This was more speculative for these devices as nearly all of them (the FlashFuse being
the only exception) are very early in their development. Nevertheless, potential issues were
predicted and addressed, such as including substantial high voltage shielding for safe op-
eration. Mostly these devices suffered from not having a clear indication to treat, leading
to broader developmental considerations, rather than focusing on specific issues that would
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become apparent when a specific indication is sought to be addressed. Many of these issues
would become apparent in the verification and validation steps in the design process.
2. Regulatory approval drives the direction these devices must take in their development.
The main driving force in regulatory approval is the intended use of the device. For some
of these devices, the intended use can be narrowed to that of existing devices, allowing a
510(k) clearance for quicker approval. Nevertheless, some testing must be done to assure
that the technological characteristics of the plasma do not raise any new questions on safety
and efficacy. For other systems, a clear predicate device may not exist. Seeking a De Novo
request is the clearest path forward for these devices.
3. Plasma characterization was successfully completed on all off these devices. All showed
themselves to be non-equilibrium plasma discharges, most of them also meeting the defi-
nition of CAP systems (again the FlashFuse being an exception). In general, few unusual
species were noted, with the exception of NO for some of the systems when flowing helium,
but further testing is required to determine if other species, such as ozone, are generated and
if they may be produced in quantities near or above regulatory limits. Voltage and current
characterization was also conducted to minimize the amount of current flowing through into
a patient.
4. Biocompatibility, at least at a cursory level, was sought in the characterization. Current was
minimized whenever possible, predominantly by using dielectric barriers or fast pulsing to
limit full development of the discharge. The discharge temperature was also sought to be
minimized, mostly staying near ambient. Generally heating of the substrate was not noted;
however, no histological studies were conducted to determine if thermal damage did occur.
In regards to chemical species biocompatiblity was neither well maintained nor satisfacto-
rily measured. In some cases, NO was measured in the plasma emission spectrum but an
absolute measurement was not obtained to determine if the levels generated poses a hazard.
In addition, solvents such as methanol were used for their ease-of-use, rather than seeking to
241
determine a biocompatible alternative.
Specifically these four areas were addressed examining five different devices. The following
subsections will explore the lessons learned from each device.
8.1.1 Electroporation System
The electroporation system is an interesting example of a combination product, where the
plasma system assists in drug delivery by opening pores in the treated cells. Due to potential
plasma-drug interactions this becomes a complex approval process, requiring an extensive amount
of testing to receive regulatory approval.
The electrode and power supply were designed to maximize the electric field delivered to the
substrate. This was achieved by having an array of sharp tips to create a locally higher electric field,
using a short pulse duration to overvoltage the gap without undergoing a complete breakdown, and
choosing a gas that should maximize the electric field during the discharge process. This device
displayed very interesting and unusual behavior in being substrate invariant for a wide range of
conditions. This is due to the short pulse duration of the system creating an incomplete breakdown
of the discharge gap regardless of the conductivity of the substrate used.
8.1.2 Modified Electrosurgical System
A Bovie electrosurgical generator was modified to generate a low temperature plasma by
adding a small tube around the electrode with helium gas flow. This provided a narrow operating
regime where a low temperature plasma could be generated without overvoltaging the electrosur-
gical generator. The behavior was found to be similar to existing laboratory plasma jets, where
both a diffuse and concentrated mode of the plasma discharge exist. A brief inactivation study was
conducted showing that the modified electrosurgical generator is capable of inactivating E. Coli
and A. Flavus.
Nevertheless, the original goal of being able to use a modified existing device for a faster
approval process was flawed. This is because the intended use of the device is the driving factor
for approval through the FDA. Since the modified system has a different intended use of microbial
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inactivation compared to the existing system’s intended use of tissue destruction or coagulation.
This eliminates the 510(k) process using the current FDA approved systems as the predicate device.
Unless a suitable predicate is found that uses different technological characteristics, a De Novo
request is the best option, which will take substantially longer than a 510(k) clearance. Instead
of using a modified existing device, a better system could be developed to better meet the new
intended use.
8.1.3 Direct Write System Using a Plasma Jet
The direct write system was developed by modifying a 3D printer to use a DBD jet instead
of thermoplastic. Due to the change in use, different patterning is required to achieve equal area
treatment. It was found that the optimal patterning has to account for the speed of the printer
head, the rate of deposition, the size of the plasma-treated area, and the desired treatment area.
Nevertheless, this system is capable of creating a wide variety of films, from metallic copper to
various polymers. Initial testing was done to create uniform films of both copper and a silane
polymer on various substrates.
The economics of this system still need to be determined. Currently the two main intended uses,
sprayable bandages and epidermal electronics, have cheaper alternatives. This requires finding a
niche market that cannot be served by the alternatives to spur funding for the development of this
system.
8.1.4 Nanosecond Pulsed System for Additive Manufacturing
The array developed in the electroporation chapter was used with helium to treat the surface of
additively manufactured parts. This initial testing with a nanosecond pulsed helium plasma showed
more than 100% strength improvement in the adhesion of a subsequently deposited thermoplastic
layer using a shear bond test. This effect is not explained by increased wetting of the treated layer,
since a polishing treatment which greatly improved the wettability did not increase the strength. In-
terestingly, longer treatment of 300 s compared to 30 s reduced the strength improvement. Further
testing is underway to elucidate the mechanism for the strength improvement.
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8.1.5 The FlashFuse System
The FlashFuse system was developed with Essentium, Inc. to create an in situ process of im-
proving the strength of additively manufactured parts containing carbon nanotubes. The system is
a DBD mounted around the nozzle of a 3D printer, where the ground electrode is the additively
manufactured part, which is conductive due to the embedded CNTs. This system was able to print
and plasma treat simultaneously, thermally welding the parts together. The plasma treated parts
have the same tensile strength and elastic modulus as injection molded parts, just with a smaller
elongation at the breaking point. This system is currently being used to create prosthetics in con-
junction with TriFusion Devices, a subsidiary of Essentium, Inc.
8.2 Future Work
There is currently no low temperature plasma medical device approved by the FDA. As such
there is still a tremendous amount of work to be done in developing such a device and even getting
the existing systems currently being used in Germany to be used in the US. There are a number of
companies working toward this goal, as mentioned in Section 2.5.2. However, most of this work
will not become public until (or unless) the company becomes successful in marketing their device.
Nevertheless, there are a number of potential uses for low temperature plasma devices, which
will certainly spur innovation in this field. The main question is whether the plasma offers a
substantially better efficacy or cost compared to the existing treatment. This is questionable for
many of the wound care treatments, where existing chemical treatments are already cheap and
effective. Ultimately the market will determine if this is a viable treatment option for CAP. Cancer
treatment currently appears to be the best option for CAP. There are no highly effective alternatives.
Chemotherapy often has a number of undesirable side effects, so if CAP could be used in lieu of
or in addition to the existing treatments to improve outcomes this would offer a substantial benefit.
For the individual systems explored in this dissertation, the future work to be done is explored
in the following subsections.
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8.2.1 Electroporation System
Electroporation is most likely going to be used in a combination product—using a device and
drug/biologic to generate the desired effect. This is currently being investigated in our lab as a way
of introducing new genes (a biologic) to plants, but the obvious reluctance of using gene therapy
in humans means that this application of electroporation is going to be quite difficult for clinical
practice. Nevertheless, the FDA has starting approving gene therapy, so this application may come
sooner rather than later as an alternative to using viral vectors. [239] The other main use would
be to insert a drug into cells as is done currently in electrochemotherapy. Either way, the FDA
is going to require strenuous testing for approval to ensure there are no unintended plasma-drug
interactions.
This system needs further testing to ensure minimal current is introduced to the patient and
over what ranges of voltages and pulse duration a sufficiently low value is maintained. Further
characterization of the electric field is desired. Since this is difficult to do experimentally, modeling
of the system can be done computationally to determine the applied electric field.
8.2.2 Modified Electrosurgical System
The Bovie system tested in this dissertation could use some more design work to integrate the
gas flow into the existing electrosurgical power supply; however, the J-Plasma system already has
helium gas flow integrated into its design, removing the need for further design on that specific
system. Further bench top testing is needed to determine how effective this exact system is beyond
the single study done so far, [265] especially compared to existing marketed systems such as the
kINPen MED plasma jet. Nevertheless, these existing systems have proven the technique; the
J-Plasma would only be building off of their work in regards to their own device.
The FDA approach is fairly clear for this system; it is based off of a Class II device, thus
unless a suitable predicate can be determined, the De Novo request is the clearest course of action
to have this type of system used for wound treatment. The main question is why has Bovie not
pursued this already? Is the market not feasible for them—either through lack of expertise in that
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subfield of medicine or lack of a compelling enough business model? Since the J-Plasma system
has been sold by Bovie to Apyx Medical, [263] it seems most likely the company is not doing
well from a business perspective and is thus not pursuing a risky development effort. However, the
Canady HeliosTM Cold Plasma Scalpel is an outgrowth from electroporation systems developed by
the same company, and this device is currently in clinical trials. [149] No matter the reason, it is
reasonable to expect this technology will be used in the US in the near future, whether it will be
a Bovie or Canady system branching into a new market, a homegrown new device, or one of the
German devices entering the US market.
8.2.3 Direct Write System Using a Plasma Jet
The basic applications that were examined for this work are already being explored for market-
ing in the US. Epidermal electronic systems are already in clinical trials, but are not a plasma based
system. [304] A variety of liquid bandages already exist as Class I devices, while sprayable ban-
dages are approved for veterinary use. The addition of a plasma opens up a variety of novel uses
and narrow applications, such as in vivo writing of these films that the existing technology may not
be able to achieve. However, that comes with the added cost and complexity of the plasma system,
and a strong case would have to be made that the added complexity is economically feasible for a
company to pursue.
Substantial development is needed for these systems. Copper deposition has been achieved,
but other metals have not been printed using a similar DBD jet system. The rate of deposition will
also need to be increased greatly for feasible use as a medical application. Especially for epidermal
electronic applications, the flexibility of the deposited metal film needs to be established without
loss of conductivity. The use of hydrogen as well may need to be reevaluated to determine if this
is allowable from a biocompatible and risk-mitigation approach.
Though the TMEVS films have undergone some optimization for film deposition, the viability
of this material as a bandage has not been conducted. The TMEVS films also did not adhere to the
pig skin substrate very well, suggesting this material may not be the optimal material for use as a
sprayable bandage. If further development of this material is found useful for a sprayable bandage,
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significant optimization needs to be done to determine the best conditions for rapid deposition,
which was not achieved in this system. In addition, the methanol solvent is not biocompatible
due to the risk of methanol poisoning. A new solvent will have to be considered both from a
biocompatible standpoint and a functionality standpoint in the plasma.
8.2.4 Nanosecond Pulsed System for Additive Manufacturing
Further work on the nanosecond pulsed plasma system for improvement of additive manufac-
turing is ongoing. This is primarily to determine the mechanism for improvement of the interlayer
bonding that was observed, as well as determining why they improvement was reduced with longer
plasma treatment time. The various hypotheses being tested are:
1. Nanoscale roughness increase. This is expected to improve bond strength by increasing the
surface area for bonding to take place. This will be measured using atomic force microscopy
(AFM), which uses a nanoscale-sized tip to probe the surface of a material, including raster-
ing over a surface to produce a three dimensional map of the local surface.
2. Oxidation of the surface. This is expected to decrease the bond strength. This effect can
be eliminated by running in an inert environment, either by running in a glove box or with
a shroud gas to avoid the entrainment of ambient air during testing. Conversely, this can be
increased by running in an oxygen rich environment, by running in an oxygen atmosphere
in a glove box, using a shroud gas of oxygen, or adding an admixture of oxygen to the gas
flow through the array. This can also be measured using X-ray photoelectron spectroscopy
(XPS), which observes the elemental composition and bonding on the surface of a material.
3. Surface functionalization. This is expected to increase the bond strength by adding a num-
ber of radical sites that will bond to the next printed layer. This should be observable using
XPS, by noting a change in the surface elemental composition (such as an increase in the
nitrogen content) or a change in the bonds of the surface (such as reducing the number of
carbon-oxygen double bonds in the PLA thermoplastic).
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By determining the dominant mechanism for the bond strength improvement, the plasma source
can be tailored to maximize that effect. This may require switching to a different plasma source.
Further optimization can be done including switching to a more economically feasible power sup-
ply (the FID power supply used costs ∼$30,000, while comparable ones can cost ∼$100s instead,
such as was investigated in Section 4.4.1), as well as other changes that may be able to make this
system integrate into a build process, rather than having to stop the print for treatment (which took
∼30 min for each single layer test—clearly not feasible for a system that consists of 100s to 1000s
of layers or more).
Further, this effect has only been observed in PLA. There are many more thermoplastics used
in AM, and each one needs to be explored to determine if the same effect occurs as well as to what
extent the effect may occur.
8.2.5 The FlashFuse System
The FlashFuse system could use further exploration to determine the extent that surface modi-
fication affected the bonding strength. Though this was assumed to not be a dominant mechanism
compared to thermal heating in the paper [17], the exact extent of this effect was not explored. This
could be done by running in an inert environment, such as an argon or helium atmosphere, which
would not react chemically with the surface. Again, a thermal camera could observe the heating
effect and XPS can be used to ensure there was no significant surface chemistry occurring.
Further development is ongoing in Essentium, Inc. to improve the FlashFuse system, such as
determining the best dielectric material, trying to balance the cost as well as the dielectric strength
of the material. Unfortunately, since this is a proprietary technology, most of the new developments
may not be made public or published in the open literature.
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cation of one-dimensional programmable-height nanostructures via dynamic stencil deposi-
tion,” Review of Scientific Instruments, vol. 79, no. 7, 2008.
[277] A. M. Abdul-Wahed, A. L. Roy, Z. Xiao, and K. Takahata, “Direct writing of metal film
via sputtering of micromachined electrodes,” Journal of Materials Processing Technology,
vol. 262, no. August 2017, pp. 403–410, 2018.
[278] A. M. Abdul-Wahed, A. L. Roy, and K. Takahata, “Microplasma drawing of thermocouple
sensors,” Proceedings of IEEE Sensors, pp. 1–3, 2017.
[279] E. Dudley, A Microplasma-Based Sputtering System for Direct-Write, Microscale Fabrica-
tion of Thin-Film Metal Structures. Master’s thesis, Case Western Reserve University, 2016.
[280] K. H. Church, C. Fore, and T. Feeley, “Commercial Applications and Review for Direct
Write Technologies,” MRS Proceedings, vol. 624, p. 3, feb 2000.
[281] S. E. Alexandrov and M. L. Hitchman, “Chemical vapor deposition enhanced by at-
mospheric pressure non-thermal non-equilibrium plasmas,” Chemical Vapor Deposition,
vol. 11, no. 11-12, pp. 457–468, 2005.
[282] T. Belmonte, G. Henrion, and T. Gries, “Nonequilibrium atmospheric plasma deposition,”
Journal of Thermal Spray Technology, vol. 20, no. 4, pp. 744–759, 2011.
[283] J. Benedikt, K. Focke, A. Yanguas-Gil, and A. Von Keudell, “Atmospheric pressure mi-
croplasma jet as a depositing tool,” Applied Physics Letters, vol. 89, no. 25, pp. 2004–2007,
2006.
[284] J. Benedikt, V. Raballand, A. Yanguas-Gil, K. Focke, and A. Von Keudell, “Thin film depo-
sition by means of atmospheric pressure microplasma jet,” Plasma Physics and Controlled
Fusion, vol. 49, no. 12 B, 2007.
[285] G. Kim, S. Park, H. Shin, S. Song, H. J. Oh, D. H. Ko, J. I. Choi, and S. J. Baik, “Two
dimensional radial gas flows in atmospheric pressure plasma-enhanced chemical vapor de-
position,” AIP Advances, vol. 7, no. 12, pp. 1–13, 2017.
281
[286] S. Guruvenket, S. Andrie, M. Simon, K. W. Johnson, and R. A. Sailer, “Atmospheric-
pressure plasma-enhanced chemical vapor deposition of a-SiCN:H films: Role of precursors
on the film growth and properties,” ACS Applied Materials and Interfaces, vol. 4, no. 10,
pp. 5293–5299, 2012.
[287] J. L. Hodgkinson and D. W. Sheel, “Advances in atmospheric pressure PECVD: The influ-
ence of plasma parameters on film morphology,” Surface and Coatings Technology, vol. 230,
pp. 73–76, 2013.
[288] S. Kang, R. Mauchauffé, Y. S. You, and S. Y. Moon, “Insights into the Role of Plasma in At-
mospheric Pressure Chemical Vapor Deposition of Titanium Dioxide Thin Films,” Scientific
Reports, vol. 8, no. 1, pp. 1–13, 2018.
[289] A. Perraudeau, C. Dublanche-Tixier, P. Tristant, C. Chazelas, S. Vedraine, and B. Ratier,
“Low-temperature deposition of TiO2 by atmospheric pressure PECVD towards photoanode
elaboration for perovskite and solid-state dye-sensitized solar cells,” EPJ Photovoltaics,
vol. 10, pp. 0–4, 2019.
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APPENDIX A
DOUBLE SPARK GAP DISCHARGE GENERATOR USER GUIDE
The user guide for the RC pulse generator circuit (see Section 4.4.1) that was delivered to the
project sponsor (EP Technologies, LLC) is on the following pages. This includes more details on
how the power supply behaved under various conditions (different values for C, R2, substrate, etc.
as shown in Figure 4.4), as well as step-by-step operating instructions and a short troubleshooting
guide.
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Double Spark-Gap Discharge 
Device User Guide 
 
Sections: 
I. Safety Warnings 
 Describes warnings for the dangers during use of this device 
II. Overview 
 Provides a discussion of the device’s contents 
III. Operating Instructions 
 Step-by-step operating instructions for using this device 
IV. Normal Operation 
 Provides voltage-current graphs of the pulses and shows general ranges for achieving 
 certain operating conditions 
V. Troubleshooting 









I. Safety Warnings 
 
Warning: For use only by properly trained personnel. Minimum training must include 
proper safely procedures around high voltage electrical equipment. 
 
Warning: This double spark-gap discharge generator contains capacitors that can store 
electrical energy for long times. Always ensure the device is grounded and ALL capacitors 
are discharged before operating, INCLUDING capacitors not connected to the circuit. 
 
Warning: This double spark-gap discharge generator can output significant 
electromagnetic interference (EMI). During use, ensure the box is closed and locked with 
all acrylic shields in place. 
 
Warning: High voltage is used to power this device. Ensure all wires are properly 
insulated, the box is properly grounded, and the load is grounded appropriately. 
 
Warning: Do not exceed voltage, current, and power ratings of device. Failure can occur if 








The double spark-gap discharge generator contains a 10 MΩ electrical ballast resistor, four 
switchable capacitors (5 nF, 500 pF, 50 pF, and stray capacitance), an optional secondary resistor 
to dampen the pulses, two independently adjustable spark-gaps, and an external trigger box 
controlling a third external trigger spark-gap. The schematic is shown below in Figure 1 with a 
legend and the inside of the box is shown in Figure 2. 
 
 
PS DC power supply used to power the double spark-gap discharge generator 
R1 10 MΩ electrical ballast resistor 
C Selected capacitor from the four switchable capacitors 
AC AC plug powering the external trigger for the main spark-gap 
CB Control box for the external trigger spark-gap 
EXT External trigger spark-gap 
MSG Main spark-gap 
SSG Second spark-gap 
R2 Optional secondary resistor used to dampen the pulses (1.1, 11, and 110 kΩ) 
G1 Grounding strap used to ground the box 
Load Corona array or DBD being powered by the double spark-gap discharge generator 
G2 Grounding wire used to ground the load 






Figure 2 View inside of box showing various components of the double spark-gap discharge 
generator 
 
 The ballast resistor, R1, is used to control the rate the selected capacitor charges. 
Changing between the four switchable capacitors (5 nF, 500 pF, 50 pF, and stray capacitance) 
changes the energy per pulse coming from the double spark-gap discharge device. See section 
IV. Normal Operation for data on the pulse characteristics for each capacitor. Note that the 
capacitors do not have interchangeable screws; the 50 pF and 500 pF capacitors are screw size 
M4 (metric), and the 5 nF capacitor has screw size #10-24. Stray capacitance is achieved by 
securing the wire to the capacitors to the screw on the main spark-gap head (see Figure 3). This 
RC circuit is rated for a maximum of 40 kV, 2.5 mA, and 32 W. There is a grounding rod 






Figure 3 Screw for stray capacitance 
 
 The spark-gap micrometers are seen in Figure 4. The main spark-gap, MSG, is controlled 
by a micrometer which ranges from -0.087 in (note that the closed gap, when the two ends touch, 
is below the zero reading on the micrometer) to 0.95 in. Increasing this gap increases the amount 
of voltage per pulse. The second spark-gap, SSG, ranges from -0.092 in (note that the closed gap, 
when the two ends touch, is below the zero reading on the micrometer) to 0.95 in. Note that these 
zero-values changed upon rebuilding of the double spark gap generator after damage due to 
shipping to EP Technologies. Though any differences in distances are the same, there is a shift 
for accounting for a new zero location which is NOT accounted for in this document. For large 
distances, the second spark-gap controls the pulse width; decreasing it further has no significant 
effect on the pulse width, instead it reduces the pulse peak voltage. The secondary resistor, R2, is 
used to dampen any oscillatory behavior in the pulse by slowly discharging current delivered to 
the load as well as draining unwanted charge from the downstream side of the main spark-gap. 
The best damping behavior occurs for R2 values between 1 kΩ and 100 kΩ. Larger values do not 
leak charge fast enough and encourage corona breakdown initially, and much smaller resistance 
values reduce the pulse maximum voltage, since significant charge leaks off through the resistor 
rather than traveling to the load (for more information see section IV. Normal Operation 






Figure 4 Side of box showing locations of the box grounding strap 
(G1), main spark-gap (MSG), and the second spark-gap (SSG) 
 
 The two grounding locations are internally connected, thus they are not separate grounds, 
but used to ground two different locations. The grounding strap on the box (G1, seen in Figure 4) 
is used to ensure the box is at earth ground and will not build up charge. If this grounding 
location is replaced, ensure that it is only replaced with high gauge grounding strap wire. The 
load ground (G2) is the marked wire next to the load input wire and is used to connect the 
ground side of the load to the circuit ground, completing a current path for the voltage pulse. 
 
 
Figure 5 Control box’s front panel for external trigger spark-gap 
 
 The external trigger box is attached to the main box; it is powered by a 12 V AC wall 




ways to operate the external trigger spark-gap. The knob on the right controls the mode for the 
external trigger. The three modes are described in the Table 1. 
 
Table 1: External Trigger Modes 
1-Single Controls the trigger via the white Single button 
2- Pulse Controls the trigger via the ON/Pulse knob 
3-Ext Trig Controls the trigger via an external device connected into the Ext Trig BNC plug 
 
The white Single button works in single mode. Pressing it causes the external trigger spark-gap 
to discharge. The Ext Trig plug connects to a 50 Ω BNC cable; a minimum voltage change of 
650 mV is required to operate the trigger. The ON/Pulse knob controls both the power for the 
entire box regardless of mode, and it also controls the frequency of the pulse in pulse mode, 
varying between a frequency of 12 Hz (just past clicking into the ON position by turning 
clockwise) and 125 Hz (farthest turning of the knob clockwise). The voltage pulses outputted 
from the box are stepped up to approximately 12 kV by the transformer inside of the main box, 
thus breaking down the external trigger spark-gap, EXT. 
 In addition to the three pulsing modes above, the box is also capable of being operated 
without an external trigger. In this self-pulsing mode, the frequency of pulses is controlled by the 
amount of current supplied from the power supply, with higher currents charging the capacitor 





III. Operating Instructions 
 
1. Connect the grounding 
strap (G1) on the outside of 
the box to earth ground. 
Ensure this is also the 
ground for the power supply 
used. 
 
2. Connect the desired load 
(corona array or DBD) to 
the unmarked output wire 
and attach the marked 
output ground wire (G2) 
appropriately. 
 
3. Open the box and remove 
the top acrylic shield held in 





4. Using the attached 
grounding rod, ensure the 
capacitors are discharged. 
Check every capacitor, 
including the ones not 
connected to the circuit. 
Stray charge can build up on 
the capacitors even when 
they are not attached to the 
circuit. It is best to check 
each capacitor multiple 
times since they do not 
always fully discharge if 
good contact not made. 
 
5. Attach the desired 
capacitor (C) to the main 
spark-gap. If stray 
capacitance is desired, 
remove the wire connecting 
the capacitors to the main 
spark-gap and secure it to 






6. Replace the secondary 
(dampening) resistor (R2) as 
needed for the required 
dampening of the pulse, 
ensuring the resistor is 
inside of its insulating tube. 
For multiple resistors in 
series it may not be possible 
to insulate the resistors in 
the insulating tube. In which 
case, make sure they are as 
far away from other 
electrical connections as 
possible. 
 
7. Visually ensure both 
spark-gaps are closed. 
(Note: the micrometer 
reading is not the actual 
spark-gap distance; the 
micrometers will be in a 






8. Replace the top acrylic 
shield and screw it down. 
Then close and lock the box. 
 
9. Connect the high voltage 
power supply to the input 
wire. Ensure it is properly 
insulated. PVC tubing or 
some other thick dielectric 
works well. Make sure the 
exposed electrical 
connections are at least 5 in 
inside of the dielectric. Is is 
also advisable to wrap the 
exposed electrical 
connections with electrical 






10. If self-triggering of the 
box is desired: 
10-a-1. Turn on the main high voltage power supply and slowly 
increase the voltage to the desired level while keeping current 
at minimum (zero if possible). DO NOT EXCEED 40 kV! 
10-a-2. Set the spark-gaps to the desired lengths. See section IV. 
Normal Operation for approximate values for spark-gaps. 
10-a-3. Slowly increase the current until the desired frequency of 
pulses is achieved. DO NOT EXCEED 2.5 mA or 32 W! 
If external triggering of the 
box is desired: 
10-b-1. Plug in the external trigger (smaller box attached to the 
box), and select the desired mode. Single is operated by the 
white ‘Single’ pushbutton. Pulse is operated by the ON/Pulse 
knob. Ext Trig is operated by the 50 Ω BNC input labeled Ext 
Trig. 
10-b-2. Set the spark-gaps to the desired lengths. See section IV. 
Normal Operation for approximate values for spark-gaps. 
10-b-3. Turn on the main high voltage power supply and slowly 
increase the voltage to the desired level while keeping current 
at minimum (zero if possible). DO NOT EXCEED 40 kV! 
The voltage should be set to approximately 100 V below the 
breakdown threshold for the main spark-gap. 
10-b-4. Increase the current on the main high voltage power 
supply, such that the desired frequency from the external 
trigger can be achieved. DO NOT EXCEED 2.4 mA or 32 W! 
10-b-5. Turn on the external trigger box using the ON/Pulse knob 
to operate the external trigger spark-gap, operating in the 
desired mode. 
11. After testing, turn off the 
power supply. If applicable, 






12. Close the spark-gaps 
(Note: the micrometer 
reading is not the actual 
spark-gap distance; the 
micrometers will be in a 
negative position to close 
the spark-gaps.) 
 
13. If desired for long term 
storage, open the box and 
remove the top acrylic 
shield. Using the attached 
grounding rod ensure the 
capacitors are discharged. 
Check every capacitor, 
including the ones not 
connected to the circuit. 
Then, replace the top acrylic 
shield and screw it down. 







IV. Normal Operation 
 
A. Important Notes: 
1. The voltage and current pulse shapes are heavily load dependent. The examples given 
below are simply a guide and may not reflect how the pulses behave for other loads. The two 
loads used in the data below are 1) a corona array directly under Pyrex petri dish with 
grounded salt water (i.e. a zero-gap distance) and 2) a corona array 5mm above a grounded 
metal plate. General trends are higher capacitive loads will have lower peak voltage pulses 
and less resistive loads will have shorter pulses. 
2. There will always be some amount of ringing in the circuit after the initial pulse. This is 
minimized by decreasing the second resistor, but by decreasing the resistance too much (less 
than ~200Ω) the pulse is affected. 
3. The double spark-gap discharge device can be operated as a single spark-gap. This happens 
when the second spark-gap is too large to break down. The distance this occurs is affected by 
both the capacitor used and the main spark-gap. 
 
B. Effect of Main Spark-Gap 
The main spark-gap is used to control the breakdown voltage of the capacitor. Note that this is 
not the peak voltage of the pulse, which is discussed in Subsection H below. Figure 6 below 
shows the relation between the main spark-gap’s setting (note that the closed gap, when the 
two ends touch, is below the zero reading on the micrometer) and breakdown voltage of the 
main spark-gap. The power supply voltage is also plotted, since this is also a controllable 
parameter through the power supply. The difference between the power supply voltage and the 
breakdown voltage is the voltage drop across the charging resistor, R1. (The self-pulsing 
frequency was around 1 to 10 Hz for every condition. The actual voltage drop across the 
resistor will vary depending on the amount of current supplied by the power supply.) The 
trend-line is a spline function used to fit the data. The data plotted consists of multiple 
substrates and all capacitors; hence it shows the breakdown voltage is not greatly affected by 
the capacitor or substrate used. Within an uncertainty of a few hundred volts, the breakdown 






Figure 6: Various Capacitors, SSGs, Substrates, R2s, and loads; self-pulsing mode; note that the 
actual results will be shifted due to a change in the zero-location of the micrometer after 
shipping 
 
For very large distances of the main spark-gap, corona discharges can become significant. This 
is noticeable as a larger current required to operate the device (i.e. the current is larger than that 
required by the resistors to operate at a particular voltage). There is not a sharp rise in voltage 
with a corona discharge, rather a slower increase due to some charge leaking across the main 
spark-gap before it fully breaks down, as can be seen in Figure 7, where the larger main spark-
gap has a lower rise time due to corona breakdown initially. 
 






























Figure 7: 50 pF Capacitor, single spark-gap configuration, R2=4.4 kΩ, corona array under Pyrex 
petri dish with grounded salt water, self-pulsing mode 
 
C. Effect of Second Spark-Gap 
The second spark-gap has an effect on both the voltage pulse magnitude and duration. At large 
gaps, the second spark-gap will not breakdown and the device operates in a single spark-gap 
configuration. This leads to very long voltage pulses for a capacitive load (like the solid red 
curve in Figure 8 below which last for microseconds), but does not greatly affect the pulse 
duration for conductive loads (e.g. spark-gaps, such as a discharge to a grounded metal plate in 
Figure 9 below). This is because the charge slowly dissipates through the resistor (R2) for a 
capacitive load, but for a conductive load the charge is able to quickly dissipate through the 
load. As the second spark-gap distance is shortened, the pulse duration and peak voltage both 
decrease. 
 




































Figure 8: 5nF Capacitor, MSG=0.6 in, R2=4.4 kΩ, corona array under Pyrex petri dish with 
grounded salt water, self-pulsing mode 
 
 
Figure 9: 500pF Capacitor, MSG=0.35 in, R2=4.4 kΩ, corona array 5 mm over grounded metal 
plate, self-pulsing mode 



































































































D. Effect of Capacitor 
The capacitor has a large effect on the voltage pulse magnitude and as a result it affects the 
voltage pulse duration as well. As the capacitor is increased the voltage pulse magnitude 
increases as can be seen in Figure 10 below, where the only parameter changed between 
conditions is the capacitor. As the voltage pulse magnitude increases, the pulse duration also 
increases, since the pulses have approximately the same rise time per unit voltage. The larger 
capacitors are also capable of achieving larger voltage pulse magnitudes, as can be seen in 
Figure 11. This is due to the load being very capacitive. The capacitor discharges to the load, 
which has a voltage determined by its capacitance. 
 
  
Figure 10: MSG=0 in, single spark-gap configuration (SSG=0 in), R2=4.4 kΩ, corona array 
under Pyrex petri dish with grounded salt water, self-pulsing mode 

















































Figure 11: Various SSGs, R2=4.4 kΩ, corona array under Pyrex petri dish with grounded salt 
water, self-pulsing mode, black outline indicates single spark-gap configuration 
 
E. Effect of R2 
The resistor acts as a second path to ground for any pulses; however it takes time for the charge 
to travel through the resistor. Smaller resistors drain off the charge faster, reducing the voltage 
quicker as seen in Figure 12. This helps reduce ringing in the voltage pulse. However, for a 
double spark-gap configuration (i.e. when the second spark-gap discharges) the resistor does 
not have much effect, as can be seen in Figure 13. For very large gaps, the resistor does not 
quickly reduce the charge build up on the downstream side of the main spark-gap, promoting 
corona discharges, as seen in section V. Troubleshooting number 4. 
 








































Figure 12: 500pF Capacitor, MSG=0 in, single spark-gap configuration (SSG=0 in), corona array 
under Pyrex petri dish with grounded salt water, self-pulsing mode 
 
 
Figure 13: 500pF Capacitor, MSG=0 in, SSG=-0.045 in, corona array under Pyrex petri dish 
with grounded salt water, self-pulsing mode 
 
















































































F. Effect of Load 
Two types of load were tested: 1) the corona array directly under a Pyrex petri dish filled with 
salt water connected to ground (gap distance is zero as seen in Figure 14) and 2) the corona 
array 5mm above a grounded metal plate (Figure 15). For small voltages, the two loads acted 
similarly, since the air between the corona array and metal acted as a dielectric, as can be seen 
in Figures 16 (double spark-gap configuration) and 17 (single spark-gap configuration) for the 
main spark-gap value of 0 in. However, for larger voltages the air began to breakdown and 
became conductive. The voltage pulse for the metal substrate was not reflected as well as the 
voltage pulse for the capacitive load (since the plasma acts as a conductive path), leading to 
lower peak voltages. The transition in the air acting as a dielectric to a conductor is noticeable 
in Figure 19 as a sharp decrease in the voltage at longer times after the pulse for larger main 
spark-gaps, which is not seen in Figure 18 for a purely dielectric load. 
 
 





Figure 15: Image of corona array 5 mm over grounded metal plate 
 
 
Figure 16: 500pF Capacitor, R2=4.4 kΩ, self-pulsing mode 






































Metal  SSG=0.055in  MSG=0.35in
Glass  SSG=0.055in  MSG=0.35in
Metal  SSG=-0.035in  MSG=0in





Figure 17: 500pF Capacitor, single spark-gap configuration, R2=4.4 kΩ, self-pulsing mode 
  












































Figure 18: 500pF Capacitor, single spark-gap configuration, R2=4.4 kΩ, self-pulsing mode 
 
 
Figure 19: 500pF Capacitor, single spark-gap configuration, R2=4.4 kΩ, self-pulsing mode 
 
 


































































































G. Effect of Triggering Mechanism 
The trigger does not have a large effect on the voltage pulse, as can be seen from Figure 20 
below. Small differences may occur since the breakdown voltage is slightly different from the 
self-pulsing mode. The trigger is prone to error at high voltages. The two types of error that 
occur are incomplete discharge of the capacitor and discharge to the trigger ground. In 
incomplete discharge the main spark-gap breaks down, but it is a weak discharge with the 
capacitor only partially discharging. Often the second spark-gap will not discharge. This occurs 
more often for the smaller capacitors. In the second type of error, the main spark-gap breaks 
down to the trigger’s ground electrode, creating no voltage pulse on the load. This is more 
common for the larger capacitors. Typically each discharge is independent of the others, so one 




Figure 20: 500pF Capacitor, MSG=0.35 in, SSG=0.145 in, R2=4.4 kΩ 
 
H. Voltage Pulse 
Many factors influence the voltage pulse on the load, including the main spark-gap, the second 
spark-gap, the capacitor, and the load itself. The maximum peak voltage is partially controlled 
by the main spark-gap, which controls the breakdown voltage. The maximum peak pulse 
voltage is at most double the breakdown voltage on the capacitor, since the voltage pulse can 
be reflected in the transmission line (i.e. the high voltage wire connecting the load and box) if 
the load resistance is greater than the transmission line’s impedance (This is often the case, 
since the transmission line has an impedance under 500 Ω). The resistivity of the load 
determines how much of the voltage pulse is reflected, with higher resistances reflecting more 

















































of the voltage and increasing the maximum peak voltage. The second spark-gap mostly affects 
the pulse duration, but too small of a second spark-gap begins to reduce the voltage pulse 
maximum, since the pulse has a fairly constant rise time per unit voltage, holding other 
parameters constant. Attempting to reduce the pulse duration below a certain threshold begins 
to significantly decrease the maximum voltage to keep the rise time per unit voltage the same. 
For large distances of the second spark-gap it will not discharge, operating in a single spark-
gap configuration. The capacitor also controls the maximum peak voltage, with higher 
capacitances able to achieve higher voltages.  
 
I. Taking Measurements 
All probes have internal impedances which will affect measurements. Use high impedance 
probes to minimize the effect. The pulse generated from the main spark-gap discharging can 
generate very large currents (~1 kA). Due to natural inductance in all wires, measuring currents 
and voltages can become very difficult. In general, use the thickest and shortest wires possible. 
This is especially true for ground wires, including grounding wires attaching the various 
ground locations in the circuit and probes. If these are not very low inductance (i.e. not a solid 
block of metal, such as the metal optical table top used in all testing in Dr. Staack’s lab) even 
the ground voltage can change, greatly affecting measurements. Some high voltage probes 
have multiple grounding locations which can be used. Electromagnetic interference (EMI) is 
also generated since the pulse has such a fast rise and fall time. Shielding all wires used can 








1. The voltage pulse appears lengthened. 
 
Solution: Shorten the second spark-gap. The second spark-gap is too large to reliably 
discharge. 
 
2. The second spark-gap did not discharge. The voltage pulse does not have a sharp end, but 
gradually trails off. 
 
Solution: Shorten the second spark-gap. The second spark-gap is too large and did not 
discharge. 
 















































3. There is significant ringing in the pulse 
 
Solution: Reduce the secondary resistor, R2. This will allow current to travel to ground over 
time, which will decrease some of the ringing and still maintain a high initial voltage pulse. 
However, most of the ringing is too fast for the time response of the resistor and cannot be 
controlled. 
 
4. Pulse does not have a sharp rise. 
 
Solution: Reduce the value of R2. The second dampening resistor is too large, allowing charge 
to build up on the downstream side of the main spark-gap encouraging initial corona discharge 
followed by an arc. 
 











































5. The frequency of pulses is too high. 
Solution: If in self-pulsing mode, reduce the current supplied to the box. If that is not possible, 
switch to the external trigger mode. If in external pulsing mode, lower the frequency knob. If 
that is not possible, switch to externally triggering the external trigger box using a function 
generator via the Ext Trig BNC connection on the external trigger box. The external trigger 
may also be operated in Single mode, being triggered manually by the operator. 
 
6. The box does not work in Pulse mode for the external trigger, but does work in the other two 
modes. 
 
Solution: Replace the 555 timer chip in the control box. There are 4 screws holding the 
stainless steel cover in place, which can be removed allowing access inside of the control box. 




MATLAB CODE TO CONTROL THE 3D PRINTER
The MatLab code used for controlling the 3D printer in Chapter 6 is included below.1 It consists
of a main code, called GCodeWriter.m, that interfaces with the 3D printer and a function, called
GCodeParser.m, that it calls if external GCode is used. This allows for greater versatility in
deciding which GCode to run, as well as giving access to the specific commands to control the 3D
printer even when supplied a GCode.
The function GCodeWriter.m connects to and sends commands to the 3D printer. It also
contains a few custom geometries that can be written from MatLab code. In addition it offers the
capability of plotting the GCode before in runs in three different ways: a step-by-step animation
of the GCode, a colored plot of the steps, and a plot of the time per area in the code. The latter two
are shown in Figure 6.4 for two different geometries, one case for “Staack’s Second Try” geometry
and the other case from a GCode generated geometry by the Slic3r software.
The function GCodeParser.m takes in the filename for a GCode file and outputs the desired
parameters. It contains a legacy code portion that was a first attempt at extracting changes in the x
and y movements in the GCode, but this legacy code relied on certain lines that were in the GCode
generated by the Slic3r software for certain cases only. As a result, a more generalized GCode was
written, but the legacy code was retained in case replicating old results was necessary.
GCodeWriter.m
1 %% 3D Printer Code
2 % This code interacts with the 3D Printer to output a 2D
3 % drawing. It accounts for the fact that the x-axis control
4 % is broken, so the z-axis control is running the x-axis
5 % servo motor.
6
7 % Authors: Matthew Burnette, Chris Campbell, and David Staack
1Thanks to Uwe Lelke’s code m2tex.m (MatLab File Exchange #24515) for generating the nicely formatted
output used here.
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8 % Version: 1.2 (Better plotting & cleaner code)
9 % 1.1.1 (Changed plotting to always have visual buffer)
10 % 1.1 (Added Matt’s Annular Run)
11 % Last Updated: 5/16/2020 at 11:19PM
12 % Requires: GCodeParser
13








22 %True runs printer
23 Show_Plots=1;
24 %Extra descriptive plots of pattern
25 Show_Plotting_Steps=0;
26 %Animation of the 3D printer pattern
27 SaveGIF=’’; %’C:\Users\...\NewGif.gif’;
28 %Absolute File Save Location
29 %Show_Plotting_Steps must also be on
30 StopTempError=1;
31 %Generally good to leave on
32 %Turn off if code is running too slow
33 GCodeFilename=’’;%...\GCode\CircleD20mm3_new.gcode’;
34 %if empty uses build in geometry below
35 %Otherwise looks for filename given
36
37 %% Open serial port to send commands to the 3D Printer
38 if Run3D_Printer
39 s=serial(’COM3’); %#ok<SERIAL>









49 %% Set Speeds
50 zfactor_x= 40; %Constant
51 zfactor_v = 40; %Constant
52 speed = 1000; %mm/minute
319
53 x_speed=speed/zfactor_v;
54 % zaxis units/min since x-servo motor broke!
55 y_speed=speed; %% mm/min
56 num_passes=10;




61 %% Staack’s First Try (Used for Initial 8 runs)
62 %{ Remove this text to comment out
63 nsegments = 10000;
64 %Note this starts at the top-center position
65 maxt = 100;
66 t = linspace(0,maxt,nsegments);
67 r = 10*cos(t/maxt*36*pi);
68 theta = t/maxt*500*pi;
69 x = r.*sin(theta);




74 %% Chris’s Spiral Try
75 %Failed for some odd reason with printer
76 %The reason for this has not been fully explored
77 %{ Remove this text to comment out
78 nsegments = 25000; %Starts in center
79 maxt = 100;
80 t = linspace(0,maxt,nsegments);
81 radius_freq = 0.005;
82 % Try a few methods to get the best r
83 %r = 10.0.*(0.5.*sawtooth(2*pi*radius_freq*t,0.5)+0.5);




88 r = 10.*((t/maxt).^0.1).*cos(t/maxt*36*pi);
89 theta = t/maxt*pi*500;
90 x = r.*sin(theta);




95 %% Staack’s Second Try (Path1) Starts in center
96 %{ Remove this text to comment out
97 Diameter = 20; % units mm circle diameter
320
98 speed = 250/60; %mm/min
99 % / 60 to get mm/s, this is the gcode speed.
100 % Note cartesian speed is constant not omega.
101 norbits = 140; %% large number of orbits increases
102 % uniformity but also increases total lenth of print
103 % these will take about 10 minutes
104
105 z = linspace(0,2*pi,norbits*90);% at least 2 deg
106 % resolution
107 ft = norbits; % theta rapidly changes helps
108 % Want to avoid spiral overlapping previous one...
109 %pri = max(primes(sqrt(ft+1)));
110 % trying to algorithm this but a guess works too
111 %fr = pri;
112 % should not have too many beating
113 %r should change rapidly also
114 fr=9; %better than 11...
115 %can’t find way to do this programatically
116 r = Diameter/2*sawtooth(z*fr,0.5);
117 % saw tooth is the right function not sine
118 t = z*ft;
119
120 % try to correct middle by decimate small r
121 r_f = r(r>=0.5);
122 t_f = t(r>=0.5);
123 r = r_f;
124 t = t_f;
125
126 % no matter what start and end at zero
127 r = [0,r,0];
128 t = [0,t,0];
129
130 x = r.*sin(t);
131 y = r.*cos(t);
132 rnew = sqrt(x.^2+y.^2);
133 tnew = atan2(y,x);
134
135 dx = diff(x);
136 dy = diff(y);
137 dL = sqrt(dx.^2+dy.^2);
138
139 time = [0,cumsum(dL/speed)];
140 fcode = 24; % times per second new position is sent
141 %this must be large enough to resolve orbits
142 ncode = fcode*round(max(time));
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143 % number of position points the lin time vector
144 linTime = linspace(0,max(time),ncode);
145 r_lin = interp1(time,rnew,linTime);
146 % these are evenly spaced in time
147 x_lin = interp1(time,x,linTime);
148 % these are evenly spaced in time
149 y_lin = interp1(time,y,linTime);
150 % these are evenly spaced in time
151 t_lin = interp1(time,tnew,linTime);
152 % these are evenly spaced in time
153 % if we send even in time points to program then
154 % matlab vector and gcode time will be the same
155
156 % send to printer code
157 x = x_lin;




162 %% Matt’s Annular Pattern
163 %{ Remove this text to comment out
164 Diameter=20; %mm
165 dtheta=.01;







173 x(1)=[]; %often bad first point to move build stage




178 %% Outputing GCode
179 cp =[0,0];
180 x = x-x(1); %Centers Gcode starting location
181 y = y-y(1); %Centers Gcode starting location
182 x_c=x/zfactor_x; % zaxis units
183
184 num_steps=length(x);
185 e = Edim*ones(1,num_steps);
186 num_steps=length(x);
187 residuedur = 0;
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207 % Only show it in 100 steps
208 % Otherwise this takes forever depending on the print!






































246 % Last second chance to abort if I realize this is not
247 % the print I want
248
249 %% Run Time-Per-Area Plot
250 %{ Remove this text to comment out
251 % Need to get points evenly spaced in time
252 dx = diff(x);
253 dy = diff(y);
254 dL = sqrt(dx.^2+dy.^2)’;
255 if min(dL)==0
256 %Sometime there is a dwell at a location which will
257 %mess with code later. If this happens a lot in the
258 %code then this analysis is not accurate. Generally,
259 %though this happens when there is a z-height change,
260 %which is relatively infrequent (hopefully)
261 badI=(dL==0);
262 dL=dL(~badI);








271 % Get a vector of cumulative time taken at each step
272 if isrow(dL)
273 time = [0,cumsum(dL/speed)];
274 else




278 % Now get a length vector for each time point
279 dt=diff(time);
280 fcode = 10/min(dt);
281 %times per second new position is sent-must be large
282 %enough to resolve orbits
283 ncode = ceil(fcode*max(time));
284 %number of position points in the linTime vector
285 linTime = linspace(0,max(time),ncode);
286
287 % Get x and y based on even-time spaced vector
288 x_lin = interp1(time,x2plot,linTime);
289 % these are evenly spaced in time
290 y_lin = interp1(time,y2plot,linTime);
291 % these are evenly spaced in time
292
293 % Guess a computational time per step
294 computetime = 5e-3;
295 % time to tell about next move estimated, because
296 % points are evenly spaced in time this should not
297 % affect uniformity
298 time_real = [0,cumsum(diff(linTime)+computetime)];
299 ResTime = mean(diff(time_real));
300
301 % Find Time in Each Cell of Grid
302 xResolution=20;
303 yResolution=20;
304 xCells = XLims(1):dX/xResolution:XLims(2);
305 yCells = YLims(1):dY/yResolution:YLims(2);
306 %Easier than using meshgrid to get x and y
307 for i=1:length(xCells)-1
308 for j = 1:length(yCells)-1
309 inds = x_lin>xCells(i) & x_lin<xCells(i+1) &...
310 y_lin>yCells(j) & y_lin<yCells(j+1);
311 xc(i,j) = (xCells(i)+xCells(i+1))/2;%#ok<*SAGROW>
312 yc(i,j) = (yCells(j)+yCells(j+1))/2;




317 % Output Time at Spot Figure
318 figMap=figure;
319 ax=axes;
















335 %% Run the Printer
336 if Run3D_Printer
337 disp(’Running the 3D printer now...’)
338 pause(0.1)
339
340 %Final checks on code before running
341 if length(y)~=num_steps
342 error(’Check length of y’)
343 elseif length(e)~=num_steps
344 error(’Check length of e’)
345 end
346
347 % Looping over pattern iterations
348 for z = 1:num_passes
349
350 % Looping over pattern steps
351 for i = 1:num_steps
352 fprintf([’Executing Line %d/%d on Pass ’,...
353 ’%d/%d\n’],i,num_steps,z,num_passes)
354 distance = sqrt((x(i)-cp(1))^2+(y(i)-cp(2))^2);
355 lengthx = abs(x(i)-cp(1));
356 lengthy = abs(y(i)-cp(2));
357 speed_m = ((lengthx/distance)*x_speed + ...
358 (lengthy/distance)*y_speed);
359 %effective speed for this move
360 dur(i) = distance/speed*60;
361
362 %tosend1 = [’G01 E’,num2str(e(i)),’ F1000’,];
363 % Turn on plasma if using E to control DBD
364 % jet flow. This never worked well, mostly
365 % manually controlled instead
366 tosend2 = [’G01 Z’,num2str(x_c(i)),...%X = broken
367 ’ Y’,num2str(y(i)),...
326
368 ’ F’,num2str(speed_m)]; % moves
369 if StopTempError
370
371 % Prevents printer from resetting due to
372 % temperature error, but we don’t use the













386 % May need pause to ensure sufficient time
387 % elapses for printer head movement time
388 if NeedPause
389 pause(dur(i)*0.95+0.001) %#ok<*UNRCH>
390 residuedur = residuedur+0.05*dur(i);
391 end
392 end
393 end %Loop over steps
394 end %Loop over print iterations
395 pause(residuedur+.02) %% finish up
396




401 end %if running printer
402
403 disp(’Code Executed Without Errors’)
GCodeParser.m
1 %% GCodeParser Reads X and Y locations from a GCode file
2 % [X,Y]=GCodeParser(filename) outputs X and Y locations
3 % from a GCode written by the slicer program from Staack’s
4 % 3D printer. This may not work with other GCodes
327
5 %
6 % [X,Y,Z]=GCodeParser(filename) outputs X, Y, and Z
7 % locations from a GCode. This may yield different results
8 % from above, since it uses a different method for parsing
9 % the GCode file. X, Y, and Z will all be vectors of the
10 % same length. Any time a value is missing the previous
11 % value is assumed (starting with a value of 0 if not
12 % initially specified in the GCode).
13 %
14 % [X,Y]=GCodeParser(filename,’NotLegacy’) outputs X and Y
15 % locations from a GCode using the newer GCode parsing





21 % outputs X, Y, and Z locations from a GCode along with the
22 % specified prefix’s values (not strings!). Desired
23 % prefixes must be specified as a cell string array, which
24 % will yield as many outputs as prefixes. For example, the
25 % prefix ’F’ can be used to see the feed (speed) rate and
26 % ’E’ will yield the extrusion amount/rate. The value is
27 % assumed to come immediately after the prefix string (no
28 % spaces).
29 %
30 % [...]=GCodeParser(___,’plot’) also plots the GCode. The
31 % plot will either by a 2D or 3D line plot depending on
32 % whether Z was written.
33 %
34 % [...]=GCodeParser(___,’Waitbar’) adds a waitbar for files
35 % read in using the newer (non-legacy) method. This can
36 % substantially slow down the code with the waitbar’s
37 % overhead, but closing the waitbar will let it get back to
38 % "full" speed (the waitbar will not open again)
39
40 % Author: Matthew Burnette
41 % Version: 2.1.1 (bug fix on waitbar)
42 % 2.1 (better error handling and bug fix)
43 % 2.0 (More general GCode parser)
44 % Last Updated: 2/13/2020 at 8:51PM
45
46 function [varargout]=GCodeParser(varargin)
47 %% Parse Inputs and Open File
48 if nargin<1 || ~ischar(varargin{1})
49 error(’StaackLab:GCodeParser:ReadFile’,...
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74 if i==nargin || ~iscellstr(varargin{i+1})
75 warning(’StaackLab:GCodeParser:Prefix’,...












88 ’Invalid input!\nIgnoring input’)
89 end







96 w=waitbar(0,’Preparing to parse the GCode’);
97 %pause(0.5) %Assume the code will take long enough to run
98 %anyway, so no need to pause
99 end
100








109 fclose(fID); %Close the file
110 catch ME




115 %% Write Outputs
116 if Waitbar && ishandle(w)
117 waitbar(1,w,’Finished Parsing, now making outputs’)
118 pause(.2)
119 end
120 X=[]; Y=[]; Z=[];
121 EnoughOutputs=true;
122 NumOut=nargout;
123 if nargout<2 && ~PlotIt %May just plot it, which is fine
124 warning(’StaackLab:GCodeParser:Output’,...



















143 if NumOut<3 || ~EnoughOutputs
144 if ~PlotIt %May just plot, which is fine
145 warning([’StaackLab:GCodeParser:’,...
146 ’Output’],[’Not Enough Outputs!’,...










157 [’Not Enough Outputs!\nNot ’,...








166 %% Plot if Desired
167 if PlotIt
168 if Waitbar && ishandle(w)
169 waitbar(1,w,’... and now plotting’)
170 pause(.2)
171 end









181 axis equal %square
182 end







189 %% Local Functions
190 function [X,Y]=LegacyCode(fID,filename)
191 %Keep for backwards compatibility with old codes...
192 LineToFind=’G1 Z’;


















211 % Loop first to get number of lines in file for waitbar
212 TotalLines=0;
213 fgetl(fID);
214 %This avoids off by 1 errors, since fgetl must first





220 frewind(fID) %Rewind file for reading the data
221 if ishandle(w) %In case it’s closed...





























































































313 LineNum=LineNum+1; %A change so increment LineNum
314 end
315 FileLineNum=FileLineNum+1;
316 Changed=false(1,pN+3); %Reset to find next useful line
317 if Waitbar && ishandle(w) %In case it’s closed...
318 waitbar(FileLineNum/TotalLines,w)
319 end
334
320 end
321 CellOutput=[{X,Y,Z},Pre];
335
